Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors by Kloth, J.S.L. (Jacqueline)
Pharmacokinetics and  
Pharmacodynamics of 
Tyrosine Kinase Inhibitors
Jacqueline SL Kloth
Pharm
acokineti
cs  and Pharm
acodynam
ics of Tyrosine Kinase Inhibitors 
              Jacqueline SL Kloth
Pharmacokinetics and 
Pharmacodynamics of 
Tyrosine Kinase Inhibitors
Farmacokinetiek en farmacodynamiek 
van tyrosine kinase remmers
Jacqueline S.L. Kloth
Colofon
Kloth, J.S.L.
Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors
ISBN: 978-94-6182-572-8
Lay-out and cover Design: Roderick van Klink
Printed by: Off page
Copyright © J.S.L. Kloth 2015, Rotterdam, The Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrival system of any nature, 
or transmitted in any form or means, without written permission of the author, or when appropriate, 
of the publishers of the publications.
The printing of this thesis was sponsored by Teva Nederland B.V., Waters Chromatography B.V., 
ChipSoft B.V., Pfizer B.V. and Boehringer Ingelheim B.V. 
Pharmacokinetics and Pharmacodynamics 
of Tyrosine Kinase Inhibitors
Farmacokinetiek en farmacodynamiek van tyrosine kinase remmers
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 1 juli 2015 om 11.30 uur
door
Jacqueline S.L. Kloth
geboren te Dordrecht
PromoTIecommIssIe
Promotor Prof.dr. A.H.J. Mathijssen
Overige leden Prof.dr. T. van Gelder
  Prof.dr. H.J. Guchelaar
  Prof.dr. W.T.A. van der Graaf
Copromotor dr. E.A.C. Wiemer
Het komt altijd goed
C. van Noord

coNTeNTs
Chapter 1  General introduction     
Part I: Pharmacokinetic approach towards improved sunitinib treatment
Chapter 2 Predictive value of CYP3A and ABCB1 phenotyping probes for   
  the pharmacokinetics of sunitinib: the ClearSun study 
       
Chapter 3 Pharmacokinetically-guided sunitinib dosing: A feasibility study   
  in patients with advanced solid tumours 
  
Chapter 4 Relationship between sunitinib pharmacokinetics and    
  administration time: preclinical and clinical evidence 
   
Part II: Pharmacodynamic aspects of treatment with tyrosine kinase inhibitors
Chapter 5 Genetic polymorphisms as predictive biomarker for survival in   
  patients with gastro-intestinal stromal tumours treated with   
  sunitinib 
  
Chapter 6 Genetic polymorphisms in angiogenesis related genes are   
  predictive for survival of patients with advanced gastrointestinal   
  stromal tumors treated with imatinib
Chapter 7 Incidence and relevance of QTc-interval prolongation caused by   
  tyrosine kinase inhibitors
 
Chapter 8 Macrocytosis as a predictive marker for survival in the treatment   
  with tyrosine kinase inhibitors 
    
Chapter 9 Summary       
Appendices Nederlandse samenvatting   
  Curriculum Vitae     
  Publications       
  PhD portfolio      
  Dankwoord    
 
9
23
43
63
85
105
123
141
153
159

chapter 1
General introduction
10
cANcer
Cancer is the second most common cause of death worldwide after cardiovascular diseases, 
responsible for an estimated 8.4 million deaths in 2012 and its incidence is still increasing.1 Through 
the introduction of many chemotherapeutic agents and hormone treatments in the last decades, 
treatment options for patients with advanced forms of cancer have improved. Mortality rates have 
decreased and in some cases cancer is now changing to become a chronic disease. More recent, 
increased insight in cancer cell biology has led to further improvement in anti-cancer treatment. Much 
attention has been focused on tyrosine kinases that comprise essential elements of cellular signalling 
cascades which control proliferation, cell survival and cell death. In cancer, tyrosine kinases can be 
found activated by mutations, thereby contributing to malignant transformation, tumour growth and 
metastasis.     
TYrosINe KINAse INHIBITors 
Targeted therapies, especially tyrosine kinase inhibitors (TKIs), have largely contributed to the recent 
improvement in anti-cancer treatment. TKIs usually act by competing with adenosine 5’- triphosphate 
(ATP) for the intracellular ATP binding site of one or more tyrosine kinases.2 ATP displacement by TKI 
binding results in inhibition of several processes which are necessary for tumour growth, such as 
angiogenesis, cell proliferation and cell migration (type I inhibitors).3 More recently, TKIs have been 
developed which are non-ATP competitive inhibitors (type II and type III inhibitors). Currently, 17 TKIs 
are available for the treatment of a broad variety of cancer types, with approval by both the US Food 
and Drug Administration and European Medicines Agency (Table 1).4 
TKIs are oral drugs which are usually administered on a daily base. In the year 2000, imatinib was the 
first TKI that became available on the market for the treatment of chronic myeloid leukaemia (CML). 
By blocking BCR-ABL, a fusion gene frequently mutated in patients with CML, imatinib is able to inhibit 
myeloid cell growth.5, 6 In a later stage, imatinib was also found to be effective in the treatment of 
gastrointestinal stromal tumours (GIST), by inhibition of c-KIT and PDGFR-α.7 c-KIT is mutated in over 
90% of GISTs and PDGFR in most c-KIT negative GIST.8-10 Since the introduction of imatinib, overall 
survival of patients with metastatic GIST has improved drastically. Earlier, only 15% of patients with 
advanced GIST were still alive 2 years after diagnosis. Nowadays, progression free survival on imatinib 
treatment is 2-2.5 years, and 10% of patients with advanced GIST has been treated with imatinib for 
more than 10 years without progression of the disease.7, 11, 12 
The introduction of sunitinib, a multi-target tyrosine kinase inhibitor of c-KIT, PDGFR-α, PDGFR-β, 
VEGF receptors 1, 2 and 3, CSF-1R and FLT3,12-14 as a second line treatment for imatinib resistant or 
intolerant GIST further increased progression free survival from 6 weeks to 27 weeks.15 And since 
2014, even a third-line TKI (regorafenib) is approved for GIST, further improving survival.16 Besides the 
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indication as second line for GIST, sunitinib has proven efficacy in the treatment of advanced renal 
cell carcinoma and neuro-endocrine tumours of the pancreas.17, 18 These are just some examples of 
how TKIs have improved anti-cancer therapies and have been implemented in today’s anti-cancer 
treatment.
Table 1 Tyrosine kinase inhibitors
TKI Inhibited kinases Indication
Afatinib EGFR EGFR+ NSCLC19
Axitinib VEGFR-1, VEGFR-2, VEGFR-3 Renal cell cancer20
Bosutinib SRC, ABL Ph+ CML21
Cabozantinib MET, VEGFR-2, RET Medullary thyroid carcinoma22
Crizotinib ALK, HGFR, RON, ROS1 ALK+ NSCLC23
Dasatinib BCR-ABL, c-KIT, PDGFR-β, SRC, EPHA-2 Ph+ CML, Ph+ ALL24
Erlotinib EGFR
EGFR+ NSCLC, metastatic pancreas 
carcinoma25
Gefitinib EGFR EGFR+ NSCLC26
Imatinib
BCR-ABL, c-KIT, PDGFR-α, PDGFR-β, DDR-1, 
DDR-2, CSF-1R
GIST, CML, ALL, dermatofibrosarcoma 
protuberans27
Lapatinib HER2, EGFR HER2+ Breast cancer28
Nilotinib 
BCR-ABL, PDGFR-α, PDGFR-β, c-KIT, CSF-1R, 
DDR
Ph+ CML29
Pazopanib
VEGFR-1, VEGFR-2, VEGFR-3, c-KIT, PDGFR-α, 
PDGFR-β, FGFR-1, FGFR-3, LTK, LCK, c-FMS
Renal cell cancer, soft tissue sarcoma30
Regorafenib
VEGFR-1, VEGFR-2, VEGFR-3, TIE2, c-KIT, RET, 
RAF-1, BRAF, PDGFR, FGFR
colorectal , GIST31
Sorafenib
VEGFR-2, VEGFR-3, PDGFR-β, C-RAF, B-RAF, 
FLT3, c-Kit
Renal cell cancer, HCC, non-medullary 
thyroid carcinoma32
Sunitinib
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, 
PDGFR-β, c-KIT, RET, FLT3, CSF-1R
Renal cell cancer, GIST, p-NET33
Vandetanib EGFR, VEGFR-2, RET Medullary thyroid carcinoma34
Vemurafenib BRAF Braf V600E+ melanoma35
PersoNALIZeD meDIcINe
Although there is (at least) 30-35% inter-patient variability in both pharmacokinetics and 
pharmacodynamics for most TKIs, these drugs are still prescribed in a fixed dosing schedule. Side 
effects are common in TKI treatment and not occasionally patients require dose reductions or 
discontinuations due to adverse effects. Furthermore, not all patients respond similarly to TKI 
treatment. A small proportion of patients suffer from initial resistance to a drug, and regardless of 
which TKI is used for which indication, eventually all patients become drug resistant resulting in 
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tumour growth. These observations suggest that personalized medicine could further improve the 
treatment with TKIs.36, 37   
Patient selection
There are several ways to improve and personalize treatment. A first step in personalized medicine 
is defining patients who are likely to have a favourable prognostic outcome of treatment in terms 
of little side effects and long survival. These patients will potentially be the best candidates for the 
treatment. Patients with a poor prognostic outcome may be prevented from side effects without 
positive treatment effects and may possibly receive another type of treatment, which in their specific 
case has a better prognosis. Patient stratification may be based on tumour characteristics, as in the 
example of patients with GIST where patients with a specific PDGFR-α mutation, D842V, have a poor 
response to imatinib treatment.9, 38, 39 For these patients, there are no standard treatment options 
available currently, but this might change in the future.  
Therapeutic drug monitoring 
A second possibility to further personalize treatment is by defining which dose a specific patient should 
get. The  large differences in the occurrence of side effects and survival to treatments suggests that 
TKIs have a narrow therapeutic window. The therapeutic window is the plasma concentration range in 
which the drug is effective, and does not result in too much (severe) side effects. It can be visualized 
in a figure with 2 boundaries. The lower boundary represents the lowest plasma concentration that 
is necessary for the drug to be effective, the upper boundary represents the plasma concentration 
above which severe side effects occur. In the ideal situation, the plasma concentration of a drug should 
be held within these boundaries, which are drug specific (Figure 1). In treatments with a narrow 
therapeutic window, therapeutic drug monitoring (TDM) may result in a more tailored treatment with 
more efficacy and less side effects. TDM is frequently applied in the treatment with anti-epileptics, 
antibiotics and in the treatment of patients with organ transplantation.40-42 In anti-cancer therapy 
however, it is relatively new and not yet standard practise.43, 44
By applying TDM, patients start with a standard dose of the drug. At steady state, pharmacokinetics 
of the drug plasma drug concentrations are measured. If a patient’s plasma concentration falls below 
the lower boundary of the therapeutic window, the daily drug dose may be increased to reach higher 
efficacy. In case the plasma concentration is too high, the drug dose may be decreased to protect the 
patient from side effects. If the plasma concentration lies within the upper and lower boundary and 
the patient does not suffer from severe side effects, no action is required with regard to the drug dose. 
A disadvantage of TDM is that the patient starts with a standard dose. Those patients with plasma 
levels above the upper limit at the standard starting dose may already suffer from severe side-effects 
shortly after start of treatment. This may be prevented by the use of predictive models.
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Figure 1 The therapeutic window of a drug
There are several factors which may influence the pharmacokinetics of a drug, such as patient 
characteristics (i.e. age, gender, BMI), genetic variability (i.e. single nucleotide polymorphisms [SNPs] 
in drug transporters and metabolizing enzymes), lifestyle habits (i.e. smoking, diet), organ function (i.e. 
kidney and liver function), illness related factors (i.e. ascites, weight loss) and the use of co-medication 
(Figure 2).36, 45 Instead of, or besides using TDM, there are several other options to personalize the 
treatment of many drugs, including that of TKIs, by using predictors for either pharmacokinetics and/
or pharmacodynamics.
Figure 2 Factors influencing systemic drug exposure
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Predictive tests and markers 
Pharmacogenetics may be such a predictor. In pharmacogenetics, a certain SNP or combination 
of SNPs within the pharmacokinetic or pharmacodynamic pathway of the drug, may be used as a 
predictor of the outcome of treatment. The outcome may be survival rate,4 the occurrence of side-
effects,46 or exposure to the drug.47
To further personalize treatment, phenotyping probes may also be applied. By using phenotyping 
probe testing, a compound with comparable pharmacokinetics as the drug of interest is administered 
to the patient. Afterwards, pharmacokinetic sampling of the mother compound and, if applicable, 
the (active) metabolite of the probe take place. As the probe and the drug of interest follow a similar 
pattern of uptake, metabolism and excretion, the ratio between the mother compound and the 
metabolite of the probe serve as a measure of the pharmacokinetic processes within that specific 
patient, regardless of possible factors that may influence the pharmacokinetics. Therefore, this may 
predict the pharmacokinetics of the drug of interest in the patient. In case of an accurate prediction, 
patients who show high  levels of the phenotyping probe, will also show high levels of the drug of 
interest. This may particularly be useful in the treatment with drugs with severe side effects, as 
these can be avoided by starting at lower dose levels in patients who are prone to high drug levels. 
Phenotyping probes are usually drugs with little or no side effects (exogenous markers), but may 
also be a compound which is naturally present within the body (endogenous markers). In anticancer 
treatment, dextromethorphan, an ingredient of cough syrup and metabolized by both CYP2D6 and 
CYP3A, is such a phenotyping probe for tamoxifen, an anti-hormone drug that is frequently applied 
in the treatment of women with breast cancer.48 An example of an endogenous marker, which may 
serve as a phenotyping probe, is the 4β-hydroxycholesterol/cholesterol ratio as a marker for CYP3A4 
activity.49
Also, the occurrence of specific side effects may serve as marker for treatment efficacy. This was 
previously shown in patients with renal cell carcinoma. Patients who developed hypertension, caused 
by inhibition of the tyrosine kinase VEGFR, had a mean increase in overall survival of 7.2 months, 
compared to patients who did not develop hypertension.50, 51 Another example is the occurrence of 
rash in the treatment of patients with lung cancer with erlotinib. Patients that do not develop a skin 
rash usually have a poor response to erlotinib.52 
Although it is well known that patients treated with TKIs show broad inter-individual variations 
in pharmacokinetics, prospective studies investigating exposure-effect and exposure-toxicity 
relationships are limited.53 In the treatment of sunitinib, a combined trough level of sunitinib and 
its active metabolite N-desethylsunitinib of at least 50 ng/mL is thought to be necessary for the 
drug to be effective in anti-cancer treatment. However, this trough level is based on preclinical and 
retrospective studies.13, 54-56 So far, no prospective studies have been performed to evaluate whether 
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TDM of sunitinib, using the combined trough level of at least 50 ng/mL as a target value, results in 
longer progression free survival than standard dosing which is currently applied. This accounts for 
most studies on TKIs, and prospective randomized controlled trials in this field are warranted before 
TDM can be applied in clinical practice.53
The work described in this thesis includes research that focuses on a pharmacokinetic approach 
towards improved sunitinib treatment (chapter 2-4), and research that focuses on pharmacodynamic 
aspects of TKI treatment (chapter 5-8). In chapter 2, hepatobiliary clearance of technetium-99m-
2-methoxy isobutyl isonitrile (99mTc-MIBI), as a phenotyping probe for the adenosine triphosphate 
binding cassette transporter ABCB1 and midazolam clearance test as a probe for cytochrome P450 
3A (CYP3A) were correlated to sunitinib pharmacokinetics. Furthermore, sunitinib exposure was 
correlated to the occurrence of severe side effects due to sunitinib. Although it has been suggested 
that patients who are treated with sunitinib may benefit from TDM, it was not known whether TDM 
of sunitinib is safe. Therefore, a feasibility study was performed in patients treated with sunitinib in a 
phase I clinical trial (chapter 3). Sunitinib dose was elevated when total trough levels of sunitinib and 
its active metabolite SU12662 dropped below a pre-defined target level of 50 ng/mL, and sunitinib 
dose was decreased when patients suffered from unacceptable toxicity.
Circadian rhythms exist throughout the body. They originate in the suprachiasmatic nucleus (SCN) in 
the hypothalamus, which is stimulated by photo neurons in the eyes.57 The pharmacokinetic processes 
absorption, distribution, metabolism and excretion are also thought to be subjected to circadian 
rhythms,58-60 resulting in intra-individual variations in drug pharmacokinetics based on administration 
time. Such variations may also exist in the treatment with sunitinib. chapter 4 describes the results of 
preclinical and clinical studies of chronicity in sunitinib pharmacokinetics. Studies were performed in 
immortalized hepatic cells, mice and patients treated with sunitinib as standard of care. 
As previously mentioned, another approach towards personalized treatment is by predicting 
treatment response and toxicity levels based the pharmacogenetic profile of the patient. In chapter 5 
and chapter 6, the efficacy of respectively imatinib and sunitinib treatment in patients with GIST was 
associated with SNPs within genes comprising the pharmacokinetic and pharmacodynamic pathway 
of the drug. 
The last chapters of this thesis focus on the occurrence of specific side-effects in the treatment of TKIs.
QTc prolongation is a possibly dangerous side-effect of many drugs, which in some cases, such as 
rofecoxib (Vioxx), results in withdrawal of the drug from the market. It is usually caused by inhibition of 
the human ether-à-go-go- related gene (hERG) , within the cardiomyocyte.61 Blocking of this potassium 
channel prevents potassium to rapidly flow out of the cell, resulting in prolonged repolarization which 
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is seen is on the surface electrocardiogram as a prolongation of the QTc interval. For many anti-cancer 
drugs, including TKIs, information on the effect of the drug on the QTc interval is lacking. In chapter 
7, the prolongation of the QTc interval after start of TKI treatment was investigated in 363 patients 
treated with 8 different TKIs. 
Several studies have described an increase in the mean corpuscular volume or erythrocytes after start 
of sunitinib or imatinib.62-66 Since both sunitinib and imatinib are inhibitors of c-KIT, and no other cause 
of macrocytosis could be appointed, this has led to the hypothesis that the increase in MCV may be 
specific for c-KIT-inhibiting TKIs. In chapter 8, we describe which TKIs result in an increase of the MCV 
in a population of 550 patients from the Erasmus MC Cancer Institute. Furthermore, we show that 
macrocytosis can be used as a predictor of survival in renal cell cancer patients treated with sunitinib.
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ABsTrAcT
Background and objective
The wide inter-patient variability in drug exposure partly explains the toxicity and efficacy profile of 
sunitinib treatment. In this prospective study CYP3A and ABCB1 phenotypes were correlated to the 
pharmacokinetics of sunitinib and its active metabolite N-desethylsunitinib. 
methods 
A correlation analysis was performed between sunitinib pharmacokinetics and 1’OH-midazolam/
midazolam ratio and parameters derived from 99mTc-MIBI scans, respectively. A population 
pharmacokinetic model (NONMEM) was built, which included the phenotype tests as covariate.  
results 
In 52 patients, the mean trough level of sunitinib plus metabolite increased from 21.4 ng/mL at 
day 1 of a cycle to 88.1 ng/mL in the 4th week of treatment. A trend for a correlation was observed 
between 99mTc-MIBI elimination constant and trough levels of N-desethylsunitinib, however, this was 
not significant. Correlations were found between 1’OH-midazolam/midazolam ratio and sunitinib 
clearance (P = 0.008) and day 1 N-desethylsunitinib trough concentrations (P = 0.005), respectively. 
Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than 
patients without grade 3 toxicities (34.4 L/h vs. 41.4 L/h; P = 0.025). 
conclusions 
Phenotype tests for ABCB1 and CYP3A4 did not explain inter-individual variability of sunitinib exposure 
sufficiently. However, the correlation between sunitinib clearance and the occurrence of severe 
toxicity suggests a direct exposure-toxicity relationship.
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INTroDucTIoN 
Sunitinib malate (Sutent®; Pfizer Pharmaceuticals Group, NY, USA) is an oral multi-targeted tyrosine 
kinase inhibitor with antitumor and anti-angiogenic activities. It is approved for first-line treatment 
of metastatic renal-cell cancer (mRCC), imatinib-resistant metastatic gastrointestinal stromal tumors 
(GIST) and pancreatic-neuroendocrine tumors (p-NET).1-3
Regular treatment schedules for mRCC and GIST consist of a flat-fixed daily dose of 50 mg (4 weeks on, 2 
weeks off) and for p-NET a flat-fixed daily dose of 37.5 mg continuously. However, dose reductions due 
to toxicity are frequently necessary (almost one in every 3 patients).1, 2, 4 Moreover, a small proportion 
of patients tolerate doses higher than 50mg daily without significant toxicity.5 A plausible explanation 
for this wide range in tolerable dose is the wide inter-patient variability in sunitinib drug exposure. 
This variability may result from differences in activity of drug metabolizing enzymes and transporters. 
To determine the activity of sunitinib metabolism in individual patients, so-called phenotype tests may 
be applied. Phenotype tests consist of the administration of a “model” or probe drug metabolized by 
an individual specific enzyme or transporter. This means that an easily detectable and safe compound 
of which the pharmacokinetic fate highly correlates with that of the drug of interest is administered to 
the patient, and different pharmacokinetic parameters of the probe drug and its metabolites, or the 
determination of a ratio between the drug and its metabolite (metabolic ratio; MR), are determined.6 
By measuring this MR, the activity of an enzyme or transporter of interest may be estimated at a 
certain moment of time, which allows the definition of an individual metabolic profile. In other words, 
the pharmacokinetics of this compound (or ‘probe’-drug) may act as a predictor for enzymatic or 
transporter function.7   
Midazolam is such a probe-drug for cytochrome P450 3A (CYP3A) as it is exclusively metabolized 
by CYP3A. CYP3A activity has been successfully associated with the pharmacokinetics and 
pharmacodynamics of several anti-cancer drugs, including docetaxel8 and irinotecan.9 One of 
the possible drawbacks of phenotype tests is the occurrence of side effects from the probe drug. 
Microdoses of midazolam have, therefore, been validated 10. The ratio between total 1’OH-midazolam 
and midazolam plasma concentration 30 minutes post-administration is now used as a predictor of 
CYP3A activity.10, 11
ABCB1 is an adenosine triphosphate binding cassette (ABC) transporter, involved in hepatic clearance 
of many classes of anticancer drugs, including sunitinib. Hepatobiliary clearance of technetium-99m 
(99mTc)-2-methoxy isobutyl isonitrile (MIBI) is markedly reduced in the presence of ABCB1 inhibitors 
in humans.12, 13 Thus, it is likely that ABCB1 is the principle mediator of 99mTc-MIBI elimination. 
Hepatic scans provide a 99mTc-MIBI elimination constant (kH) and can be used as a probe of ABCB1 
activity.14 Hepatic 99mTc-MIBI clearance (kHxliver volume) has previously been studied as a predictor of 
vinorelbine clearance.15
As sunitinib is primarily metabolized by CYP3A (Figure 1), resulting in the formation of its active 
metabolite N-desethylsunitinib, midazolam is a putative probe-drug for sunitinib metabolism.16 The 
hepatic elimination of sunitinib is primarily mediated by ABCB1 and ABCG2.17 Therefore, hepatic 99mTc-
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MIBI scan, as a probe for ABCB1, may also serve as a possible predictor of sunitinib pharmacokinetics.
The primary aim of this study was to investigate whether these CYP3A and ABCB1 phenotype probes 
correlate with the clearance of sunitinib (‘ClearSun’), and may therefore be used as a predictor of 
sunitinib exposure. This may ultimately be used in clinical practice to dose this drug on an individualized 
way, instead of the current flat-fixed dosing standard. As a secondary aim, we studied the association 
between drug exposure and sunitinib-induced toxicity.
meTHoDs
In four centres in Australia (Westmead Hospital, Sydney and Canberra Hospital, Garran) and the 
Netherlands (Erasmus MC Cancer Institute, Rotterdam and Academic Medical Centre, Amsterdam), 
patients with solid tumours treated with single agent sunitinib were asked to participate in this study 
between February 2009 and September 2011. Patients were eligible at any cycle during treatment, 
and all dose levels of sunitinib were allowed in the study. Additional eligibility criteria were age at 
least 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; adequate 
hematopoietic, hepatic, and renal functions. Patients were excluded for any significant systemic 
disorders and pregnancy. All patients provided informed consent according to federal and institutional 
guidelines. The trial was conducted in accordance with current Good Clinical Practice and approved by 
the local ethical committee.
study design
This was a prospective pharmacokinetic study of patients treated with sunitinib. Patients were asked 
to undergo three study tests at day 1 of a new treatment cycle and in the fourth week of continuous 
treatment. Study tests consisted of pharmacokinetic sampling of sunitinib concentrations, 1’OH-
midazolam/midazolam MR assessment and 99mTc-MIBI liver scans at both time-points during the 
study. Demographic and clinical data of patients were reported on case record forms designed for 
data collection in this study. All plasma samples for pharmacokinetics on sunitinib and midazolam, and 
the performed 99mTc-MIBI lever scans were anonymized by a third party, according to the instructions 
stated in the Codes for Proper Use and Proper Conduct in the Self-Regulatory Codes of Conduct (www.
federa.org). 
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Figure 1  Schematic figure for sunitinib, midazolam and 99mTc-MIBI metabolism and/or transport. Abbreviations: 
99mTc-MIBI, technetium-99m-2-methoxy isobutyl isonitrile; CYP3A, cytochrome P-450 enzyme 3A; ABCB1; ATP-
binding cassette sub-family B member 1; ABCG2, ATP-binding cassette sub-family G member 2; min, minutes
Pharmacokinetic sampling of sunitinib
Pharmacokinetic blood withdrawal was performed on day 1 and at repeated continuous dosing of 
sunitinib treatment and stored at -80°C at the participating center. A limited blood sampling regimen 
was used with accurately timed blood samples taken pre-dose and at t=4h, t=8h and t=24h after 
sunitinib administration. All pharmacokinetic measurements of sunitinib were undertaken at the 
Laboratory of Translational Pharmacology of Erasmus MC Cancer Institute. Sunitinib and its active 
metabolite N-desethylsunitinib in human plasma were quantified using a validated UPLC-MS/MS 
method consisted of a Waters Acquity UPLC sample manager coupled to a triple quadruple mass 
spectrometer operating in the multiple reaction monitoring mode (MRM) with positive ion electrospray 
ionisation (Waters, Etten-Leur, The Netherlands). The multiple reaction monitoring transitions were 
set at 399→326, at 371→283 and at 409→326 for sunitinib, N-desethylsunitinib and the deuterated 
internal standard sunitinib-d10, respectively. Chromatographic separations were achieved on an 
Acquity UPLC® BEH C18 1.7 µm 2.1 x 50 mm column eluted at a flow-rate of 0.250 mL/min on a gradient 
of acetonitrile. The overall cycle time of the method was 4 minutes. The calibration curves were linear 
over the range of 0.200 to 50.0 ng/mL with the lower limit of quantification validated at 0.200 ng/
mL for both sunitinib and N-desethylsunitinib. As sunitinib was found to be extremely sensitive to 
light causing the Z (cis)-isomer to rapidly convert to the E (trans)-isomer, the sample extraction and 
cleaning-up were performed under sodium light and in amber vials. The extraction of 100 µL of plasma 
involved a simple liquid-liquid extraction with tert-butyl methyl ether.18
Plasma concentrations were corrected for dose-adjustment, using the assumption that dose 
adjustment of sunitinib results in equally adjusted exposure to sunitinib and its active metabolite. 
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1’oH-midazolam/midazolam metabolic ratio assessment
A micro-dose of midazolam (75 μg) was administered orally before sunitinib administration as a 
measure of CYP3A activity as previously validated.10 1’OH-midazolam/midazolam MR was determined 
30 minute post-administration in a single plasma sample using liquid chromatography tandem mass 
spectrometry as previously described.19 Midazolam and 1-hydroxymidazolam were quantitated 
using a fully validated method with an API 4000 triple quadruple mass spectrometer (AB Sciex, 
Concord, ON, Canada) coupled to an Agilent series 1100 (Waldbronn, Germany) LC system. The 
mass spectrometer was operated in the multiple reaction monitoring (MRM) mode with positive ion 
electrospray ionization. The MRM transitions were 326→291, 342→324 and 330→295 midazolam, 
1-hydroxymidazolam and internal standard midazolam-d4 (IS), respectively. Chromatography was 
performed on a Phenomenex Kinetex C18 analytical column (50 mm × 2.1 mm, 2.6 μm; Torrance, CA, 
USA) using water and acetonitrile with 0.1% formic acid under gradient conditions. One ml of plasma 
was submitted to enzymatic hydrolysis using β-glucuronidase and a liquid-liquid extraction procedure 
was performed using hexane-chloroform as previously described.10 The limits of quantification were 
0.05 and 0.1 ng/ml for midazolam and 1-hydroxymidazolam, respectively. 
All pharmacokinetic measurements on midazolam were performed by the department of Clinical 
Pharmacology & Toxicology of Geneva University Hospitals (Switzerland) using the method described 
by de Loor et al.19
Hepatic technetium labelled sestamibi (99mTc-mIBI) clearance
Within 2 days before the start of the treatment and after repeated daily dosing, hepatic elimination of 
99mTc-MIBI was determined and interpreted as an indicator of ABCB1 (P-glycoprotein, MDR1) activity.14 
A correlation analysis was performed between 99mTc-MIBI kH and both sunitinib dose-adjusted trough 
levels and clearance. All hepatic 99mTc-MIBI scans were interpreted by a single person (M.W.) at 
Westmead Hospital, Sydney, Australia.
Definition of Toxicity
All adverse events were graded according to National Cancer Institute-Common Terminology 
Criteria for Adverse Events version 3.0 scores at the participating centres. Clinical symptoms and 
haematological abnormalities were considered drug induced, such as: fatigue, mucosal inflammation, 
hand-foot syndrome, thrombocytopenia, neutropenia and any other adverse events higher than grade 
2. The considerations if an adverse event is related to sunitinib treatment were up to the investigators 
discretion. 
statistical Design and Data Analysis
To correlate phenotype tests (1’OH-midazolam/midazolam MR and hepatic 99mTc-MIBI scans) with 
sunitinib dose-adjusted trough levels, Spearman’s correlation coefficient was calculated using SPSS 
version 17.0. The paired Student’s t-test was used to compare sunitinib trough levels, 1’OH-midazolam/
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midazolam MR assessments and 99mTc-MIBI kH at day 1 of a treatment cycle and after repeated daily 
dosing. 
A population PK model was developed in order to identify the correlation between both phenotype 
tests and clearance of sunitinib and N-desethylsunitinib. Nonlinear mixed effects modeling (NONMEM 
version 7.1, ICON, Ellicot City, Maryland, USA with Piraña as modeling environment20) was used to 
develop an integrated base compartmental model for sunitinib (2-compartmental model) and 
N-desethylsunitinib (1-compartmental model) (Supplementary figure 120, 21). This base pharmacokinetic 
(PK) model was selected according to change in objective function value ( OFV,  D OFV > 3.84, P < 
0.05), successful minimization, successful covariance estimation, and goodness-of-fit plots. Parameter 
estimation was performed by first order conditional estimation method with interaction. Due to 
unknown bioavailability (F), all the parameter estimates (except for absorption rate constant of 
sunitinib (k
a,p
)) were presented as apparent terms relative to F. For N-desethylsunitinib, parameters 
were estimated relative to F and fm, the fraction sunitinib metabolized to N-desethylsunitinib. Ka,p was 
fixed to 0.195 h-1 according to the result from an informative sunitinib modeling.22 Inter-individual 
variability (IIV) in all parameters was described by an exponential error term and provided as both 
percentage of coefficient variation (%CV) and variance (calculated as (%CV/100)2). And the residual 
error was modeled using a combined error model with additive error terms fixed to lower limit of 
quantification (LLOQ). Results presented in Supplementary table 1.
Subsequently, the phenotype tests were tested as covariates on clearance parameters for both 
compounds in a univariate analysis. P-values were calculated by chi-squared distribution from D OFV. 
Goodness-of-fit was judged by various graphical and statistical measures.23
The independent t-test was used to test a possible correlation between both sunitinib clearance and 
dose-adjusted trough levels and the occurrence of toxicities, as well as for the correlation between 
both phenotype tests and the occurrence of toxicities.
A probability value of less than 0.05 was considered statistically significant.
resuLTs
 
Patient characteristics
A total of 52 patients were enrolled in this study. Forty-two of all participating patients underwent a 
midazolam clearance test at start of a new cycle and in the fourth week of treatment (steady state). 
A total of 39 patients had 99mTc-MIBI scans of the liver at both time points and were evaluable for the 
analysis. Of the 52 patients enrolled in this study, 28 patients had undergone a dose reduction or 
temporary discontinuation of treatment due to toxicity. As sunitinib has linear pharmacokinetics, a 
dose-reduction could not have influenced the outcomes of this study.24 Patient’s demographics and 
disease characteristics are summarized in Table 1.
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Table 1 Patient characteristics
characteristic Value
Total no. of patients 52
Age (years) 59 (29-81)
Sex
                 Male 33 (64)
                 Female  19 (36)
Mean BSA m2 2.01
   Range 1.26-2.5
Ethnicity
                 Caucasian 47 (90)
                 Asian 3 (6)
                 Hispanic 1 (2)
                 Other 1 (2)
Type of malignancy
                 RCC 43 (83)
                 p-NET                    7 (13)
                 GIST 2 (4)
ECOG performance status
                0 29 (56)
                1 21 (40)
                2 2 (4)
Duration of treatment (months) 9 (0-54)
Dose of sunitinib 
                 0 mga 6 (12)
                 25 mg 6 (12)
                 37.5 mg 14 (26)
                 50 mg 26 (50)
Previous dose reduction 28 (54)
Values are expressed as mean (range) or n (%)
Abbreviation: N, number of patients; BSA, Body Surface Area; RCC, renal cell carcinoma; p-NET, pancreatic 
neuro-endocrine tumor; GIST, gastrointestinal stromal tumor; ECOG, Eastern Cooperative Oncology Group
a Patients who did not use sunitinib by the time of pharmacokinetics measurements were excluded from the 
analysis 
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sunitinib pharmacokinetics and drug elimination phenotype
Mean combined trough levels of sunitinib and N-desethylsunitinib, adjusted for dose, were 21.4 ng/
mL (range 10.5 - 38.3 ng/mL) at day 1 of a new course, and 88.1 ng/mL (range 22.3 - 189.7 ng/mL) in 
the 4th week of a treatment cycle (mean difference 66.7 ng/mL, P < 0.005; Table 2). In the population 
PK model, a mean clearance of 36.5 L/h for sunitinib and metabolic clearance of 91.3 L/h for the 
metabolite was estimated (Supplementary Table 1). 
A good correlation between 1’OH-midazolam/midazolam MR on the 1st day and in the 4th week of a 
treatment cycle was found (P = 0.003), as well as between hepatic 99mTc-MIBI kH at day 1 and week 4 
(P < 0.001, Supplementary Figure 2). 
The 1’OH-midazolam/midazolam MR did not significantly correlate with combined trough levels of 
sunitinib and metabolite at steady state (n = 42, P = 0.22, Table 3). However, the ratio correlated with 
N-desethylsunitinib levels at 24 hours after first intake of sunitinib in the first course of treatment (n 
= 21, P = 0.005, Figure 2). There was no correlation between 1’OH-midazolam/midazolam MR and 
N-desethylsunitinib/sunitinib MR at steady state (n = 42, P = 0.60). The correlations between hepatic 
99mTc-MIBI kH and N-desethylsunitinib trough levels during any course were substantial, although not 
significant (n = 39, P = 0.067).
At steady state, the 1’OH-midazolam/midazolam MR weakly correlated with the clearance of sunitinib 
(n = 42, P = 0.0081), but not with clearance of N-desethylsunitinib (n = 42, P = 1). 
We found no significant correlation between hepatic 99mTc-MIBI kH and sunitinib clearance or 
N-desethylsunitinib clearance (n = 39, P = 1). 
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Table 2 Pharmacokinetics of sunitinib and N-desethylsunitinib, and CYP3A and ABCB1 phenotype tests during 
treatment with sunitinib.
n Day 1 n steady-state Difference P
mean
Pharmacokinetic measurementsa
Sunitinib trough level (ng/mL) 51 16.4 ±5.4 46 57.9 ±22.5 
(19.1-151.1)
41.6 <0.005
(7.2-28.9)
N-desethylsunitinib (ng/mL) 51 5.0 ±2.4 46 30.1 ±12.8 25.2 <0.005
(1.5-13.0) (3.2-57.8)
Sum (ng/mL) 51 21.4 ±6.7 46 88.1 ±31.4 
(22.3-189.7)
66.7 <0.005
(10.5-38.2)
Phenotype tests
1’OH- midazolam/midazolam 
metabolic ratio
48 2.73 ±2.18 42 2.78 ±2.0 0.05 0.86
(0.3-9.9) (0.2-7.9)
99mTc-MIBI scanb 48 1.23 ±0.66 42 1.19 ±0.53 
(0.45-2.81)
0.05 0.55
(0.42-3.56)
Values are expressed as mean ±SD (range)
Abbreviations: 99mTc-MIBI, technetium-99m-2-methoxy isobutyl isonitrile
a all pharmacokinetic measurements were adjusted for dose
b described as distribution of elimination constant (kH) min-1 x 10-2
Table 3 Correlation between pharmacokinetics and phenotype tests at steady state
Parameter 1’oH- midazolam/midazolam mr 99mTc-mIBI scan
(r2/Δ oFV, P-value)
(r2/P-value)
C
trough
 sunitiniba 0.06 (0.126) 0.01 (0.540)
C
trough
 N-desethylsunitiniba 0.01 (0.478) 0.09 (0.067)
Suma 0.04 (0.217) 0.01 (0.520)
CL sunitinib 6.992 (0.0081) 0 (1)
CL N-desethylsunitinib 0 (1) 0 (1)
a trough levels at steady state treatment
Abbreviation: C-trough, trough concentration; CL, clearance; R2, correlation coefficient; OFV, Objective 
Function Value; 99mTc-MIBI, technetium-99m-2-methoxy isobutyl isonitrile 
Chapter 2
2
33
Figure 2 Correlation (R = 0.59, P = 0.005) between 1’OH-midazolam/midazolam MR (x-axis) and  N-desethylsunitinib 
trough concentration after the first intake of sunitinib (y-axis). Each dot expresses an individual patient; the line 
expresses the correlation coefficient.
Abbreviation: MR, metabolic ratio
Toxicities
All patients experienced at least grade 1-2 toxicity from sunitinib treatment. Twenty-two (42%) of 52 
patients suffered from grade 3 toxicities and 28 patients (54%) underwent a dose reduction at any time 
Hand-foot syndrome was the most frequently reported grade 3 toxicity, occurring in 6 patients (12%, 
Table 4). Interestingly, patients with any type of grade 3 toxicity had a significantly lower clearance 
of sunitinib than patients without grade 3 toxicities (34.4 L/h vs. 41.4 L/h; P = 0.025), suggesting an 
exposure-toxicity relationship. Combined trough levels of sunitinib and metabolite at steady state were 
positively correlated with the occurrence of fatigue (P = 0.007). There was no significant correlation 
between 1’OH-midazolam/midazolam MR and occurrence of severe toxicities (P = 0.23).
No toxicities were seen as a result of the use of the midazolam clearance tests or the 99mTc-MIBI-scans.
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Table 4 Toxicity seen during treatment with sunitinib.
Adverse effect Grade 1 – 2 Grade 3 
NoN-HemAToLoGIcAL
Fatigue 42 (81) 4 (8)
Stomatitisa 33 (63) 2 (4)
Diarrhea 31 (60) 2 (4)
Nausea 21 (40) 4 (8)
Hand-foot syndrome 21 (40) 6 (12)
Hypertension 21 (40) 5 (10)
Anorexia 20 (39) 1 (2)
Taste alterations 21 (40)  
Skin rash 19 (37)
Hypothyroidism  7  (14)
Any  52 (100) 22 (42)
HemAToLoGIcAL
Thrombocytopenia 25 (48)
Leukopenia 25 (48)
Values are expressed as n (%).
Abbreviation: n, number of patients 
a Stomatitis including aphetic ulceration and mucositis of the mouth.
DIscussIoN
Considering that sunitinib is mainly metabolised by CYP3A4 to its active metabolite N-desethylsunitinib, 
and eliminated in the liver by ABCB1 (and ABCG2) transporters, probe drugs for CYP3A and ABCB1 
activity were used in this study. Earlier publications suggested that midazolam clearance or MR, and 
hepatic 99mTc-MIBI elimination scans can be used as a predictor of CYP3A activity and ABCB1 activity, 
respectively.10, 25, 26
Although in the current study a significant correlation between 1’OH-midazolam/midazolam MR and 
the clearance of sunitinib was found, no correlation was seen between 1’OH-midazolam/midazolam 
MR and the active metabolite of sunitinib. This is somewhat surprising, as the conversion of sunitinib 
into N-desethylsunitinib is thought to be fully CYP3A-mediated.16 The elimination of N-desethylsunitinib 
by other pathways or by efflux transport may have interfered, resulting in this negative outcome. 
Variable drug uptake may also have confounded an existing relationship. Furthermore, considering 
first order kinetics, non-continuous dosing of midazolam may have influenced the outcome. To predict 
sunitinib metabolism by use of an ABCB1 probe, we correlated the hepatic 99mTc-MIBI elimination 
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constant with the clearance of, and exposure to, sunitinib and its active metabolite. We found no 
significant correlations between hepatic clearance of 99mTc-MIBI and pharmacokinetic measurements 
of sunitinib. However, a substantial, although not significant, correlation was seen between 99mTc-MIBI 
kH and trough concentrations of N-desethylsunitinib. Sunitinib is eliminated by a number of efflux 
transporters other than ABCB1, such as ABCG2, and so 99mTc-MIBI elimination may be an incomplete 
probe for biliary elimination of this drug.16 On the other hand, the stronger correlation between the 
99mTc-MIBI and the sunitinib metabolite, suggests that ABCB1 is relatively more important than ABCG2 
in the transport of N-desethylsunitinib. 
A strong correlation was seen in hepatic 99mTc-MIBI kH between the first day and fourth week of a 
treatment cycle, indicating that the ABCB1 efflux transporter is not affected by sunitinib treatment 
over this time period. Also for 1’OH-midazolam/midazolam MR, a significant correlation was seen 
between the first day and fourth week of treatment, although the correlation coefficient was low. In 
addition, there was a large inter-individual variation in 1’OH-midazolam/midazolam MR, suggesting a 
substantial inter-individual variation in CYP3A activity. 
Various drugs are well-known modulators of CYP3A4 activity, but no CYP3A4 inhibitors or inducers 
were started or stopped during the study period. Hypothetically, four weeks of sunitinib treatment 
may have affected CYP3A activity, leading to an altered 1’OH-midazolam/midazolam ratio. Other 
factors which may potentially change CYP3A activity, such as food intake, smoking and daily variation 
in drug intake may also have caused this variation.27, 28
All patients in our study experienced at least grade 1 toxicity and 42% of them had grade 3 toxicity. 
There was a significantly lower clearance of sunitinib in patients with grade 3 toxicity, as previously 
prescribed by Houk et al.29 These data suggest a direct relationship between exposure to sunitinib and 
toxicity, and emphasize the need of a more tailored sunitinib treatment than current clinical practice. 
Thirty-three patients in our study suffered from any grade of diarrhea, as an indicator of mucosal 
inflammation. Inflammation  may suppress drug metabolizing enzymes and efflux transporters and 
may hypothetically be the cause of increased levels of sunitinib. 
coNcLusIoN
Overall, we may conclude that although 1’OH-midazolam/midazolam MR may significantly correlate 
with measures of sunitinib pharmacokinetics, it does not predict variability in sunitinib exposure 
sufficiently to be useful in a clinical dosing-strategy. The same is true for the ABCB1 probe tested. 
However, this study provides important new information to unravel the clinical pharmacokinetics of 
sunitinib.  Additional research remains necessary to provide more information on the variability in 
the pharmacokinetics of sunitinib. For example, possibly pharmacogenetic variation in genes coding 
for transporters or enzymes, like CYP3A*22, may explain pharmacokinetic variation for a large(r) 
part.30 Furthermore, therapeutic drug monitoring can contribute to tailored sunitinib treatment,30, 
31 although this can only be applied after the start of treatment Ultimately, to prevent patients from 
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toxicity shortly after start of treatment, possible phenotyping probes should be used to determine the 
starting dose, and therapeutic drug monitoring to determine dose levels during treatment. Hopefully, 
all these efforts will provide tools to finally optimize the dosing of sunitinib, leading to a minimum of 
side-effects and a maximized anti-tumour effect.31
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supplementary table 1 Parameter estimated of the base model for sunitinib and N-desethylsunitinib
Parameter estimate (rse) IIV, 
%cV
 (rse) IIV,
variance
sunitinib
    CL,p, L·h-1 36.5 (5.5%) 31.2% (10.9%) 0.0974
    k
a.p
, h-1 0.195 - -
    Vc,p, L 616 (23.1%) 74.4% (19.5%) 0.553
    Q,p, L·h-1 281 (11.0 %) - -
    Vp,p, L 1800 (9.1%) 41.2% (12.9%) 0.170
    Proportional error 0.0459 (17.9%) - -
    Additive error, ng/mL 0.2 - -
N-desethylsunitinib
    CL,m, L· h-1 91.3 (6.8%) 43.6% (8.1%) 0.190
    Vc,m, L 358 (18.3%) - -
    Proportional error 0.0473 (20.2%) - -
    Additive error, ng/mL 0.2 - -
supplementary figure 1 PK model for sunitinib and N-desethylsunitinib. K
a,p
: absorption rate constant of sunitinib; 
Vc,p: apparent central volume distribution of sunitinib; Vp,p: apparent peripheral volume distribution of sunitinib; 
Q: apparent intercompartmental  flow of sunitinib; CL,p: apparent clearance of sunitinib; Vc,m: apparent volume 
distribution of N-desethylsunitinib; CL,m: apparent clearance of N-desethylsunitinib.
Dose 
sunitinib
Central
sunitinib
Vc,p
Central
N-desethylsunitinib
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supplementary figure 2 Correlation in 1’OH-midazolam/midazolam MR (A) and hepatic 99mTc-MIBI kH (B) between 
the first day and fourth week of sunitinib treatment. Each dot expresses an individual patient; the line expresses 
the correlation coefficient. 
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ABsTrAcT
Background Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a 
pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing 
based on PK levels.
methods Patients were treated with sunitinib 37.5 mg once daily. At day 15 and 29 of treatment, 
plasma trough levels of sunitinib and N-desethyl sunitinib were measured. If the total trough level 
(TTL) was <50 ng/mL and the patient did not show any grade ≥3 toxicity, the daily sunitinib dose was 
increased by 12.5 mg. If the patient suffered from grade ≥3 toxicity, the sunitinib dose was lowered 
by 12.5 mg. 
results Twenty-nine out of 43 patients were evaluable for PK assessments. Grade ≥3 adverse events 
were experienced in seven patients (24%) at the starting dose and in nine patients (31%) after dose 
escalation. TTLs were below target in 15 patients (52%) at the starting dose. Of these, 5 patients (17%) 
reached target TTL after dose escalation without additional toxicity.  
conclusion In a third of the patients that were below target TTL at standard dose, the sunitinib dose 
could be increased without additional toxicities. This could be the basis for future studies and the 
implementation of a PK-guided dosing strategy in clinical practice.
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INTroDucTIoN
Sunitinib (Sutent®) has proven efficacy as single agent in several solid tumor types and is approved 
for use in advanced renal cell cancer (RCC), imatinib-resistant or -intolerant gastrointestinal stromal 
tumors (GISTs) and pancreatic neuroendocrine tumors (pNET).1-3 Recent findings demonstrated 
a positive dose-efficacy relationship for sunitinib treatment.4 As deduced from pharmacokinetic/
pharmacodynamic preclinical data, target total plasma concentrations of sunitinib plus active 
metabolite (N-desethylsunitinib) are in the range of 50 to 100 ng/mL.5-9 In line with these preclinical 
data, total trough levels (TTLs) below 50 ng/mL have been associated with decreased therapeutic 
efficacy in patients compared to patients with TTL above this level.7 It is therefore hypothesized that 
for optimal sunitinib therapy a TTL above 50 ng/mL should be reached in each individual patient. 
However, sunitinib exposure shows considerable variation due to patient non-compliance (for 
example due to drug-related toxicity), drug interactions with co-medication, variability in oral drug 
availability and many other factors.10 Despite this considerable inter-patient variability in systemic 
exposure, sunitinib is currently prescribed at a fixed dose. Given the narrow therapeutic index, the 
large inter-individual variability in systemic exposure, and the positive exposure-efficacy relationship, 
there is a strong rationale for pharmacokinetically (PK) guided dosing also known as therapeutic drug 
monitoring (TDM) of sunitinib.4, 7, 11 Such an approach could contribute to a tailor made sunitinib 
treatment with improved therapeutic efficacy and decreased risk for toxicity.12
Thus far, no prospective clinical trials investigating the safety and efficacy of PK guided dosing for sunitinib 
therapy have been performed. Hence, the ultimate proof that reaching target trough concentrations 
increases treatment efficacy remains to be awaited. As a first step towards individualized PK based 
dosing, we investigated the safety and feasibility of PK-guided sunitinib dosing in a pilot study by 
measuring sunitinib trough levels. The main purpose of the study was to assess whether PK-guided 
dosing could be performed without causing additional toxicities. Establishing a feasible and safe PK-
guided dosing strategy could provide a rationale for a large prospective clinical trial. 
meTHoDs
Patient population
This multicenter prospective pilot trial (NCT01286896) was initiated in 2011 and was performed 
in three medical centers in The Netherlands. Eligible patients were patients with histologically or 
cytologically confirmed advanced tumors for which sunitinib was considered standard therapy or 
patients with advanced or metastatic tumors for whom no standard therapy was available. 
Other inclusion criteria included age ≥ 18 years; an Eastern Cooperative Oncology Group (ECOG) 
performance status ≤ 1; measurable or evaluable disease according to Response Evaluation Criteria 
Solid Tumors (RECIST) 1.1 criteria; estimated life expectancy > 12 weeks; adequate hematologic, 
hepatic and renal function; no cardiac instability within the previous six months. Additionally, patients 
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should be able and willing to undergo blood sampling; and patients should be able to swallow oral 
medication.
The protocol was approved by local independent ethics committees, and the study was conducted in 
accordance with the Declaration of Helsinki. All patients received information regarding the purpose 
and conduct of this study and provided written informed consent. 
study design
Eligible patients started treatment at a dose level of 37.5 mg sunitinib once daily continuously. At day 
15 of sunitinib treatment, TTLs of sunitinib plus N-desethylsunitinib were measured. If the TTL was 
<50 ng/mL and the patient did not experience any grade ≥ 3 toxicity (CTCAE 4.02), the daily sunitinib 
dose was increased by 12.5 mg at day 22. At day 29, seven days after the first dose adjustment, the 
second TTL was measured. If indicated, a second dose adjustment based on TTL and/or toxicity was 
performed at day 36, as described before. After 8 weeks a final TTL evaluation was performed. No 
further dose increments were allowed.
If the patient suffered from grade ≥ 3 toxicity or intolerable grade 2 toxicity despite supportive care at 
any moment during the study, the sunitinib treatment was interrupted until adequate recovery (CTC 
grade < 2) was achieved. Subsequently, sunitinib treatment was resumed at the next lowest dose 
level. Sunitinib dose levels allowed within this study were 12.5, 25, 37.5, 50 and 62.5 mg QD. Patients 
experiencing grade > 2 toxicity with sunitinib 12.5 mg once daily, discontinued the treatment and went 
off study. No dose escalations were allowed after a previous dose reduction for toxicity. Treatment 
was continued until progressive disease, until patient refusal or until adverse events which required 
discontinuation of therapy were observed.
Pharmacokinetic analyses
Samples for pharmacokinetics (PK) were collected at day 15 ± 1 day, day 29 ± 1 day and after 8 weeks 
(day 57 ± 1 day) of sunitinib treatment. EDTA blood samples were collected and, thereafter, directly 
sent to the laboratory by ordinary mail at ambient temperature. After receipt of the samples, within 
36 h after blood collection, plasma was harvested and stored at -20°C until analysis. 
Trough levels of sunitinib and N-desethylsunitinib in plasma were measured by LC-MS/MS as described 
before.13 TTLs were determined by calculating the sum of sunitinib and N-desethylsunitinib plasma 
levels and were reported to the treating physician within one week after blood collection. Patients 
were evaluable for pharmacokinetic analyses if they had undergone all three PK blood samplings. 
safety assessments
Adverse events (AE), serious adverse events (SAE) and their relationship with study medication were 
assessed throughout the study. The incidence and severity of AEs were evaluated and graded using 
the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.02 (CTCAE 4.02). 
Patients who received at least one dose of the study treatment were included in the safety evaluation.
Chapter 3
3
47
Figure 1 Patient flow diagram
statistical analysis
The number of patients recruited was based on the number estimated to be required to evaluate at 
least 8 patients for toxicity after PK guided dose escalation. It was expected that 45% of patients would 
experience clinically relevant toxicity at the starting dose of 37.5 mg once daily.14-18 In addition, it was 
expected that about 50% of the patients without toxicity (55%) would have TTL ≥ 50 ng/mL.15, 16 In 
both occasions, patients were not eligible for dose escalation. Thus, to be able to evaluate at least 8 
patients after dose escalation, it was necessary to include about four times as many patients (at least 
30 patients). 
Descriptive statistics were used to summarize the patient characteristics, toxicity data, response data 
and sunitinib TTLs. 
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Table 1 Baseline characteristics of all evaluable patients
characteristic N (percentage)
Gender            
                Male    28      (67)
                Female    14      (33)
Age (y)                                              61      (28 – 74)
Bodyweight (kg)                               77      (44 – 108)
ethnicity                                               
                 Caucasian    42      (100)
ecoG Performance status                 
                0    10      (24)
                1    32      (76)
Primary tumour                                   
                Neuroendocrine carcinoma      8      (19)
                Colorectal carcinoma      8      (19)
                Renal cell carcinoma      6      (14 )
                Adenocarcinoma of unknown primary (ACUP)      3      (7)
                Uveal melanoma      3      (7)
                Miscellaneous*      14    (33)
clinical stage, pre-treatment             
                Locally advanced      2      (5)
                Metastatic   40      (95)
Prior treatment                                  
               TKI therapy      5    (36)
                Chemotherapy   31     (74)
                        1 regimen   12     (29)
                        2 regimens     3      (7)
                        ≥3 regimens  17      (40)
               Surgery  28      (67)
               Radiotherapy  16      (38)
*Miscellaneous: pancreatic carcinoma (n=2), hepatocellular carcinoma (n=2), oesophageal carcinoma 
(n=2), prostate carcinoma, cervix carcinoma, head and neck carcinoma, mesothelioma, liposarcoma, 
ewing sarcoma, myo-epithelioma, osteosarcoma.
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ResuLTs
Patient population
From April 2011 until June 2012, 43 patients with a variety of advanced solid tumors were enrolled 
(18 patients at the Netherlands Cancer Institute - Antoni van Leeuwenhoek Amsterdam, 15 patients at 
the University Medical Center Utrecht and 10 patients at the Erasmus MC Cancer Institute Rotterdam). 
Forty-two patients received at least one dose of sunitinib and were evaluable for toxicity assessments. 
Twenty-nine patients completed all three pharmacokinetic blood samples and were therefore 
evaluable for pharmacokinetic assessments (see Figure 1 for the CONSORT diagram). In total, 14 out 
of 29 patients were evaluable for toxicity assessment after PK-guided dose escalation. At the time of 
the database lock (August 2012), four patients (9.5%) were still on sunitinib therapy. Demographical 
and clinical characteristics for all patients are provided in Table 1.
Target trough levels
After 14 days of sunitinib treatment, the median TTL was 49.5 ng/mL [IQR 41.8 – 64.0] (see Table 2). 
Considerable inter-patient variability of TTLs was observed at the starting dose with a coefficient of 
variation (CV%) of 32.1%. Moreover, 15 out of 29 patients (52%) did not reach the target TTL of 50 
ng/mL at the starting dose of 37.5 mg per day. Therefore, dose escalations to 50 mg per day were 
indicated in 15 patients. However, in one patient it was not possible to increase the sunitinib dose 
due to hematological toxicity, and therefore dose escalation was performed in 14 patients. At the 
second PK evaluation (day 29), the median TTL was increased to 57.6 ng/mL [IQR 48.3 – 61.9] with 
an inter-patient variability of 35.2% for the entire population of 29 patients. The 14 patients that had 
undergone dose escalation after day 15 PK measurement (median TTL 42.0 ng/mL [IQR 36.3-47.3]) 
reached median TTL of 51.3 ng/mL [IQR 44.7-58.7] at day 29. In 2 patients dose escalation at day 15 
resulted in reduced TTL at day 29. Moreover, 19 out of 29 patients (66%) reached the target TTL. Of the 
10 patients below the target level, the sunitinib dose was increased to 62.5 mg per day in 3 patients 
and dose escalations were not possible due to toxicity in 7 patients. At the final PK evaluation (day 57), 
the median TTL was reduced to 51.8 ng/mL [40.3 – 63.7] with an inter-patient variability of 45.0% and 
15 patients (52%) reached the target TTL. Six patients in group 2 showed a decrease in TTL throughout 
the study without dose adjustments. In 2 cases this resulted in TTL below the target TTL at day 57. In 
Figure 2, the measured TTLs of individual patients at day 15, day 29 and day 57 are presented.
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PK guided dosing
Based on TTL reached at day 15, two patient groups were distinguished: Group 1 consisted of patients 
who did not reach target TTL and Group 2 of patients who reached target TTL. Based on toxicity in 
the first 8 weeks of treatment, these groups could be subdivided further into four patient subgroups 
with different results of the PK guided dosing strategy. The defined groups were as follows: Group 1a 
patients with TTL <50 ng/mL at day 15 and no relevant toxicity (n = 5; 17%), Group 1b patients with 
TTL < 50 ng/mL at day 15 with relevant toxicity (n = 10; 34%), Group 2a patients with TTL > 50 ng/mL 
at day 15 and no relevant toxicity (n = 8; 28%), Group 2b patients with TTL > 50 ng/mL at day 15 with 
relevant toxicity (n = 6; 21%). As shown in Table 2, the 5 patients (17%) who did not reach target TTL 
at day 15 and had PK-guided dose elevations without relevant toxicity, tolerated treatment with 47% 
higher mean daily dose compared to standard therapy. After 8 weeks of treatment the distribution of 
daily sunitinib doses in the study population was as follows: 2 patients using 62.5 mg, 4 patients using 
50 mg, 15 patients using 37.5 mg, and 8 patients using 25 mg. Presumably without PK-guided dosing 
the result would have been 21 patients on 37.5 mg, 8 on 25 mg, and therefore a possible under-dosing 
in 6 of 29 (21%) of patients.
In Figure 3, an overview of all dose adjustments and TTLs is shown per individual patient within the 8 
week study period.
Figure 2 TTLs measured at day 15, day 29 and day 57 of sunitinib treatment of all patients who were evaluable for 
PK evaluation, stratified by patient group. The black bars represent the median TTL.
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Treatment toxicity
The most frequently occurring treatment related adverse events are listed in Table 3. Grade ≥3 adverse 
events were observed in 29 patients (69%). The main grade ≥ 3 adverse events attributed to study 
treatment included hypertension (14%), fatigue (12%), anemia (12%), thrombocytopenia (12%) and 
hand-foot syndrome (HFS) (10%). Common grade 1 or 2 non-hematologic treatment-related toxicities 
were fatigue (60%), nausea (50%), dysgeusia (55%), oral mucositis (52%), diarrhea (40%), HFS (33%) 
and vomiting (29%). 
Six patients discontinued sunitinib treatment (at the standard dose of 37.5 mg per day) due to adverse 
events before the final PK-evaluation at day 57; five of these discontinuations were considered 
treatment related and included fatal cardiac failure (n = 1, grade 5), fatigue, increased blood bilirubin, 
nausea (all n = 1, grade 3) and fatigue (n = 1, grade 2). Dose reductions of sunitinib due to treatment 
related adverse events during the PK evaluation period were performed in sixteen patients (Group 1b 
+ 2b). Moreover, nine of these patients (56%, group 1b) who had an initial TTL guided dose increase 
did not tolerate this higher dose level, as shown in Figure 3. In addition, five patients discontinued 
sunitinib treatment due to toxicity after the PK evaluation period; two of these discontinuations were 
considered treatment related and included a combination of anemia and thrombocytopenia (n = 2, 
grade 3). 
The main purpose of the study was to assess whether PK-guided dosing could be performed without 
causing additional toxicities. Therefore, the occurrence of toxicities in the patients who required dose 
escalations (Group 1) was compared with patients who did not need dose interventions based on PK 
and remained at the standard dose (Group 2). In all patient groups, the frequency of grade ≤ 2 toxicity 
was similar. TTLs above the target level at day 15 of therapy did not correlate to frequency of severe 
toxicity (grade ≥ 3). In Group 1, 10 out of 15 patients (67%) experienced severe toxicities and in Group 
2 with TTL > 50 ng/mL, 6 out of 14 patients (43%) experienced severe toxicity. 
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Figure 3 Course of sunitinib dose levels and TTLs during the first 8 weeks of treatment of all individual patients who 
were evaluable for PK evaluation, stratified by patient group. On the X-axis is the week number, on the Y-axis both 
sunitinib dose level and TTLs are presented. Grey dots represent TTLs. Black squares represent dose levels. The 
dotted line represents the target TTL (50 ng/mL).
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Group 1a: patients with TTL<50 ng/mL at day 15 and without toxicity; Group 1b:  patients with TTL<50 
ng/mL at day 15 and with toxicity; Group 2a: patients with TTL>50 ng/mL at day 15 and without 
toxicity; Group 2b:  patients with TTL> 50 ng/mL at day 15  and with toxicity.
DIscussIoN
In this pilot study, the safety and feasibility of PK guided sunitinib dosing was investigated. At the 
standard dose of 37.5 mg, 52% of patients did not reach target TTLs of sunitinib after 14 days of 
sunitinib treatment. Ultimately, 5 out of 29 patients (17%) had successful dose escalations with final 
doses of 50 mg (n = 3) and 62.5 mg (n = 2), leading to TTLs above the target without causing additional 
toxicities. This implies that PK guided sunitinib dose escalations rather than fixed doses can contribute 
to optimization of therapy in a part of the patients. 
Similar to classical anticancer chemotherapy regimens, it is often reasoned that increasing the dose of 
an anticancer drug in patients who lack toxicity might increase the likelihood of treatment efficacy.19-22 
Fixed dosing may lead to under-dosing due to inadequate drug exposure in some patients. Dosing 
to toxicity might lead to overdosing and unnecessary side effects since in some patients adequate 
drug exposure will already be accomplished with a lower dose. This is complex since drug exposure, 
toxicity and efficacy generally do not show a linear relationship and it is not known whether toxicity is 
accompanied by adequate exposure. Therefore, therapeutic drug monitoring for the individualization 
of dosing of anticancer drugs with an considerable and unpredictable inter-patient variability in 
pharmacokinetics is gaining popularity. For example, PK-guided dosing has been mentioned for 
docetaxel leading to a decrease in the inter-patient variability of drug exposure.23 However, to our 
knowledge, the current study is the first study in which PK guided dosing is applied to sunitinib 
treatment.  
The sunitinib starting dose of 37.5 mg (continuously once-daily) was based on previously reported 
studies investigating a continuous dosing strategy for sunitinib.14-16 Since no safety data were available 
regarding long term continuously daily dosing of high doses sunitinib, the highest dose level was 
maximized to 62.5 mg per day.14-16, 24
A limitation of this study is that target TTL have not been established in clinical studies, thus far. The 
association between sunitinib exposure and efficacy was based on the steady state area under the 
concentration-time curve (AUC).4 Since AUC and trough level increase both proportionally with dose, 
these parameters should correlate with each other.7, 25 Hence, the target plasma levels used in this 
study were deduced from preclinical studies.5, 6, 8, 9 Furthermore, our study was performed in a small 
cohort of patients with a large variety of advanced solid tumors and without a control group. Therefore, 
it was not possible to investigate the relationship between plasma exposure and treatment efficacy. 
In the previously reported studies, mean TTLs were approximately 40-65 ng/mL and inter-patient 
variability was high with a coefficient of variation (CV) of more than 30%.14-16, 24 Our patient cohort 
showed comparable results after 14 days of treatment (before any dose change) with median TTL 
of 49.5 ng/mL and an inter-patient variability of 31.2%. When assuming that target TTLs are needed 
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for adequate treatment responses, this means that more than half of the patients were at sub-target 
levels (< 50 ng/mL) at the standard dose. 
Based on the elimination half-life of sunitinib (±40h) and N-desethylsunitinib (±80h) it was expected 
that steady state concentrations would be reached within 14 days of treatment and that parent 
and metabolite accumulate 3-4 fold and 7-10 fold, respectively.25 However, no significant drug 
accumulation was observed after three weeks of continuous sunitinib treatment in previous studies.15, 
26 Additionally, in case of a dose escalation from 37.5 mg to 50 mg (33% increment) more than 90% 
of the new steady state level would already be reached after two half-lives since the new steady 
state is close to the former level. Therefore, TTL measurement seven days after a dose escalation was 
expected to be adequate. However, in some patients TTLs still tended to increase after two weeks of 
sunitinib treatment even when the dose remained equal. A longer period before collection of the first 
TTL sample was considered, but this would postpone potential beneficial dose increments. In addition, 
it was observed that TTLs in 2 out of 8 patients decreased to below the target TTL without a dose 
reduction after 8 weeks of treatment. It is not known whether this is due to unexplained intra-patient 
variability, patient non-adherence (despite using diaries and pill counts) or whether sunitinib levels 
tend to decrease after long term treatment as was shown for imatinib27 and sorafenib.28, 29 Hence, 
further insights in TTLs and inter-patient pharmacokinetic variability during sunitinib treatment are 
warranted to allow rational design of future PK-guided dosing studies.30
The total occurrence of toxicity grade 3 or higher observed in this study was consistent with previously 
reported studies on continuous daily dosing regimens of sunitinib.14-16, 24 Due to the small patient 
number this study was not powered to compare the occurrence of toxicities within the different 
patient subgroups. 
Of all 16 patients who required dose reductions due to toxicity (Group 1b + 2b), 7 patients suffered 
from toxicities at the standard dose and would also have experienced these toxicities if they were 
treated without the PK-guided dosing strategy. The same goes for 1 patient in the study who died due 
to a probably treatment related adverse event (diffuse cardiac ischemia followed by cardiac failure) 
at the starting dose of 37.5 mg per day. However, as could be expected, patients did experience 
additional toxicities after PK-guided dose escalations (9 patients). These toxicities were manageable 
by dose reductions.
As suggested by previous data, it was expected that toxicity was correlated to sunitinib exposure4 
However, results indicated that the frequency of severe toxicities (grade ≥ 3) was not correlated to 
TTL at day 15, as toxicity levels at that time-point were comparable in the patients with TTL <50 ng/
mL (Group 1) and TTL >50 ng/mL (Group 2). Probably toxicity is also correlated to cumulative sunitinib 
exposure instead of the initial steady state TTL, as was also reported for absolute neutrophil counts 
by Houk et al.4 
In addition, the daily sunitinib doses after 8 weeks of treatment in our patient cohort also give insights 
in a possible added value of a PK-guided dosing strategy. Six patients (21%) were treated with sunitinib 
doses above the standard dose of 37.5 mg per day. These patients would probably be under-dosed in 
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a fixed dosing regimen. 
There are several benefits of a PK guided dosing approach for sunitinib. First, one could hypothesize, 
based on our results and previous work by other groups, that if an effective TTL cannot be reached at 
a dose level with tolerable toxicity in these patients, TTL assessments could substantiate the choice to 
switch to another more effective therapy. Second, when assuming that TTLs > 50 ng/mL are needed 
for adequate treatment responses, 17% of patients (the 5 patients in Group 1a (TTL < 50 ng/mL and 
no toxicity)) benefit from PK-guided dose increases without additional toxicity. Third, compared 
to a toxicity based approach, additional toxicities might be avoided since adequate drug exposure 
is reached before toxicity occurs. However, efficacy of both approaches have not been studied or 
compared in great detail so far.
In the current oncology field we are more and more searching for personalized treatments options for 
a sometimes small number of patients. With little effort we can sometimes optimize the treatment 
options we already have. Individualizing dosing of sunitinib based on a simple measurement of plasma 
concentration is worthwhile to investigate further in order to utilize the scarce treatment options 
available for many tumor types in a most optimal way. Further research is therefore required to 
investigate the safety and therapeutic efficacy of PK guided dosing of sunitinib in order to reach a 
systemic exposure above the target TTL compared with that from a standard fixed dose. 
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ABsTrAcT
Background and objective Circadian rhythms may influence the pharmacokinetics of drugs. This study 
aimed to elucidate whether the pharmacokinetics of the orally administered drug sunitinib are subject 
to circadian variation. 
methods We performed studies in male FVB-mice aged 8-12 weeks, treated with single-dose sunitinib 
at 6 dosing times. Plasma and tissue samples were obtained for pharmacokinetic analysis and to 
monitor mRNA expression of metabolizing enzymes and drug transporters. A prospective randomized 
cross-over study was performed in which patients took sunitinib once daily at 3 courses at 8AM, 
1PM and 6PM. Patients were blindly randomized in two groups, which determined the sequence of 
sunitinib dosing time.  Primary endpoint in both studies was the difference in plasma area-under-the-
concentration-time-curve (AUC) of sunitinib and its active metabolite SU12662 between dosing times. 
results Sunitinib and SU12662 plasma AUC in mice followed a ~12h-rhythm as a function of 
administration time (p≤0.04). The combined AUC
0-10h
 was 14-27% higher when sunitinib was 
administered at 4AM and 4PM, than at 8AM and 8PM. Twenty-four hr-rhythms were seen in the mRNA 
levels of drug transporters and metabolizing enzymes. In 12 patients, sunitinib trough concentrations 
were higher when the drug was taken at 1PM or 6PM, than when taken at 8AM (C
trough1PM
 66.0ng/mL; 
C
trough-6PM
 58.9ng/mL; C
trough-8AM
 50.7ng/mL, p=0.006). The AUC was not significantly different between 
dosing times.
conclusions This indicates that sunitinib pharmacokinetics follow a ~12h-rhythm in mice. In humans, 
morning dosing resulted in lower trough concentrations, probably resulting from differences in 
elimination. This can have implications for therapeutic drug monitoring.
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KeYPoINTs
Sunitinib is known for its narrow therapeutic window and wide inter-patient variability in drug 
exposure, which in part may be explained by a within-patient variability in drug exposure, possibly 
due to daily variations in absorption, distribution, metabolism and excretion of sunitinib.
In this study, we showed that the area under the concentration-time curve of sunitinib and its active 
metabolite SU12662 follows a 12-hour rhythm in mice. Patients had lower trough concentrations of 
both sunitinib and SU12662 when the drug was administered in the morning, rather than intake at 
later moments of the day.
This is particularly interesting, since therapeutic drug monitoring (TDM) is currently being suggested 
as a step forward in the individualization of sunitinib treatment. In TDM, drug dose may be increased 
or decreased based on trough concentrations to aim for better survival. Therefore, it is crucial to take 
the administration time into account to prevent erroneous dose escalations or reductions.
INTroDucTIoN
Sunitinib (Sutent®; Pfizer Pharmaceutical Group, New York, NY, U.S.A.) is a multi-targeted tyrosine 
kinase inhibitor that is registered for the treatment of advanced clear cell renal cell carcinoma (RCC), 
imatinib-resistant or intolerant gastrointestinal stromal tumors (GIST), and pancreatic neuro-endocrine 
tumors (pNET).1-5 There is a broad inter-patient variability in plasma concentrations of sunitinib, which 
may be due to patient non-compliance, drug-drug interactions (CYP3A4-modulating drugs) and inter-
patient variability in pharmacokinetics.6 Besides inter-patient variability in drug exposure, there also 
may exist variability within a patient due to intra-patient variations in pharmacokinetic processes.
After oral intake, sunitinib is absorbed from the gastrointestinal tract, resulting in peak plasma 
concentrations 6-12 hours after administration.1 Food has no significant effect on the exposure to 
sunitinib.1, 7 In the liver, sunitinib is mainly metabolized by the cytochrome P450 enzyme 3A4 (CYP3A4) 
to its primary active metabolite SU12662, which is further converted by CYP3A4 into several inactive 
compounds. Both sunitinib and SU12662 are eliminated from the body via the bile in the feces through 
efflux transporters in the liver, namely the ATP-binding cassette sub-family B member 1 (ABCB1) and 
sub-family G member 2 (ABCG2).8
Enzymes and transporters involved in the pharmacokinetics of drugs, such as CYP3A4 and ABCB1, 
have time-dependent variations in expression which may have profound effect on the exposure 
to several drugs.9, 10 These variations may change the efficacy and/or toxicity profile of drugs. This 
was previously shown in patients treated with tacrolimus, a drug frequently used to prevent organ 
rejection after transplantation, where morning administration resulted in higher AUC levels than 
evening administration.11
Two previous studies have compared the toxicity levels of patients treated with sunitinib in the 
morning with those of patients treated with sunitinib in the evening. No differences in toxicity levels 
between morning and evening dosing of sunitinib were found in either study. Although the authors 
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concluded that it is safe to take the drug either in the morning or at night, sunitinib pharmacokinetics 
were only examined during morning sunitinib administration and these studies were not designed to 
study the chrono-efficacy and chrono-tolerance of sunitinib exposure.12, 13
Several studies have shown an association between higher exposure to sunitinib and improved 
survival.14, 15 In order to improve the efficacy of sunitinib treatment, we wanted to gain insight into 
possible time-dependent changes in sunitinib pharmacokinetics, for which we designed a translational 
study. The primary aim of this study was to examine whether administration time of sunitinib 
influences its pharmacokinetics. We studied the effect of administration time on pharmacokinetic 
parameters of sunitinib by measuring sunitinib and its active metabolite in plasma and organ tissue 
of mice as well as in plasma of cancer patients treated with monotherapy sunitinib. As a secondary 
aim, we studied the daily variation in the activity of sunitinib-metabolizing enzymes and transporters 
in murine hepatocytes and bowel tissue and through the midazolam clearance test in patients, which 
is a well-known marker of CYP3A activity.16
meTHoDs
Mice
Seven groups of 18 male FVB mice with the age of 8-12 weeks were used in this study. For logistic 
reasons, mice were housed under normal and reversed 12 hours light/12 hours dark cycles (lights on/
off or off/on at 8 AM and 8 PM) for at least one week before start of the experiment. Mice were fed a 
standard diet ad libitum. Three hours before pharmaceutical treatment, mice were fasted until 1 hour 
after administration. Water was available ad libitum throughout the entire experiment. This study was 
approved by an independent Animal Ethical Committee under protocol number EMC139-12-19. 
study protocol
Sunitinib was dissolved in acidified water with a pH of maximum 6.0, at a concentration of 5 mg/mL. 
All mice were administered a fixed single dose of 1.06 mg, which was based on a dose of 42.4 mg/kg 
and mean weight of mice of 25 g. Every four hours, one group consisting of 18 mice was administered 
a single dose sunitinib through gavage, starting at 8AM. 
At six different times after the administration of sunitinib (t = 1, 2, 3, 5, 10, 20 h), three mice with 
identical sunitinib dosing time were administered isoflurane as anesthetic followed by eye extraction 
for 1 mL blood withdrawal and euthanasia by cervical dislocation. Directly after euthanasia one liver 
lobe and the small bowel were removed. Blood from each single mouse was separately processed to 
plasma. Both plasma and tissue samples were snap-frozen in liquid nitrogen and stored at -80°C until 
further analysis. 
The seventh group of mice served as a control group and was administered solvent. Mice in this group 
were sacrificed with four hours intervals. Blood and organs of the mice in this group were collected 
Chapter 4
4
67
and stored under the same conditions as those of the treated mice. Quantitative real-time PCR was 
applied on tissue samples to reveal potential time-dependent changes in the circadian expression 
of murine orthologues of genes encoding drug transporters and metabolizing enzymes involved in 
sunitinib pharmacokinetics, using known core clock genes as a control (see supplementary material).
Patients
A prospective randomized cross-over trial was performed in patients treated with sunitinib at the 
Department of Medical Oncology of the Erasmus MC-Cancer Institute, Rotterdam, the Netherlands. 
Patients were allowed to participate in the study at any time during sunitinib treatment, with both 4 
weeks on/2 weeks off treatment and with continuous dosing regimen. Patients could participate in the 
study if (i) aged ≥ 18 years, (ii) having histologically or cytologically confirmed diagnosis of advanced 
renal cell carcinoma, GIST or pancreatic neuro-endocrine tumor for which treatment consisted of 
monotherapy sunitinib, (iii) using any stable dose of sunitinib at study entry (defined as at least 2 
weeks continuous dosing without dose modifications), (iv) hematologic, renal and liver functions were 
adequate, and (v) written informed consent was given. Exclusion criteria consisted of (i) pregnancy or 
breastfeeding, (ii) medical unstable condition requiring treatment, (iii) symptomatic central nervous 
system metastases or history of psychiatric disorder that would prohibit the understanding and giving 
of informed consent, (iv) major surgery within 2 weeks before start of the protocol, (v) use of CYP3A4 
inhibiting or inducing drugs, (vi) problematic blood withdrawal and (vii) a known allergy to sunitinib 
and/or midazolam. 
study protocol
Patients were randomized to start intake of sunitinib either at 8AM (group A) or 6PM (group B) in the 
next treatment course after inclusion. In the course thereafter a cross-over was performed to 6PM 
for group A and 8 AM for group B. Accordingly, the sequence of the time of dosing of sunitinib in 
group A was morning-evening and in group B evening-morning.  During both courses, patients were 
hospitalized for 24 hours in the third or fourth week of the treatment cycle, when steady state plasma 
concentrations were achieved.8 Blood samples for pharmacokinetic measurements were taken at 
time-points t = 0, 1, 2, 4, 6, 8, 12 and 24 hours after oral sunitinib intake. 
At both hospitalization days, patients were subjected to a midazolam clearance test as a marker of 
hepatic CYP3A activity, 2 hours after administration of sunitinib. Midazolam (2.5 mg) was administered 
intravenously through slow infusion, and blood withdrawals for determining the pharmacokinetics of 
midazolam and its metabolite 1’OH-midazolam were taken at time-points t = 0.5, 2 and 6 hours after 
administration, as previously described by Lee et al.17
After amendment of the study protocol, based on the outcome of the animal experiments, a subset 
of patients was asked to participate in the study for a third treatment course in which sunitinib was 
taken at 1PM. 
This study was approved by the local medical ethical board (MEC2012-138), and registered at the 
Relationship between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
4
68
Dutch trial registry (www.trialregister.nl, number NTR3526). According to the instructions stated 
in the Codes for Proper Use and Proper Conduct in the Self-Regulatory Codes of Conduct (www.
federa.org) all samples for pharmacokinetic assessment on sunitinib and midazolam were coded and 
anonymized. The analytical methods for sunitinib and midazolam quantification are described in the 
supplementary material. Parameters for sunitinib and SU12662 pharmacokinetics were combined 
AUC, trough concentrations and clearance of sunitinib. 
statistics
For a probability of 83% that the study would detect a treatment difference at a two-sided 0.05 
significance level, and a 20% true mean difference in AUC and/or clearance between treatment 
times, 18 patients were required. This is based on the assumption that the within-patient standard 
deviation of the pharmacokinetic parameters is 0.2. Patients were considered eligible after completing 
pharmacokinetic blood withdrawal during two treatment courses. To compare parameters of sunitinib 
pharmacokinetics between morning, afternoon and evening dosing time of sunitinib, the Wilcoxon 
signed-rank test was used. CircWave Batch v5.0 with cosinor analysis was used for harmonic regression 
analysis of circadian oscillation using a 24-hour wave in the expression of genes, and a 12-hour wave 
in the pharmacokinetics of sunitinib, with forward linear harmonic regression using an F-test. User 
defined alpha was chosen at 0.05. 
resuLTs
sunitinib pharmacokinetics in mice
A total of 108 mice were treated with a single dose of sunitinib at six different time points over 24 
hour. Cosinor analysis of the concentration-time curves from time zero to 10 hours (AUC
(0-10)
) plot 
showed a clear 12-hour rhythm in the exposure to sunitinib and SU12662 (p = 0.0342, and p = 0.0027 
respectively; Figure 1A) and the combined exposure (p = 0.0174) as a function of administration time. 
The combined AUC of sunitinib and SU12662 was 14-27% higher when the drug was administered at 
4AM and 4PM, rather than at 8AM and 8PM. 
Figure 1B-e shows the areas under the concentration-time curves of sunitinib and SU12662 for liver 
and 3 consecutive sections of the intestine, corresponding with duodenum, jejunum and ileum, 
respectively. As is shown, oscillations also occur in the accumulation of sunitinib and its metabolite in 
these tissues. However, the 12-hour rhythm was only statistically significant for SU12662 accumulation 
in the duodenum (p = 0.0179, Figure 1c) but not for sunitinib or SU12662 accumulation in other 
tissues. Sunitinib and SU12662 concentrations in both plasma and tissue samples showed a broad 
inter-mouse variability.
Quantitative real-time PCR on liver tissue samples taken from mice in various stages of their circadian 
rhythm revealed daily fluctuations with a 24 hour period in the activity of the clock genes Bmal1, 
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Cryptochrome 1 (Cry1), Dbp, Period 2 (Per2), and Rev-erbα. This was confirmed by the cosinor analysis 
(p ≤ 0.0214), showing that the mice in normal and reversed light-dark cycle were properly entrained at 
the time of the experiment (supplementary Figure 1). 
In the liver, cosinor analysis showed circadian fluctuations in the mRNA levels of Abcb1a, Abcb1b, 
and Cyp3a11 (p ≤ 0.047), but not in the expression  of Abcg2 (p = 0.254, supplementary Figure 2A). 
In duodenum and jejunum, the expression of Abcb1a, Abcg2 an Cyp3a11 followed a circadian rhythm 
(p  ≤ 0.0162, supplementary Figure 2B and 2c). In the ileum, only a circadian variation in Abcb1a 
expression was seen (p < 0.001, supplementary Figure 2D). This implicates circadian expression of the 
genes involved in the uptake and metabolism of sunitinib as a cause for daily variations in sunitinib 
pharmacokinetics. The peak activities, as judged by their mRNA expression levels for these genes were 
all at different times of the day. 
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Figure 1
Daily variations in area under the concentration-time curve (AUC) for sunitinib (black) and SU12662 (dotted line) in 
plasma (A), liver (B), duodenum (C), jejunum (D) and ileum (E) of FVB mice treated with a single dose sunitinib. The X-axis 
indicates the time of sunitinib administration, the Y-axis represents the mean AUC corresponding with the 6 consecutive 
administration times. Gray areas indicate it was dark in the cages of the mice, white areas indicate it was light.
Patient demographics
Twenty-seven patients were included in this study, of whom 16 patients completed at least 2 courses 
with pharmacokinetic blood withdrawals (group A, n=7; group B, n=9). One patient was excluded from 
the study due to inability to withdraw blood, and one patient retracted informed consent before the 
end of the study protocol. Nine patients stopped sunitinib treatment during the study due to toxicity 
or progressive disease. A subgroup of twelve patients had pharmacokinetic measurements during 3 
courses using sunitinib at three different times of the day each course. All patients used sunitinib as 
first line anti-cancer treatment.
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Group A and group B were comparable in sex, age, number of courses within the study protocol and 
amount of dose reductions before and within the study protocol. From the 16 patients who completed 
at least 2 courses with pharmacokinetic blood withdrawals, three patients underwent dose reductions 
in between the study courses. Six patients had already undergone dose-reductions before the start of 
the study protocol. There were no dose escalations prior to, or during the study protocol in any of the 
patients. Demographic characteristics are presented in Table 1.
 
Table 1 Descriptives of 27 individuals who participated in the clinical study
characteristic Value 
cohort A B
No of patients 13 (48.1) 14 (51.9)
No of courses within study
   0-1 6 (46.2) 5 (35.7)
   2 7 (53.8) 9 (64.3)
   3 5 (38.5) 7 (50.0)
Sex
   Male 10 (76.9) 12 (85.7)
   Female 3 (23.1) 2 (14.3)
Age (years) 63.1 (10.9) 61.3 (7.4)
WHO-PS
   0-1 13 (100) 13 (92.9)
   2 0 (0) 1 (7.1)
Tumour type
   RCC 13 (100) 12 (85.7)
   p-NET 0 (0) 2 (14.3)
Dose-reductions during study 2 (22.2) 1 (11.1)
Duration of sunitinib treatment (months) 16.7 (26.8) 19.3 (22.2)
Abbreviations: no, number of patients; WHO-PS, World Health Organization Performance Score; 
RCC, renal cell carcinoma; p-NET, pancreatic neuro-endocrine tumor.
Values are expressed as n (%), except for age and duration of treatment, which are mean (SD)
sunitinib pharmacokinetic parameters
Mean AUC
τ 
(AUC from time zero to end of dosing period) in 16 patients was 1599 ± 592 ng x h/mL, 
when sunitinib was administered at 8AM (AUC
8AM
) and 1444 ± 536 ng x h/mL when sunitinib was 
administered at 6PM (AUC
6PM
). In the 12 patients who underwent pharmacokinetic blood sampling 
during three courses, no difference was seen in AUC
1PM
 when compared to dosing times 8AM (p = 
0.21) or 6PM (p = 0.24), as is shown in Figure 2. However, a relevant difference in combined trough 
concentrations was seen between morning and evening dosing (n=16, C
trough-8AM
 50.7 ± 17.6 ng/mL, 
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C
trough-6PM
 58.9 ± 21.6 ng/mL; p = 0.006). This was also seen when comparing morning dosing and dosing 
at noon (n = 12, C
trough-8AM
 56.0 ± 19.6 ng/mL; C
trough1PM
 66.0 ± 25.2 ng/mL; p = 0.003). The clearance of 
sunitinib was not significantly different between the three dosing times (CL
8AM
 42.0 ± 14.7, CL
1PM
 40.2 
± 13.5, CL
6PM
 39.8 ± 9.8, p ≥ 0.5). Patients in group A had slightly higher AUC
8AM
 than patients in group 
B. For all other pharmacokinetic parameters, there were no significant differences between the both 
treatment groups (Table 2).
 
Figure 2 24-hour concentration curves of sunitinib and SU12662 for patients treated with sunitinib at 8AM, 1PM 
and 6PM.
midazolam clearance test 
Three out of 16 patients did not undergo midazolam clearance tests at both hospitalization days, as a 
patient’s request. In the remaining 13 patients there was no significant difference in the ratio between 
midazolam and 1’OH-midazolam between the administration times 10AM and 8PM (mean difference 
in 1’OH-midazolam/midazolam ratio 0.0184, p = 0.256). Group A was not different from group B in 
outcome of the 1’OH-midazolam/midazolam ratio in the morning nor in the evening (Table 2). 
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Table 2 Pharmacokinetic parameters in group A and group B
Pharmacokinetic 
measurement
Group A Group B P-value
mean (sd) mean (sd)
AUC
8AM
1832 (623) 1314 (426) 0.048
AUC
1PM
1965 (679) 1572 (665) 0.340
AUC
6PM
1711 (663) 1274 (377) 0.092
C
trough8AM
64.1 (22.6) 48.1 (16.4) 0.094
C
trough1PM
76.3 (26.2) 58.6 (23.6) 0.249
C
trough6PM
69.0 (27.8) 52.4 (15.4) 0.122
CL
8AM
35.1 (14.0) 45.5  (12.0) 0.145
CL
1PM
34.5 (16.5) 44.3 (25.4) 0.435
CL
6PM
36.0 (12.9) 42.7 (5.8) 0.235
1’OH-MD/MD
10AM
0.081 (0.014) 0.095 (0.027) 0.251
1’OH-MD/MD
8PM
0.087 (0.027) 0.121 (0.084) 0.311
Abbreviations AUC8AM, AUC1PM, AUC6PM, combined area under the concentration-time  curve of sunitinib and 
SU12662; Ctrough8AM, Ctrough1PM, Ctrough6PM, combined trough concentration of sunitinib and SU12662; 
CL8AM, CL1PM, CL6PM, sunitinib clearance. Both measurements at sunitinib dosing time 8AM, 1PM and 6PM 
respectively; 1’OH-MD/MD, ratio between 1’OH-midazolam and midazolam at 10AM and 8PM
Units of AUC in ng·h/mL, Ctrough ng/mL, CL L/h.
DIscussIoN
In this translational study, sunitinib pharmacokinetics in mice showed daily variations depending on 
the time of administration. Sunitinib and SU12662 AUC follow a similar oscillation pattern as a function 
of administration time, with 14-27% higher combined plasma AUC when sunitinib was administered at 
4AM or 4PM, rather than at 8AM or 8PM, which is in the middle of the active or inactive phase of the 
mouse. Although a recent study in rabbits revealed significant differences in the exposure to sunitinib 
between dosing at 8AM or 8PM, this was not seen in our study in mice.18
Both the sunitinib and  the SU12662 AUC in plasma follow a similar pattern in an apparent 12-hour 
rhythm. The oscillation pattern is probably due to circadian rhythms in both Cyp3a11 enzyme activity 
and expression of the efflux transporters Abcb1a, Abcb1b and Abcg2. The 12-hour rhythm in sunitinib 
and SU12662 pharmacokinetics may be due to counteracting activities of these drug transporters and 
metabolizing enzyme, since we observed variation in mRNA expression with peak levels at different 
times of the day.
In the 16 patients treated with sunitinib, the plasma AUC was equal at 3 dosing times, which is in 
contrast to our pre-clinical results. Despite the equality in daily exposure to sunitinib, the trough 
concentrations of sunitinib were significantly lower when patients were administered sunitinib in the 
morning, than at noon or evening dosing. Trough concentrations were sampled just before the intake 
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of a new dose of sunitinib. In this phase of the pharmacokinetic process metabolism and elimination 
are the most important determinants of drug concentrations. 
This study showed that the midazolam clearance test in patients was similar at 10AM and 8PM, 
suggesting similarity in hepatic CYP3A activity between these time-points. Since CYP3A4 has a key 
role in sunitinib metabolism,8 this suggests that sunitinib metabolism was similar at morning and 
evening dosing. Based on the midazolam clearance test, it can be assumed that metabolism did not 
vary between these time-points. Therefore it is hypothesised that the difference in sunitinib trough 
concentrations may be attributed to daily changes in elimination. 
The daily variation in sunitinib trough concentrations is relevant for future research. For sunitinib 
and other TKIs, a threshold concentration for efficacy is known.15 Therapeutic drug monitoring 
(TDM) is currently being investigated as a potential improvement of sunitinib therapy, using trough 
concentrations of sunitinib and SU12662 as an indicator for daily exposure. In these studies, dose 
levels of sunitinib are increased if trough concentrations are below the threshold. A recently published 
study revealed that it is feasible to dose sunitinib based on trough concentrations, with threshold 
concentrations between 50-100 ng/mL.19 Patients in our study had less fluctuations in daily sunitinib 
concentration when sunitinib was administered at noon or in the evening. Therefore, the chance of 
dropping below the threshold of 50 ng/mL, where sunitinib is thought to be ineffective, is smaller 
when the drug is administered at these times of the day, although the daily exposure is the same. 
Patients dosed in the morning may therefore potentially undergo erroneous dose escalations and 
suffer from more toxicity.20
Interestingly, the daily variation in sunitinib AUCs observed in mice was not confirmed in patients. 
The discrepancy between pre-clinical models and patients may be due to various reasons. First, the 
pharmacokinetics of sunitinib may be different between mice and humans due to species specificity in 
the orthologous of CYP-enzymes and drug transporters involved in the pharmacokinetics of sunitinib. 
Second, the mice in this study only received a single dose of sunitinib and therefore steady-state plasma 
concentrations were not reached at the time of pharmacokinetic sampling. This is in contrast with the 
patients in our study who were administered sunitinib for at least 2 weeks before pharmacokinetic 
sampling took place. A third explanation can be that while mice were kept under strict light/dark cycles 
resulting in synchronized behavior, the circadian rhythm in the patients in this study may be disturbed 
by life style or during the hospital stay for pharmacokinetic sampling. pharmacokinetic samples were 
taken both during day times and during night hours, which resulted in waking of the patient. Fourthly, 
the mice in this study were genetically homogeneous, while in the human population there is genetic 
heterogeneity.
Of note, there were some limitations in the pre-clinical study. From each mouse only one blood 
withdrawal for pharmacokinetic determination was possible. Therefore, the AUC is calculated from 
sunitinib concentrations that are measured in different mice, which showed a large inter-individual 
difference in sunitinib and SU12662 concentrations. These large variations in pharmacokinetics may 
have been due to several causes. For instance, sunitinib was administered through gavage. Possibly, 
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the solvent was partially left in the gavage tube and it was not noticed whether mice vomited after 
gavage. Also, mice ranged in age from 8-12 weeks and therefore may differ in weight. In addition, mice 
were fasted from 3 hours before gavage until 1 hour after oral gavage, to make sure the stomachs of all 
mice were empty at the time of sunitinib administration. However, this may have caused stress to the 
animals and may have affected the phase of peripheral circadian rhythms, although analysis of mRNA 
levels of the core clock genes excluded the latter possibility.
This study was not designed to detect differences in pharmacodynamics (efficacy of treatment and 
toxicity) between different dosing times of sunitinib. Patients were allowed to participate at any time 
during sunitinib treatment, and there was a broad variation in the on-treatment time between patients. 
Six out of 16 (38%) patients had previously undergone dose reductions due to severe toxicity, and at 
the time of participation in the study these patients were treated at a dose level with an acceptable 
toxicity profile. Therefore, differences in toxicity levels between dosing times were not an endpoint in 
this study. However, previous studies have reported that toxicities from sunitinib treatment are similar 
in morning and evening dosing.12, 13
coNcLusIoN
Altogether, we conclude that daily variation in the pharmacokinetics of sunitinib exists, most likely 
resulting from differences in sunitinib elimination. Patient’s plasma trough concentrations of sunitinib 
are higher when administered in the afternoon or evening, and during these dosing times more stable 
drug concentrations are achieved than when administered in the morning. It is therefore advised 
that sunitinib should be dosed in the afternoon or evening in daily clinical practice, and if TDM is 
implemented in clinical practice, the administration time of sunitinib should be taken into account.
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suPPLemeNTArY mATerIAL
Pharmacokinetic measurements on sunitinib and midazolam
All pharmacokinetic assessments for sunitinib, SU12662, midazolam and 1’OH-midazolam were 
performed at the Laboratory of Translational Pharmacology of the department of Medical Oncology in 
the Erasmus MC-Cancer Institute. Tissue samples from mice were diluted in human plasma (1:4 w/v) 
into a 2-mL eppendorf tube. Hereafter a 5-mm stainless steel bead (Qiagen, Venlo, The Netherlands) 
was added and the samples were homogenized with a Tissuelyser (Qiagen, Venlo, The Netherlands) 
and processed for 4 minutes at 40 Hz. Beads were removed and homogenized samples were stored 
at -70ᴼC until analyses. Sunitinib and SU12662 concentrations in tissues and plasma were quantitated 
using a validated UPLC-MS/MS method as previously described by de Bruijn et al.
Midazolam and 1’OH-midazolam were quantitated using a fully validated method with a Waters 
2795 Separation Module coupled to a Quatro micro API Mass spectrometer (Waters, Etten-Leur, The 
Netherlands). The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode 
with positive ion electrospray ionization. The MRM transition was 326→244 for midazolam, 342→324 
for 1’OH-midazolam and 301→255 for the internal standard temazepam (IS). Chromatography was 
performed on a Zorbax Eclipse XDB-C8 analytical column, 150 mm × 4.6 mm, 5 μm (Agilent, Amstelveen, 
The Netherlands) using water and acetonitrile with 0.1% formic acid under gradient conditions. 
The sample extraction and cleaning-up involved a simple liquid-liquid extraction by addition of 50 
µL aliquots of 4% ammonium hydroxide, 100 µL of internal standard solution and 1 mL aliquots of 
N-butylchloride to 200 µL plasma. The limits of quantification were 0.400 for midazolam and 0.200 
ng/ml for 1’OH-midazolam. 
Individual pharmacokinetic parameters were estimated by non-compartimental anlaysis in the 
software WinNonlin. In the experiment with mice, mean concentrations of sunitinib and SU12662 
at each time-point after administration of sunitinib were calculated from 3 sacrificed mice at that 
specific time-point, with minimum and maximum value. Mean AUC, minimum and maximum AUC 
were calculated using the corresponding sample values.
semi-quantitive real time Pcr
Total RNA was isolated from mice liver and intestine tissue using TriPure reagent (Roche Diagnostics) 
according to the manufacturer’s protocol. RNA quality and concentrations were analyzed using the 
Nanodrop ND1000 (NanoDrop Technologies). One ug of RNA was used for cDNA preparation using 
iScript (Biorad) according to the manufacturer’s protocol.
Semi-quantitative RT-qPCR was performed using Platinum Taq DNA polymerase (Invitrogen) according 
to the manufacturer’s protocol on a Biorad C1000 Touch Thermal Cycler using a standard 2-step 
amplification program with annealing/extension at 600C. Reactions for samples with housekeeping 
genes (B2M, Hprt and/or Gapdh) were always performed within the same plate as reactions for genes 
of interest. qPCR data represents the average of at least 2 housekeeping genes. The primers used for 
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RT-qPCR are presented in supplementary table 1. Relative gene expression was calculated using the 
comparative C(t) method and was normalized to relative expression at time 8AM (relative expression = 1).
supplementary table 1 Primers used for RT-qPCR of mice liver and intestine tissue
Gene Forward primer reverse primer
B2M 5’-CCGGCCTGTATCCAGAAA-3’ 5’-ATTTCAATGTGAGGCGGGTGGAAC-3’
Hprt 5’-CGAAGTGTTGGATACAGGCC-3’ 5’-GGCAACATCAACAGGACCTCC-3’
Gadph 5’-CAGAACATCATCCCTGCATCC-3’ 5’-GTCATCATACTTGGCAGGTTTCTC-3’
Bmal1 5’-GCACTGCCACTGACTACCAAGA-3’ 5’- TCCTGGACATTGCATTGCAT-3’
DBP 5’-ACCGTGGAGGTGCTAATGAC-3’ 5’-CCTCTTGGCTGCTTCATTGTT-3’
Per2 5’-GGCTTCACCATGCCTGTTGT-3’ 5’-GGAGTTATTTCGGAGGCAAGTGT-3’
Cry1 5’-CAGACTCTCGTCAGCAAGATG-3’ 5’-CAAACGTGTAAGTGCCTCAGT-3’
Rev-erbα 5’- ACCTTACTGCTCAGTGCCTGGAAT-3’ 5’- TGGACCTTGACACAAACTGGAGGT-3’
Cyp3a11 5’- ACCTGGGTGCTCCTAGCAAT-3’ 5’- ACCATCAAACAACCCCCATGT-3’
Abcb1a 5’- CAGATACCATACAGAAATGCGA-3’ 5’- CTCAATGATCCTGATGATGTGG-3’
Abcb1b 5’- GCATTACTAATCAAAGTGGACCC-3’ 5’- ATCAAACCAGCCTATCTCCT-3’
Abcg2 5’- AAGTCTTCGTTGCTAGATGTC-3’ 5’- GTCATCTTGAACCACATAACCT-3’
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supplementary figure 1 Relative mRNA expression of the genes involved in the regulation of circadian rhythms 
measured with 4-hours intervals in mouse liver (A), ileum (B), jejunum (C) and duodenum (D) of FVB mice by 
quantitative real-time PCR, normalized to relative expression at 8AM. Circadian rhythms were shown in the 
expression of Bmal1, Per2, Cry1, Rev-erbα and Dbp. Gray areas indicate it was dark in the cages of the mice, white 
areas indicate it was light.
4
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supplementary figure 2 Relative mRNA expression of Cyp3a11, Abcb1a, Abcb1b and Abcg2 measured with 4-hours 
intervals in mouse liver (A), ileum (B), jejunum (C) and duodenum (D) from FVB mice. Data are relative to expression 
at time 8AM. Gray areas indicate it was dark in the cages of the mice, white areas indicate it was light.
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ABsTrAcT
Background The purpose of this study was to identify single nucleotide polymorphisms (SNPs) that are 
associated with outcome to treatment with sunitinib in patients with advanced GIST.
methods In this retrospective multicenter study 49 SNPS in genes encoding proteins involved in the 
pharmacokinetic and pharmacodynamic pathway of sunitinib, as well as clinical factors, were explored 
for their association with progression free survival (PFS) and overall survival (OS) in 127 patients with 
advanced GIST who have been treated with second line sunitinib. 
results PFS was significantly longer in carriers of the TT genotype in POR rs1056878 C/T (Hazard Ratio 
[HR] 4.310, 95% CI: 1.457-12.746, p = 0.008). The presence of the T-allele in SLCO1B3 rs4149117 G/T 
(HR 2.024, 95% CI: 1.013-4.044, p = 0.046), the CCC-CCC alleles in SLC22A5 haplotype (HR 2.603, 95% 
CI: 1.216-5.573, p = 0.014), and the GC-GC alleles in the IL4R haplotype (HR 7.131, 95% CI: 1.518-
33.496, p = 0.013) were predictive for OS. When these factors were combined in a model, PFS and 
OS were significantly longer with an increasing number of favorable genetic alleles (HR 0.654, 95% CI 
0.512-0.836, p = 0.001 and HR 0.359, 95% CI 0.156-0.826, p = 0.016 respectively).
Discussion This study shows that polymorphisms in genes encoding for proteins involved in the 
pharmacokinetic and pharmacodynamic pathway of sunitinib are associated with survival in GIST 
patients. If validated, this may help to identify patients that benefit more from treatment with sunitinib 
and therefore may be useful in therapeutic decision making.
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INTroDucTIoN
Since the introduction of imatinib as first line treatment for advanced gastrointestinal stromal tumors 
(GIST), progression free survival and overall survival of patients with this malignancy has dramatically 
improved. Unfortunately, eventually the vast majority of patients develop resistance to imatinib, 
mainly due to secondary mutations, while in others severe toxicity occurs, both resulting in the need 
to switch to second line treatment with sunitinib (Sutent; Pfizer Pharmaceuticals Group, New York, 
NY).1 Sunitinib is a multi-targeted tyrosine kinase inhibitor.2, 3 Its clinical value in the treatment of 
patients with metastatic GIST has been shown in a randomized trial showing a median time to tumor 
progression of 27.3 weeks for patients treated with sunitinib, versus 6.4 weeks for patients treated 
with placebo.1 However, there is a large inter-individual difference in the efficacy of sunitinib in patients 
with GIST. This may in part be explained by the presence of specific mutations within the tumor4 but 
another factor that may contribute to the variability in efficacy may be germline genetic variation. 
In patients treated with sunitinib for metastatic renal cell cancer, single nucleotide polymorphisms 
(SNPs) in genes related to the pharmacokinetic and pharmacodynamic pathways of sunitinib have 
been associated with outcome in terms of progression-free survival (PFS) and overall survival (OS).5 
In patients with GIST, the role of germline genetic polymorphisms as biomarkers predicting outcome 
has never been investigated. To further personalize treatment in this group of patients, it is meaningful 
to get better insight into the factors predicting the efficacy of a drug before starting, especially when 
alternative treatment options exist such as in the case of advanced GIST. Therefore, we performed 
a multicenter association analysis to explore whether polymorphisms in candidate genes within the 
pharmacokinetic or pharmacodynamic pathway of sunitinib are associated with PFS and OS in patients 
with GIST. 
meTHoDs
study population and design
From a large multicenter Dutch cohort of 365 patients with GIST, those patients who have been 
treated with second line sunitinib were selected. Patients had started sunitinib treatment between 
March 2004 and June 2014 in the Erasmus MC Cancer Institute, Leiden University Medical Center, 
Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, or University Medical Center 
Groningen. Sunitinib could be administered in a 4 weeks on/2 weeks off treatment scheme, or in a 
continuous dosing regimen, with any dose of sunitinib. Patients who have had dose reductions or dose 
escalations were allowed to be included in this study. 
Demographic data of patients was retrospectively collected in an electronic case record form, designed 
for this study. Collected patient characteristics were age, gender, self-declared ethnicity, Eastern 
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Cooperative Oncology Group (ECOG) WHO performance score, weight, length, tumor characteristics 
(i.e. histology, mutation status, mitotic index (per 50 HPF), site of origin tumor, previous surgery), prior 
therapy and therapy after sunitinib, and survival estimates. For PFS and OS, data collection took place 
until August 2014. 
From each patient one sample of whole blood, serum or tumor surrounding tissue containing germline 
DNA was collected for DNA isolation. Samples could be either residuals or prospectively obtained 
samples in a study approved by the local medical ethical board. Samples were stored at -20◦C or colder 
at the local hospital laboratory until further process. All samples were anonymized, according to the 
Codes for Proper use and Proper Conduct in the Self-Regulatory Codes of Conduct (www.federa.org).
Genetic polymorphisms and haplotype estimation
Forty-nine SNPs in 23 genes involved in the pharmacokinetics and pharmacodynamics of sunitinib 
were selected for genotyping, based on literature (see Table 1). SNPs were selected from the genes 
ABCB1, ABCC2, ABCG2, CYP1A1, CYP1A2, CYP3A4, NR1I2, NR1I3, POR, SLCO1B3, SLC22A1, SLC22A4 
and SLC22A5 within the pharmacokinetic pathway and  the genes FLT1, FLT3, IL-4R, IL-8, KDR, PDGFRA, 
RET and VEGFA within the pharmacodynamic pathway.
DNA isolation and genotyping were performed at the department of Clinical Pharmacy and Toxicology, 
Leiden University Medical Center. DNA was isolated from serum or whole blood using Magna Pure 
compact (Roche, Almere, the Netherlands), or from tumor surrounding tissue using Maxwell (Promega, 
Leiden, the Netherlands). DNA isolated from serum or tissue was pre-amplified as described before.6
SNPs were determined using the QuantStudio 12K Real-Time PCR System (Life Technologies, Bleiswijk, 
the Netherlands), with custom designed arrays. Custom designed pyrosequencing assays were used 
to enhance the call-rate above 90%. The mean genotype call-rate was 98.6% with a lowest call-rate 
of 93.2% and highest call-rate of 100%. The allele frequencies of seven out of 49 SNPs were not in 
Hardy Weinberg equilibrium, but frequencies were comparable to the frequencies reported in the 
National Center for Biotechnology Information (NCBI) website (www.ncbi.nlm.nih.gov) and all SNPs 
were therefore kept within the analysis. 
SNPs within a gene were tested for linkage disequilibrium (LD) using Haploview (Broad Institute). 
Haplotypes were estimated for polymorphisms with an LD of more than 95%. The maximum likelihood 
estimates of haplotype probabilities were calculated using PLINK software, version 1.7 (http://pngu.
mgh.harvard.edu/purcell/plink/). Haplotype probabilities with a likelihood ≥95% were included in the 
statistical analysis. Haplotypes were formed from SNPs in NR1l3 (rs2307418, rs2307424, rs4073054), 
PDGFRA1 (rs1800810, rs1800812, rs1800813), PDGFRA2 (rs2228230, rs35597368), IL8 (rs1126647, 
rs4073), SLC22A5 (rs2631367, rs2631370, rs2631372), VEGFA (rs2010963, rs699947, rs833061), IL4R 
(rs1801275, rs1805015).
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Table 1 Selected polymorphisms within the pharmacodynamic and pharmacokinetic pathway of sunitinib
Gene Protein sNP Allele change
Pharmacodynamic genes
IL4 IL4 rs2243509 C/T
IL4R rs18012759 A/G
rs18050109 A/G
rs18050159 T/C
IL8 IL8 rs407312 A/T
rs112664712 A/T
IL13 IL13 rs18009259 C/T
rs205419 G/A
FLT1 FLT1 rs799341813 A/G
FLT3 FLT3 rs193343714 T/C
FLT4 VEGFR3 rs687701115 C/G
KDR VEGFR2 rs187037716 A/T
rs207155914 C/T
rs230594816 C/T
PDGFRA1 PDGFRA1 rs180081014 C/G
rs180081214 G/T
rs180081314 A/G
PDGFRA2 PDGFRA2 rs222823017 C/T
rs3559736814, 16 C/T
RET RET rs179993914 G/A
VEGFA VEGFA rs157036016 G/A
rs201096316, 18 G/C
rs2564815 C/T
rs302503919 C/T
rs69994716, 18, 19 A/C
rs83306118, 19 C/T
5
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Pharmacokinetic genes
ABCB1 ABCB1 rs104564220, 21 C/T
rs8687558, 21 G/T
rs2865690722 C/T
ABCC2 ABCC2 rs71762021 C/T
ABCG2 ABCG2 rs22311378 G/A
rs22311428, 21 C/A
CYP1A1 CYP1A1 rs104894314 A/G
CYP1A2 CYP1A2 rs76255114 A/C
CYP3A4 CYP3A4 rs27405748 A/G
NR1l2 NR1l2 rs381405514 C/T
rs105419114 G/A
NR1l3 NR1l3 rs23074245, 14 C/T
rs23074185, 14 A/C
rs40730545, 14 G/T
POR POR rs105786823 C/T
SLC1B3 OATP1B3 rs41491178 G/T
SLC22A1 hOCT1 rs62803120, 21 G/A
rs6833698, 21 C/G
rs693520720 G/A
SLC22A4 OCTN1 rs10501528 C/T
SLC22A5 OCTN2 rs26313678 C/G
rs26313708 T/C
rs26313728 C/G
statistics
PFS was defined as the time between the first day of sunitinib treatment, and the day of progressive 
disease (PD), or death due to PD, whatever came first. If PD had not occurred in a patient, or in those 
cases where a patient was lost to follow-up, the patient was censored at the day of last follow-up. OS 
was defined as the time between the first day of sunitinib treatment and the date of death. Patients 
who had not died or of whom it was unknown whether they had died were censored at the last day 
of follow up. 
All SNPs and haplotypes were univariately tested against PFS and OS using the Kaplan-Meier method 
with the log-rank test. Patient characteristics were also univariately tested against PFS and OS, using 
either the Kaplan-Meier method with the log-rank test, or Cox regression analysis, based on the type 
of data. Variables and SNPs with a p-value ≤ 0.10 in the univariate analysis were selected for inclusion 
in a multivariate Cox-regression analysis, using PFS and OS as dependent variables. For SNPs, the best 
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fitted model (multiplicative, wildtype dominant or mutant dominant) was chosen to enter into the 
multivariate analysis, based on the univariate analyses. Missing data from baseline characteristics that 
were associated with PFS or OS in the univariate analysis, were randomly imputed before entering the 
variable in the multivariate regression model. Depending on the variable, 1-40% of data was imputed. 
Multivariate analysis were performed twice, with and without replacement of missing variables. If 
results were similar in size and direction of effect, replacement was considered legitimate.
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 
17.0 (SPSS, Chicago, IL). Given the explorative nature of this study, all results from multivariate analysis 
with p-value ≤ 0.05 were considered statistically significant and no correction for multiple testing was 
performed.
resuLTs
study population
The study population consisted of 127 patients with GIST treated with sunitinib, of whom 63% were 
men. The mean age at start of sunitinib was 61.2 ± 13.4 year. The stomach was the most frequent site 
of primary GIST location (38%). In fourteen patients (11%) a c-KIT exon 9 mutation was found, and 58 
patients (46%) had a tumor with an exon 11 mutation in c-KIT in the primary tumor. Other mutations 
were found in c-KIT exon 13 (n = 2), exon 14 (n =1), exon 17 (n =2) or in PDGFR exon 18 (n = 7). In 43 
patients (33.8%) the mutation in the primary tumor was unknown.  Most patients (76%) received 
sunitinib in an intermittent dosing scheme, starting sunitinib with 50 mg a day (n = 91, 72%) during the 
first 4 weeks, continued by 2 weeks off-dosing. 
At the time of analysis, 110 patients had stopped sunitinib treatment. In 87 patients (85%), this was 
because of PD and in all other cases because of severe toxicity. In the entire population, the median 
PFS was 7.6 months (interquartile range [IQR] 3.1-17.0 months) and the median OS was 18.3 months 
(IQR 9.7-29.3 months). The baseline characteristics of the study population are presented in Table 2. 
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Table 2 Baseline characteristics
Variable N (%) or mean (sd)
Gender
  male 80 (63)
  female 47 (37)
Age at start sunitinib (years) 61.2 (13.4)
Hospital
  LUMC 60 (47)
  EMC 43 (34)
  NKI 18 (14)
  UMCG 6 (5)
Primary location tumor
  stomach 48 (38)
  small bowel 36 (28)
  colon 7 (5)
  rectum 6 (5)
  unknown 30 (24)
Histology of primary tumor
  spindle cell 70 (55)
  epitheloid 12 (9)
  mixed 21 (17)
  unknown 24 (19)
Mutation
  exon 9 14 (11)
  exon 11 58 (46)
  other mutation or wild type 32 (25)
  unknown 21 (16)
WHO PS at start sunitinib
  0-1 98 (77)
  2-3 11 (9)
  unknown 18 (14)
Type of sunitinib treatment
  intermittent 97 (76)
  continuous 28 (22)
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Variable N (%) or mean (sd)
  unknown 2 (2)
Dose of sunitinib at start treatment
  12.5 mg 1 (1)
  25 mg 5 (4)
  37.5 mg 28 (21)
  50 mg 91 (72)
  unknown 3 (2)
Reason to stop sunitinib
  PD 87 (69)
  toxicity 23 (18)
  continued treatment 17 (13)
Abbreviations: BSA; body surface area, LUMC; Leiden University Medical Center, EMC; Erasmus MC 
Cancer Institute, NKI; Netherlands Cancer Institute, UMCG; University Medical Center Groningen, 
WHO PS; World Health Organization performance score, PD; progressive disease
Pharmacogenetic biomarkers for PFs
In the univariate analysis, PFS was longer for patients with the presence of the T-allele in KDR 
rs1870377 T/A (p = 0.033), the presence of the G-allele in IL13 rs20451 G/A (p = 0.025), the presence 
of the C-allele in VEGFA rs25648 T/C (p = 0.014), and in the absence of 2 GCT copies in the VEGFA 
haplotype (p = 0.042) in the pharmacodynamic genes. With respect to the pharmacokinetic SNPs that 
were tested, the presence of the homozygous TT-allele in POR rs1057868 C/T (p = 0.008), and the 
absence of two CCC-copies in the SLC22A5 haplotype (p = 0.007) were univariately associated with 
prolonged PFS. From the baseline characteristics length (HR 1.028; 95% CI: 1.002-1.055, p = 0.032), 
mitotic index of the primary tumor (HR 1.006, 95% CI: 1.000-1.012, p = 0.042), age at start of sunitinib 
(HR 0.986; 95% CI: 0.972-0.999, p = 0.037) and the reason to stop imatinib (PD 13.7 months, other 
than PD 29.9 months;  p = 0.01) were included in the multivariate analysis. 
Only the homozygous TT genotype in POR rs1057868 C/T (HR 0.232, 95% CI: 0.078-0.686, p = 0.008) 
was associated with PFS in the multivariate Cox regression analysis (Table 3). A trend towards shorter 
PFS was seen for the presence of 2 copies of the CCC SLC22A5 haplotype, compared to 1 or 0 copies 
(HR 2.358, 95% CI: 0.978-5.684, p = 0.056). 
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Pharmacogenetic biomarkers for os
In the univariate analysis two pharmacodynamic SNPs within VEGFA were predictive for longer OS 
(rs1570360 G/A, absence of the A allele; p = 0.005 and rs699947 C/A, presence of the C-allele; p = 
0.036), as well as the presence of a CGG-copy in the PDGFRA1 haplotype (p = 0.007) and the presence 
of the GC-other or other-other alleles in the IL4R haplotype (p = 0.008). Within the pharmacokinetic 
pathway, the presence of the C-allele in ABCC2 rs717620 C/T (p = 0.006), as well as presence of the 
T-allele in SLCO1B3 rs4149117 G/T (p = 0.054). Two haplotypes within the pharmacokinetic pathway 
were associated with longer OS: the absence of 2 CTT-copies in NR1l3 (p < 0.0001) and the absence of 
2 CCC-copies in SLC22A5 (p = 0.001).
From the baseline characteristics that were univariately tested against OS, a better survival was seen 
in patients who stopped imatinib for another reason than PD (PD 25.8 months OS, other than PD 55.4 
months OS, p = 0.001), the absence of liver metastasis at start of sunitinib (44.2 vs 27.4 months, p = 
0.093), and the absence of metastases at the time of diagnosis (37.6 vs 25.8 months OS, p = 0.025). 
Multivariate Cox regression analysis showed SLCO1B3 rs4149117 G/T, the absence of a T-allele (HR 
2.024, 95% CI: 1.013-4.044, p = 0.046), the presence of 2 copies of the CCC SLC22A5 haplotype (HR 
2.603, 95% CI: 1.216-5.573, p = 0.014), and the presence of 2 copies of the GC IL4R haplotype (HR 
7.131, 95% CI: 1.518-33.496, p = 0.013) as predictors for OS, as well as PD as a reason to stop imatinib 
(HR 3.025, 95% CI: 1.358-6.742, p = 0.007) and the presence of metastases at the time of the primary 
diagnosis GIST (HR 1.773, 95% CI: 1.044-3.012, p = 0.034). Data are presented in Table 4. 
Favorable genetic profile
Polymorphisms and haplotypes that were significantly associated with OS (SLCO1B3 rs4149117 G/T, 
the presence of the T-allele, the absence of a CCC-copy in the SLC22A5 haplotype and the absence of a 
GC-copy in the IL4R haplotype) were combined in a favorable genetic profile for PFS and OS, using the 
number of favorable genetic factors. 
The number of favorable genetic factors was significantly associated with longer survival (PFS 9.2 vs 
15.6 vs 28.4 months for respectively one, two or three favorable genetic factors, p = 0.005). There was 
only 1 patient with no favorable genetic factors in our population. In a multivariate regression model 
including the clinical factors (reason to stop imatinib, length and mitotic index of the primary tumor), 
this was confirmed (HR 0.654, 95% CI 0.512-0.836, p = 0.001, Figure 1A).
OS was significantly longer with an increasing number of positive predicting genetic factors (mean OS 
16.0 vs 31.5 vs 49.5 months for respectively one, two or three positive predictive genetic factors, p 
= 0.001). This was confirmed in a multivariate regression analysis, including the amount of favorable 
genetic factors and the clinical factors reason to stop imatinib, metastasis at primary diagnosis and 
liver metastasis at the start of sunitinib (HR 0.359, 95% CI 0.156-0.826, p = 0.016, Figure 1B).
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Figure 1. PFS (Figure 1A) and OS (Figure 1B) in patients with GIST treated with sunitinib being carriers of one, two 
or three favorable genetic variations
DIscussIoN
Patients with GIST treated with sunitinib have a large inter-patient difference in PFS and OS. This may 
in part be explained by various tumor cell-related factors such as secondary mutations and by some 
clinical factors.4 However, genetic polymorphisms within the pharmacokinetic and pharmacodynamic 
pathways may add to this as they affect the exposure to and the efficacy of the drug, and thereby 
influence the outcome of treatment as well. In this explorative study we showed in a population of 
129 patients with GIST, that polymorphisms in both the pharmacokinetic (SLCO1B3, SLC22A5 and POR) 
and the pharmacodynamic (IL4R) pathway of sunitinib are associated with PFS and OS in patients with 
advanced GIST treated with sunitinib. 
These findings indirectly suggest that survival to sunitinib in patients with GIST is subjected to 
exposure to sunitinib and its active metabolite. Sunitinib is metabolized by CYP3A4 and CYP3A5 into 
its active metabolite SU12662. This is converted to several inactive compounds by the same enzymes. 
The activity of cytochrome P450-enzymes is regulated by P450 oxydoreductase (POR). In our study, 
rs1056878, otherwise known as POR*28, was associated with prolonged PFS in sunitinib treated 
patients with GIST. Rs1056878 encodes for the amino acid variant A503V, and has been associated 
with lower activity of CYP1A2, CYP2D6, CYP3A5, but not of CYP3A4.7 The finding that the polymorphic 
variant of rs1056878 is associated with better PFS suggests that carriers of this variant have a lower 
activity of metabolizing enzymes resulting in higher plasma concentrations. Sunitinib is a substrate of 
the ATP-binding cassette ABCB1 and ABCG2 efflux transporters, playing a role in both uptake and efflux 
of sunitinib. However, none of the SNPs in these genes were associated with survival in our analysis. The 
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precise role of members of the organic cation transporter novel (OCTN) family and the organic anion-
transporting peptide (OATP) family in sunitinib absorption and elimination is unclear. However, SNPs 
in SLC22A5, which is the gene encoding for OCTN2, have been found to be associated with survival to 
imatinib in patients with GIST and CML.8 Interestingly, we found the SLC22A5 haplotype, consisting of 
rs2631367, rs2631370 and rs2631372 to be significantly associated with longer OS. Carriers of the two 
CCC-copies had significantly shorter OS than patients with other allelic combinations. This is consistent 
with the finding in imatinib treated patients with GIST.8 Other member of the OCTN family that were 
tested in this study did not show a significant association with PFS or OS. In SLCO1B3, which encodes 
OATP1B3, rs4149117 was also associated with prolonged OS. Possibly, sunitinib is a substrate of these 
efflux transporters as well, but this needs to be elucidated.
The homozygous GC-copy in the IL4R haplotype consisting of rs1801275, rs1805015 (Ser478Pro and 
Gln551Arg) was significantly associated with longer OS. In a previous study, SNPs in IL4R have been 
associated with the development of renal cell carcinoma.9 The finding that SNPs within IL4R are 
associated with OS in patients with GIST treated with sunitinib may be related to IL4R being involved 
in the tumor biology of GIST as well. 
A limitation of this study is that no pharmacokinetics of sunitinib as an intermediate endpoint were 
measured in this group of patients. Therefore, it can only be assumed that the effects of the SNPs on 
survival is caused by differences in pharmacokinetics. In a recent pharmacogenetic-pharmacokinetic 
study, CYP3A4*22 was found to have an effect size of > 20% on clearance.10 However, this finding was 
not statistically significant.
Another limitation of this study is the sample size. Although this is the largest pharmacogenetic study 
in patients with GIST treated with sunitinib so far, the number of patients with specific genotypes 
is too small to draw conclusions from. Since this was an exploratory study, no formal correction for 
multiple testing was performed and results from the multivariate analyses with a p-value less than 0.05 
were considered significant. Currently, the False Discovery Rate (FDR) is frequently used to control for 
reporting false positives in exploratory studies. Therefore, we calculated FDR values for each separate 
endpoint in a post-hoc analysis. FDR was below 10% for all SNPs with p<0.05 indicating a low likelihood 
of false positive findings. 
In our current study, SNP that were found associated with prolonged PFS, were not associated with 
OS and vice versa. This is somewhat surprising, since PFS and OS can be expected to be related to 
each other. However, while PFS only includes the effects of sunitinib treatment, OS also embodies 
the effects of any subsequent lines of treatment. Patients in our study received sunitinib over a broad 
area of time. In the first years after the registration of sunitinib, no good third line of treatment was 
available, but patients were frequently offered other treatment in the context of clinical studies. Since 
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recently, regorafenib has been approved for third line treatment of GIST after failure of imatinib and 
sunitinib.11 This may have caused a bias in the overall survival in our analysis. Still, we showed in a large 
group of patients that genetic polymorphisms can serve as a biomarker for overall survival.
Progressive disease as the reason to stop imatinib treatment was univariately associated with both 
worsened PFS and worsened OS. In the multivariate analysis this was only confirmed for OS, but not 
for PFS. The existence of metastases at the time of the primary diagnosis was also associated with 
worse OS. Possibly, the tumor has a more aggressive behavior when metastasis are present at first 
diagnosis and when the tumor has already progressed on imatinib, rather than the patient switched 
to sunitinib for other reasons, resulting in shorter OS. 
Previously it has been described that primary mutations in c-KIT and PDGFRA may be predicting for 
the survival obtained by sunitinib in patients with GIST, this was not seen in our study. This may be 
explained by the fact that all patients were pre-treated with imatinib. It has been shown that during the 
treatment with imatinib, secondary mutations may arise, leading to imatinib-resistance.4 Therefore, 
mutations that are found in the primary tumor may not be representative of the mutations within the 
tumor after treatment with imatinib. 
Altogether we may conclude that polymorphisms in genes encoding for proteins related to the 
pharmacokinetic and pharmacodynamic pathways of sunitinib are associated with survival in patients 
with GIST treated with sunitinib. When validated in the future, this may be useful to predict which 
patient is going to respond to sunitinib therapy, and which patients may better respond to other 
treatment types.
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ABsTrAcT
Background Imatinib is first line therapy for advanced gastrointestinal stromal tumors (GIST). 
Clinical response is high, but primary and secondary resistance are common. This study explores 
the effects of single nucleotide polymorphisms (SNPs) in genes related to the pharmacokinetics and 
pharmacodynamics of imatinib on its efficacy in patients with advanced GIST. 
methods In 255 advanced patients with GIST, a retrospective pharmacogenetic pathway analysis was 
performed using genotype data from 36 SNPs in 18 genes, as well as clinical factors, to investigate their 
effects on progression free survival (PFS) and overall survival (OS. Selected genetic and clinical factors 
were entered into a multivariate model. 
results In the multivariate model significant hazard ratios were found for PFS in patients with 
synchronous metastasis (HR 1.74, P=0.005), KIT exon 9 mutation (HR 1.94, p=0.040), and the SNPs KDR 
rs2305948 (TT genotype, HR 4.57, p=0.041) and VEGFA rs1570360 (AA genotype, HR 1.77, p=0.025). 
Significant hazard ratios for OS were found in patients with synchronous metastasis (HR 2.07, p=0.004), 
and the SNPs KDR rs1870377 (AA genotype, HR 2.33 ,p=0.017), VEGFA rs1570360 (AA genotype, HR 
2.01, p=0.026) were found, whereas a T allele in SLCO1B3 rs4149117 was associated with longer OS 
(HR 0.475, p=0.017).
conclusion This exploratory pathway analysis of imatinib efficacy in advanced GIST patients shows 
that polymorphisms in VEGFA, KDR and SLCO1B3 may be predictive for an effect on PFS and/or OS. 
If validated, these SNPs may serve as biomarkers to identify patients with an increased chance of 
progressive disease. 
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INTroDucTIoN
Imatinib mesylate (Gleevec®, Glivec®, Novartis, Switzerland) is the first line therapy for chronic 
myeloid leukemia (CML) and advanced gastrointestinal stromal tumors (GIST).1,2 It has revolutionized 
the treatment of these two malignancies in achieving marked survival benefit with limited toxicity.3 
In these two malignancies, clinical response to this oral tyrosine kinase inhibitor (TKI) is determined 
by etiologic mutation(s), as well as by germline genetic variations.4,5 Single Nucleotide Polymorphisms 
(SNPs) are the most common genetic variations in germline. SNPs can have various outcomes, ranging 
from silent mutations to affecting gene expression and enzyme function. The pharmacokinetics and 
pharmacodynamics of imatinib may be changed in due to SNPs in genes encoding for enzymes and 
target protein regulating imatinib pharmacology. 
GIST is a mesenchymal tumor of the digestive tract, often caused by gain-of-function mutations 
in the genes encoding for KIT or PDGFR-α or –β.6,7 These mutations result in ligand independent 
autophosphorylation of these receptors leading to uncontrolled proliferation of the interstitial cells of 
Cajal, which serve as pacemaker cells in the gastrointestinal tract. However, in some GISTs no KIT or 
PDGFR- α or - β mutations are found. This group of so called ‘wild type’ GIST becomes increasingly rare 
as new mutations in other genes are found to be etiologically related to this malignancy.8 KIT mutations 
are routinely screened in GIST to predict imatinib efficacy which is dependent on the location of the 
KIT mutation; presence of exon 11 mutations predict good response to imatinib, whereas mutations 
in exon 9 are predictive for limited objective response to imatinib in the standard dose.4 Disease 
progression has also been associated with a variety of clinical factors, such as the location of the 
primary tumor.9 It may also result from decreased imatinib concentrations; a mechanism called 
pharmacokinetic resistance.10
In CML treatment, complete cytogenetic response to imatinib has been associated with germline 
SNPs in genes encoding for enzymes which have a role in the metabolism of imatinib. In addition, 
polymorphisms in the genes encoding for the efflux transporter ABCG2 and for the influx transporter 
SLC22A1, have been associated with poor response and progression to advanced disease, respectively.11 
For patients with advanced GIST treated with imatinib, associations have been reported for SNPs 
in SLC22A4 and SLC22A5 and time to progression. The effects of the genes encoding for the influx 
transporters OCTN1 and OCTN2, respectively, was independent of mutational status and tumor size.12 
Since this single report, no studies have been published exploring the effects of SNPs on the efficacy of 
imatinib in patients with advanced GIST.
Therefore, this study investigates the effects of genetic variants on imatinib efficacy in patients with 
advanced GIST. A pharmacogenetic pathway analysis was performed including SNPs in genes encoding 
proteins and enzymes related to the pharmacokinetics and pharmacodynamics of imatinib.
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meTHoDs
Patients
For this retrospective study GIST patients were included who have been treated in four Dutch referral 
centers (Erasmus MC Cancer Institute, Leiden University Medical Center, Antoni van Leeuwenhoek - 
Netherlands Cancer Institute and University Medical Center Groningen). All patients had a histology of 
proven GIST and documented advanced disease, being either relapsed or metastatic. Patients started 
imatinib therapy between November 2000 and May 2013. All patients had to be treated at least until 
the first evaluation of anti-tumor activity, with the exemption of patients with clinical progression 
before this moment, who were scored as such. DNA was obtained from residual blood samples that 
were collected for routine patient care or, in the Erasmus MC Cancer Institute, after specific informed 
consent was obtained (MEC 02.1002), and stored at -20°C or colder until genotyping. In the Antoni 
van Leeuwenhoek - Netherlands Cancer Institute only serum of these samples was stored. If a residual 
blood or serum sample was not available, DNA was obtained from residual formalin fixated paraffin 
embedded (FFPE) resection specimen. All samples were anonymized by a third party and the Code for 
Proper Secondary Use of Human Tissue was adhered to (www.federa.org/codes-conduct).13
sNP selection
SNPs in genes related to imatinib pharmacokinetics and pharmacodynamics were selected using a 
pathway approach. Metabolizing enzymes and potential targets of imatinib were selected and the 
literature was screened for SNPs in applicable genes. Using Haploview and HapMap data (release 28), 
SNPs in linkage were identified to efficiently select candidate SNPs. A minimum minor allele frequency 
of 0.1 was set. Additionally, the database of the National Institute of Environmental Health Sciences 
was used to select only the SNPs with an expected functional change. Finally, a total of 36 SNPs in 18 
genes were selected (Table 1).
Genotyping
DNA was isolated from blood, serum or FFPE samples using the MagnaPure Compact (Roche 
Diagnostics, Almere, the Netherlands) and stored at -20°C or colder. For optimal genotyping results, 
DNA isolated from serum and FFPE samples was pre-amplified.14 A custom array was developed for 
the QuantStudio™ 12K Flex Real-time PCR system (Life Technologies, Bleiswijk, the Netherlands) and 
DNA was genotyped according to the manufacture’s protocol. To achieve a satisfactory call rate for 
all SNPs, a number of SNPs were subsequently genotyped using commercially available realtime PCR 
genotyping assays (Life Technologies, Bleiswijk, the Netherlands) according to the manufacture’s 
protocol or in house developed Pyrosequencing assays (Qiagen, Venlo, the Netherlands.
To explore haplotypes in the study population Haploview 4.215 and Plink 1.716 were used. SNPs in the 
same gene were tested and considered to be in a haplotype in case D’ was at least 95%. Only patients 
with a ≥95% probability of the assigned allele were included in the analyses. 
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Table 1 selected SNPs in pharmacokinetics and pharmacodynamics of imatinib
Gene rs number chromosome Allele change change type call rate p value HWe study mAF
ABCG2 rs2231137 4 G/A Splicing 93.7 0.016 0.061
ABCG2 rs2231142 4 C/A Splicing 99.6 0.225 0.128
SLC22A5 rs2631367 5 C/G TFBS 97.6 0.502 0.45
SLC22A5 rs2631370 5 T/C TFBS 99.6 0.226 0.39
SLC22A5 rs2631372 5 C/G TFBS 100 0.776 0.294
SLC22A1 rs628031 6 G/A Splicing 98.8 0.378 0.421
SLC22A1 rs683369 6 C/G Splicing 99.6 0.561 0.281
SLC22A1 rs6935207 6 G/A TFBS 95.7 0.114 0.236
ABCB1 rs1045642 7 C/T Splicing 99.6 0.316 0.498
ABCB1 rs868755 7 G/T Splicing 99.6 0.546 0.433
ABCB1 rs28656907 7 C/T TFBS 91 0.285 0.517
SLC22A4 rs1050152 5 C/T Splicing 99.6 0.713 0.409
CYP3A4 rs2740574 7 A/G TFBS 99.6 0.046 0.047
POR rs1057868 7 C/T nsSNP 99.6 0.468 0.323
ABCC2 rs717620 10 C/T TFBS 99.2 0.346 0.186
CYP1A1 rs1048943 15 A/G nsSNP 100 0 0.045
CYP1A2 rs762551 15 A/C TFBS 99.2 0.867 0.304
SLCO1B3 rs4149117 12 G/T Splicing 92.2 0.311 0.126
PDGFRA rs1800810 4 C/G TFBS 99.2 0.382 0.231
PDGFRA rs1800812 4 G/T TFBS 99.6 0.284 0.234
PDGFRA rs1800813 4 A/G TFBS 98.4 0.421 0.217
PDGFRA rs2228230 4 C/T Splicing 100 0.95 0.186
PDGFRA rs35597368 4 C/T Splicing 100 0.153 0.135
KDR rs1870377 4 A/T nsSNP 97.6 0.332 0.239
KDR rs2071559 4 C/T TFBS 99.2 0.489 0.457
KDR rs2305948 4 C/T nsSNP 100 0.935 0.086
VEGFA rs1570360 6 G/A TFBS 96.5 0.041 0.319
VEGFA rs2010963 6 G/C TFBS 98 0.284 0.336
VEGFA rs25648 6 C/T Splicing 100 0.104 0.188
VEGFA rs3025039 6 C/T miRNA 100 0.012 0.131
VEGFA rs699947 6 A/C TFBS 96.5 0.614 0.51
VEGFA rs833061 6 C/T TFBS 93.7 0.219 0.498
FLT4 rs6877011 5 C/G miRNA 100 0.54 0.073
RET rs1799939 10 G/A Splicing 100 0.514 0.161
FLT3 rs1933437 13 T/C Splicing 99.2 0.27 0.411
FLT1 rs7993418 13 A/G Splicing 100 0.19 0.19
Splicing; Splicing modifying, TFBS; Transcription Factor Binding Site, nsSNP; Non-Synonymous SNP, miRNA; Micro 
RNA aleration, HWE; Hardy Weinberg Equilibrium, MAF; Minor Allele Frequency
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statistics
Clinical and demographic factors were collected from patient files, including ethnicity. Progression 
free survival (PFS) was defined as the time between the date of start of imatinib treatment and the 
date of progressive disease, according to either clear clinical progression or to RECIST 1.1 definition of 
progressive disease. If patients were still on treatment at the last date of follow-up, PFS was censored 
at that date. Overall survival (OS) was defined as the time between the date of start of imatinib 
treatment and death due to GIST. OS was censored at the last date of follow-up if a patient was alive at 
that time, or a day before death if a patient died due to an unrelated event or disease. 
SNPs and haplotypes were univariately tested with Kaplan Meier analysis for an association with PFS 
and OS, using the general model. Clinical factors were tested univariately with either Kaplan Meier or 
Cox regression. If univariate analyses showed a trend for a difference in survival, with the threshold 
for the p value set a P < 0.1, these factors were entered into the multivariate Cox regression model. 
For genetic factors the most appropriate genetic model was selected (multiplicative, dominant or 
recessive). These models tested for associations for either PFS or OS with the respective variables 
found in the univariate analyses. Missing clinical factors were imputed using SPSS multiple imputation 
tool with the following factors entered: sex, age at diagnosis, length, weight, ethnicity (Caucasian or 
else), histology (spindle cell or else), primary tumor location (stomach or else), mutation (KIT exon 
9, KIT exon 11, or rest group), metastasis at diagnosis, WHO performance score at start of imatinib 
treatment, liver metastasis at start of imatinib, and WHO performance score at start of sunitinib 
treatment, liver metastasis at start of sunitinib. Data at the start of sunitinib was used, as these are be 
correlated with liver metastasis and WHO performance at start of imatinib. The number of imputations 
was set at 100 and the results of the pooled analyses was reported. Factors in these analyses with P < 
0.05 were deemed statistically. Due to the explorative nature of this study no correction for multiple 
testing was performed. SPSS version 20 (IBM Corp., Armonk, NY, United States) was used. 
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resuLTs
study population
DNA was available for a total of 255 patients. The majority of the samples was isolated from residual 
blood (215 patients) and smaller numbers from serum (26 patients) and FFPE samples (14 patients). 
The baseline characteristics of the study population are depicted in Table 2, including the percentages 
of missing data per variable. The median PFS for the study population was 37.6 months (95% confidence 
interval (CI): 27.8 - 47.3 months) and the median OS 84.7 months (95% CI: 74.0 - 95.5 months). At 
the time of analysis, 132 patients (51.8%) had had progressive disease, 95 patients (37.3%) had died 
due to GIST and 10 patients had died due to other diseases, such as myocardial infarction or lung 
cancer. The median time of follow-up was 72 months (95% CI: 61.1 - 82.8 months), as calculated by 
the reversed Kaplan Meier estimator.
Baseline characteristics associated with PFS were length (p=0.003), ethnicity (p=0.027), histology 
(p=0.017), mutation status (p=0.040) and synchronous metastasis at the time of diagnosis (p=0.0001) 
(Table 3). Overall survival was associated with length (p=0.004), primary location (p=0.085), histology 
(p=0.003), synchronous metastasis (p=0.0003) and the WHO performance score at start of imatinib 
(p=0.026) (Table 4). Mutation status was not associated with OS (p=0.554, data not shown). These 
factors were included in the applicable Cox regression model.
6
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Table 2: baseline characteristics of study population
median or N (%)
Age at diagnosis (years) 59 
Length (cm) 174 
Weight (kg) 78 
sex male 151 (59.2)
female 104 (40.8)
ethnicity Caucasian 220 (86.3)
other 20 (7.8)
unknown 15 (5.9)
Primary location stomach 94 (36.9)
other 107 (42.0)
   small bowel 75 (29.4)
   rectum 20 (7.8)
   colon 10 (4.0)
   esophagus 2 (0.8)
unknown 54 (21.1)
Histology spindle cell 228 (60.8)
epithelioid and mixed 52 (20.4)
unknown 48 (18.8)
mutation found KIT exon 11 126 (49.4)
KIT exon 9 22 (8.6)
other 58 (22.8)
unknown 49 (19.2)
mitosis index ≤ 5 per 50 HPF 37 (14.5)
>5 per 50 HPF 122 (47.8)
unknown 96 (37.7)
metastases at diagnosis present 102 (40.0)
not present 151 59.2)
unknown 2 (0.8)
Liver metastasis present 147 (57.6)
not present 108 (42.4)
WHo Ps 0-1 208 (81.6)
2-Mar 13 (5.1)
unknown 34 (13.3)
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Pharmacogenetic factors associated with PFs
In the univariate analysis, SNPs related to the pharmacodynamics of imatinib showed (a trend for) 
shorter PFS for patients with AA genotype in KDR SNP rs1870377 (TT+AT vs AA, p=0.052) and for the 
TT genotype in KDR rs2305948 (CC+CT vs TT, p=0.019). The AA variant in VEGFA rs1570360 was also 
associated with shorter PFS (GG+GA vs AA, p=0.027) (Table 3). All SNPs related to the pharmacokinetics 
of imatinib did not show an association with PFS in univariate tests.
Together with the selected clinical factors, these SNPs were entered into the multiple imputed Cox 
regression model. This model showed that presence of synchronous metastasis and a KIT exon 9 
mutation are predictive for shorter PFS (HR 1.74, p=0.050 and HR 1.94, p=0.040, respectively). The 
KDR rs2305948 and VEGFA rs1570360 SNPs also showed a significant association for PFS, and in both 
cases the homozygote minor variant was associated with shorter PFS (HR 4.57, p=0.041 and HR 1.77, 
p=0.025, respectively).
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Pharmacogenetic factors associated with os
In the univariate analysis, rs4149117 in SLCO1B3 was associated with PFS. Patients with the GG 
genotype in SLCO1B3 rs4149117 had longer PFS (GG vs GT+TT, p=0.042), see Table 4. The AA genotype 
in KDR rs1870377 and the AA genotype in VEGFA r1570360 were associated with shorter OS (p=0.037 
and p=0.027, respectively). 
When these SNPs were entered into the multiple Cox regression model together with the selected 
clinical factors, only synchronous metastasis was significantly associated was (HR 2.08, p=0.004). 
The AA genotype in KDR rs1870377 and in VEGFA rs1570360 were associated with a shorter OS 
as compared to patients with at least one wild-type allele (HR 2.3, p=0.017 and HR 2.01, p=0.026, 
respectively). The GG genotype variant in SLOC1B3 showed a shorter OS compared to patients either 
GT or TT (HR 0.47, p=0.017).
 
(un)favorable genetic profile
The study population was sorted into a group with a favorable genetic profile (195 patients) and a 
group with an unfavorable profile (46 patients), based on the multivariate analysis of PFS. For selection 
into the unfavorable profile, patients had to have either the AA genotype in KDR rs1870377, the TT 
genotype in KDR rs2305948, or the AA genotype in VEGFA rs1570360. Univariate Kaplan Meier curves 
of PFS and OS showed a significant difference for both groups. The median PFS for patients with the 
unfavorable profile was 18.8 months short of the PFS for the favorable profile (43.8 vs 25.0 months, 
p=0.004). The difference in median OS was 32.3 months (66.6 vs 98.9 months, p=0.008), as showed 
in Figure 1. Taking the selected clinical factors into account, this effect was consistent in the multiple 
imputed multivariate Cox regression model for PFS (HR 2.00, 95% CI 1.30 - 3.01, p=0.002) and for OS 
(HR 2.62, 95% CI 1.56 - 4.39, p=0.0003), as depicted in Table 5.
Figure 1 Progression free survival (PFS) and overall survival (OS) in months of GIST patients treated with imatinib 
according to (un)favorable genetic profile. Out of a total of 255 patients, 195 had a favorable profile and 46 had an 
unfavorable profile (the latter based on either AA genotype in KDR rs1870377, TT genotype in KDR rs2305948, or 
AA genotype in VEGFA rs1570360). For PFS, p=0.004, for OS, p=0.008
Time after start imatinib (months)
129630
Pr
ob
ab
ili
ty
 o
f o
ve
ra
ll 
su
rv
iv
al
1,0
0,8
0,6
0,4
0,2
0,0
P = 0.008
Page 1
Time after start imatinib (months)
129630
Pr
ob
ab
ili
ty
 o
f p
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l 1,0
0,8
0,6
0,4
0,2
0,0
P = 0.004
Page 1
6
117
Ta
bl
e 
5 
m
ul
ti
va
ri
at
e 
an
al
ys
is
 w
it
h 
ge
ne
ti
c 
pr
ofi
le
 o
f p
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l (
PF
S)
 a
nd
 o
ve
ra
ll 
su
rv
iv
al
 (O
S)
 in
 G
IS
T 
pa
ti
en
ts
 t
re
at
ed
 w
it
h 
im
ati
ni
b
PF
s 
m
ul
ti
va
ri
at
e 
co
x 
re
gr
es
si
on
 a
na
ly
se
s
o
s 
m
ul
ti
va
ri
at
e 
co
x 
re
gr
es
si
on
 a
na
ly
se
s
 N
 p
ati
en
ts
H
R
95
%
 C
I
p 
va
lu
e
H
R
95
%
 C
I
p 
va
lu
e
Le
ng
th
1.
01
3 
pe
r 
cm
0.
99
4 
- 1
.0
33
0.
18
0
1.
02
1 
pe
r 
cm
0.
99
7 
- 1
.0
45
0.
09
0
in
cr
ea
se
in
cr
ea
se
et
hn
ic
it
y
Ca
uc
as
ia
n
22
0
1
0.
22
2
n/
a
no
n-
Ca
uc
as
ia
n
20
0.
56
3
0.
22
4 
- 1
.4
14
Pr
im
ar
y 
lo
ca
ti
on
st
om
ac
h
91
n/
a
1
0.
10
0
el
se
w
he
re
10
6
0.
66
2
0.
40
4 
- 1
.0
82
H
is
to
lo
gy
sp
in
dl
e 
ce
ll
15
5
1
0.
25
8
1
0.
11
2
ep
it
he
lio
id
 a
nd
 m
ix
ed
52
1,
29
5
0.
82
8 
- 2
.0
25
1,
51
6
0.
90
8 
- 2
.5
31
sy
nc
hr
on
ou
s 
m
et
as
ta
si
s
ab
se
nt
15
1
1
0.
00
5
1
0.
00
5
pr
es
en
t
10
2
1,
82
0
1.
23
8 
- 2
.6
74
1,
97
8
1.
22
3 
- 3
.2
00
m
ut
ati
on
KI
T 
ex
on
 9
22
1,
89
1
1.
01
1 
- 3
.5
38
0.
04
6
KI
T 
ex
on
 1
1
12
6
1
n/
a
ot
he
r 
gr
ou
p
58
1,
30
3
0.
87
4 
- 2
.0
08
0.
23
0
W
H
o
  p
s
0-
1
20
7
n/
a
1
0.
27
7
2-
M
ar
11
1,
74
1
0.
64
1 
- 4
.7
32
KD
R 
rs
18
70
37
7,
ot
he
r 
vs
19
5
1
0.
00
2
1
0.
00
03
KD
R 
rs
23
05
94
8 
an
d
A
A
 o
r 
TT
 o
r 
A
A
46
2,
00
4
1.
30
2 
- 3
.0
85
2,
61
6
1.
55
7-
 4
.3
93
VE
G
FA
 r
s1
57
03
60
In
 m
ul
ti
va
ri
at
e 
an
al
ys
es
 m
is
si
ng
 c
lin
ic
al
 fa
ct
or
s 
w
er
e 
im
pu
te
d,
 th
e 
po
ol
ed
 a
na
ly
si
s 
of
 1
00
 im
pu
ta
ti
on
s 
is
 re
po
rt
ed
; H
R=
 H
az
ar
d 
Ra
ti
o:
 H
R 
> 
1.
0 
in
di
ca
te
s 
as
so
ci
ati
on
 
w
it
h 
w
or
se
 s
ur
vi
va
l a
nd
 v
ic
e 
ve
rs
a:
 t
he
 e
ff
ec
t 
of
 t
he
 m
ut
ati
on
 h
as
 K
IT
 e
xo
n 
11
 c
om
pa
re
d 
to
 b
ot
h 
KI
T 
ex
on
 9
 a
nd
 t
he
 o
th
er
 g
ro
up
 (o
th
er
 m
ut
ati
on
s 
in
 K
IT
, P
DG
FR
 
or
 ‘w
ild
-t
yp
e’
):
 9
5%
 C
I=
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
, n
/a
= 
no
t 
ap
pl
ic
ab
le
Time after start imatinib (months)
129630
Pr
ob
ab
ili
ty
 o
f o
ve
ra
ll 
su
rv
iv
al
1,0
0,8
0,6
0,4
0,2
0,0
P = 0.008
Page 1
6
Genetic Polymorphisms in Angiogenesis Related Genes are Predictive for Survival of Patients with Advanced Gastrointestinal Stromal Tumors treated with Imatinib
118 Chapter 6
DIscussIoN
This exploratory pharmacogenetic study shows that SNPs in the genes encoding for VEGFA, KDR (also 
known as VEGFR2) and SLCO1B3 (also known as OATP1B3) are associated with PFS and OS in patients 
with advanced GIST treated with imatinib. To the best of our knowledge, this cohort of 255 patients 
is the largest patient group to be used for a pharmacogenetic study concerning imatinib treatment 
in GIST. The median follow-up of 72 months is long enough to qualify these data as mature. The SNP 
selection for this study was performed using predefined criteria, including a biological rationale based 
on imatinib pharmacology and expected functionality. Therefore, the SNPs found warrant validation 
in a prospective study.
So far, only one small pharmacogenetic study exploring the effects of SNPs in genes related to imatinib 
pharmacokinetics on its efficacy was performed in patients with advanced GIST. This Italian study 
investigated 31 SNPs in a population of 54 patients.12 Three SNPs in the influx transporters SLC22A4 
(rs1050152) and SLC22A5 (rs2631367 and rs2631372) were associated to time to progression, 
independent of mutational status, tumor size, age and sex. These SNPs were also tested in the present 
study, but the univariate tests with the general model were inconclusive.
Several SNPs in vascular endothelial growth factor A (VEGFA) were tested. VEGFA has many effects, 
most prominently being the activity in angiogenesis. In this study, the AA genotype in rs1570360 was a 
predictive marker for both PFS and OS. Other SNPs in VEGFA such as rs699947 have been associated to 
imatinib effect in CML patients, but none other of the tested SNPs showed a significant association in 
this study population.5 In adjuvant GIST patients, SNPs in VEGFA have been tested for effect on relapse 
rate, but for none of those SNPs, which were also tested in this study, an association was observed.17
The kinase insert domain receptor (KDR) is a tyrosine kinase receptor for VEGF. The TT genotype in 
rs2305948 had a profound effect on PFS, despite only two patients had this genotype. Larger studies 
will need to be performed to assess this SNP in this setting. The AA genotype in rs1870377 appears 
to have a negative effect on OS (and less so on PFS) in the present study population, but this was not 
seen in the study that also investigated SNPs in KDR in for an effect on GIST relapse rate.17 In contrast, 
a study with CML patients reported better clinical outcome for patients with the AA genotype in 
rs1870377.5 This contradiction may be caused by differences in tumor biology of solid vs hematological 
malignancies.
Patients with at least one T allele in rs4149117 in SLCO1B3 had longer OS. The solute carrier organic 
anion transporter family member (SLCO) 1B3 is an influx transporter with imatinib as a substrate and 
mainly expressed in hepatocytes, and also in leucocytes.18 Although this SNP did not show a trend 
when tested for PFS in the general model, the GG vs GT+TT model did show a trend (data not shown). 
A recent study performed with Brazilian CML patients reported that the frequency of patients with 
the TT genotype was higher in the responder group than in the non-responder group.19 These results 
6
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are in line with a Japanese study, which found enhanced transporter function in patients with the TT 
genotype, as measured by higher intracellular imatinib levels.20 
In order to perform multivariate analyses, missing baseline factors were imputed, assuming that these 
data were missing at random. In the analysis of PFS, the significant clinical and genetic factors in the 
imputed model had a similar size and direction of effect as in the non-imputed model. KDR rs1870377 
was not significantly associated with PFS in the imputed model and it had a different direction of effect 
in the non-imputed model. For OS, the variables had similar size and direction of effect in both the 
imputed and non-imputed Cox regression model, thus legitimating the imputation of missing variables.
The distribution of the mutational status and location of the primary tumor differed to clinical trials. 
This may be attributed to the specific selection biases affecting both clinical trials (with a generally 
fitter study population) and retrospective studies (where baseline data may be missing). To include 
GIST patients whose DNA was not available by means of residual blood or serum samples, pathology 
samples were used instead, if these could be obtained. Out of the 38 SNPs tested, 5 were not in 
Hardy-Weinberg equilibrium. These SNPs were retained in the analyses, as the MAF was did not differ 
substantially from the National Center Biotechnology Information database (www.ncbi.nlm.nih.gov/
snp), and patient selection due to the retrospective nature of the study was considered the most 
plausible reason. The raw genotyping output indicated adequate assay quality and duplications gave 
the compatible results.
As previously reported, the effects of the oncogenic somatic mutation on imatinib efficacy were also 
found in this study. Tumors with a KIT exon 11 mutation were more sensitive to imatinib, especially 
compared to tumors with KIT exon 9 mutations.4 Having GIST metastases was clearly associated with 
reduced survival. These metastases may be considered heterogeneous and some clones will progress 
despite imatinib activity in the majority of GIST lesions.21 Other clinical factors were not associated 
with survival in this advanced patient group, even though factors such as the primary tumor site have 
been reported in other studies.9 Remarkably, SNPs in pharmacokinetic genes encoding for ABCB1, 
ABCG2, SLC22A1, SL22A5 or CYP3A4, or haplotypes herein were not associated with a difference in 
survival, despite previous, sometimes conflicting, reports.5,10-12,17,22-25 
This retrospective exploratory study investigated the effects of polymorphisms in genes related to the 
pharmacokinetics and pharmacodynamics of imatinib in the treatment of advanced GIST. One SNP in 
the pharmacokinetic pathway (rs4149117 in SLCO1B3) and two SNPs related to pharmacodynamics 
(rs1870377 in KDR, and rs1570360 in VEGFA) showed significantly different Hazard Ratios for PFS or 
OS. These polymorphisms, together with clinical factors such as tumor mutation and metastases, may 
identify patients who are most at risk of developing progressive disease before it can be expected in 
this population. If these findings are validated, they may proof useful in selecting patients whom may 
benefit from more frequent evaluation of antitumor efficacy.
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Incidence and relevance of QTc-interval prolongation 
caused by Tyrosine Kinase Inhibitors
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ABsTrAcT
Background Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc-interval on 
the ECG. QTc-interval prolongation increases the risk for life threatening arrhythmias. However, studies 
evaluating the effects of TKIs on QTc-intervals are limited and only consist of limited patient numbers.
methods In this multicentre trial in four centres in the Netherlands and Italy we screened all patients 
who were treated with any TKIs. To evaluate the effects of TKIs on the QTc-interval we investigated 
ECGs prior to and during treatment with erlotinib, gefitinib, imatinib, lapatinib, pazopanib, sorafenib, 
sunitinib, or vemurafenib.
results A total of 363 patients were eligible for the analyses. At baseline measurement, QTc-intervals 
were significantly longer in females than in males (QTc
females
 = 404 ms vs. QTc
males
 = 399 ms, P = 0.027). A 
statistically significant increase was observed for the individual TKIs sunitinib, vemurafenib, sorafenib, 
imatinib, and erlotinib, after the start of treatment (median ΔQTc ranging from +7 to +24 ms, P < 
0.004). The CTCAE grade for QTc-intervals significantly increased after start of treatment (P = 0.0003). 
Especially patients who are treated with vemurafenib are at increased risk of developing a QTc ≥ 470 
ms, a threshold associated with an increased risk for arrhythmias.
conclusion These observations show that most TKIs significantly increase the QTc-interval. Particularly 
in vemurafenib treated patients, the incidence of patients at risk for arrhythmias is increased. 
Therefore, especially in case of combined risk factors, frequent ECG controls in patients treated with 
TKIs are strongly recommended.
7
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INTroDucTIoN
Long QT syndrome (LQTS) is a myocardial repolarization disorder characterized by prolongation of 
the QT-interval on the surface electrocardiogram (ECG). The clinical presentation of LQTS consists of 
palpitations, syncope, seizures, and sudden cardiac death due to a characteristic arrhythmia known as 
torsades de pointes (TdP).1-3
Several factors, such as gender, age, electrolyte disturbances, cardiovascular diseases (CVD) and 
different types of drugs can affect the duration of the QT-interval.4, 5 Due to the risk of fatal arrhythmias, 
the US Food and Drug Administration (FDA) now obliges to perform thorough studies to evaluate the 
potency of new drugs to induce QT-interval prolongation in preclinical and early phase I clinical trials 
in healthy individuals.2 However, for new anticancer drugs these studies are usually not performed in 
healthy individuals because of their toxicity profile.6, 7 
As with many drugs, tyrosine kinase inhibitors (TKIs) are reported to prolong the QT-interval.8-16 In vitro 
studies demonstrated that lapatinib and imatinib interact with the phosphorylation of the cardiac 
hERG channel. This results in a reduction of the repolarizing current (IKr), which can lead to action 
potential prolongation and subsequent QT-interval prolongation.11, 13
In a small prospective clinical study to evaluate the cardiac safety of lapatinib in 21 patients, an overall 
QTc increase of 8.63 ms was seen.9 In three prospective post-marketing studies in patients with solid 
tumours treated with sorafenib (N = 31), pazopanib (N = 48) and sunitinib (N = 24) a modest increase 
of 9.0 ms of QTc-interval with the use of sorafenib, 4.4 ms after start of pazopanib and 9.6 ms after 
start of sunitinib was seen.8, 12, 16
Still, these drugs have been approved by the FDA because they appear highly effective in situations 
where treatment options are limited. With an increasing number of TKIs on market, a relative long 
on-treatment time, and the application in the adjuvant setting, which is for example already standard 
for imatinib in patients with localised GIST with a high risk to relapse, and which is being explored for 
other TKIs in various tumour types, thorough QTc studies in this group of drugs is necessary to get more 
insight into their cardiac safety. In this multicentre study performed in four centres in the Netherlands 
and Italy, we describe the incidence and relevance of QTc-interval prolongation in patients with cancer 
treated with different types of TKIs.
meTHoDs
study design
We undertook a retrospective study in patients with solid malignancies, who were treated with any 
type of TKI. Patients from four centres in the Netherlands (Erasmus MC Cancer Institute, Rotterdam, 
Leiden University Medical Centre, Leiden, and Netherlands Cancer Institute – Antoni van Leeuwenhoek, 
Amsterdam) and Italy (Salvatore Maugeri Foundation, Pavia) were included.
7
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This study was reviewed and approved by the Erasmus MC Medical Ethical Board (MEC 2013-148). 
All ECGs were obtained as standard clinical care. Demographical and clinical characteristics of the 
analysed cohort were collected using clinical record forms designed for this study.
Patients were considered eligible if they were aged ≥ 18 years, were treated for solid tumours with any 
type of TKI and if at least one ECG prior to start of TKI treatment and one ECG during treatment with 
TKI were available. Exclusion criteria were as follows: ECGs which do not match criteria for accurate 
QTc-interval measurements (intra-ventricular conduction delay and/or pace-maker driven rhythm), 
missing ECGs at baseline or during therapy, and patients with a time-lapse between baseline ECG 
and start of TKI treatment > 1 year. Patients who were subsequently treated with different TKIs were 
included once. 
Definition of QTc prolongation
Since increases of the heart rate results in shortening of the QT-interval, a correction for heart rate was 
applied using the Bazett formula:17
    QTc = QT/√RR
In this formula RR is the interval between two subsequent R-tops. 
QTc was discretized according to the common terminology criteria for adverse events (CTCAE) 
guidelines version 4.03 (grade 0, QTc < 450; grade 1, QTc 450 – 479 ms; grade 2, QTc 480 – 499 ms; 
grade 3, QTc ≥ 500 ms; grade 4, QTc ≥ 500 ms with life-threatening signs or symptoms; grade 5, death).18 
Relevant CVD were defined as myocardial infarction and/or heart failure.
Outcome measures used in this study were: i) the quantitative difference in terms of QTc-interval 
between on therapy and baseline ECG measurements (ΔQTc, ms), ii) the transition from a condition of 
normal repolarization to a condition in which QTc is prolonged to an extent with high risk of arrhythmia 
as a consequence of the TKI therapy (i.e., from QTc < 470 to QTc ≥ 470 ms),3, 19 iii) clinically relevant 
ΔQTc (defined as ΔQTc ≥ 30ms, above which the risk for TdP is significantly increased)20, 21 and iv) QTc-
interval CTCAE grade increase during TKI therapy.18
 statistical analyses
The distribution of the quantitative variables analysed deviated significantly from normality (Shapiro-
Wilk test P < 0.05), thus they were described by median (IQR). The presence of statistically significant 
differences in terms of QTc distributions before vs. during TKI therapy were tested by the Wilcoxon 
Signed Rank Test for paired samples. Differences in terms of quantitative variables distribution as 
function of categorical outcomes were tested by the Wilcoxon Rank-Sum test or by the Kruskal-
Wallis test as appropriate. The McNemar test was applied to compare the distributions of categorical 
variables before vs. during TKI therapy. Differences in terms of categorical variables distributions 
between binary outcomes were evaluated by the Fisher’s exact test. The impact of quantitative and 
categorical variables on the probability of binary outcomes was tested by stepwise logistic regression. 
Calcium and potassium levels, age, gender, co-medications and the presence of relevant cardiovascular 
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diseases and/or diabetes mellitus were tested as potentially informative variables in the analysis 
since they are known to influence the QTc interval and the risk of developing drug induced LQTS.26 
Both baseline and on therapy calcium and potassium levels were discretized into three levels (hypo-, 
normo- and hyper-) according to lab-specific normality ranges and analysed as categorical variables. 
Ethnicity, time-lapse between baseline ECG and start of TKI treatment, tumor type and recruitment 
center were considered potential confounders when evaluating multivariate models. The significance 
threshold was set to P-value < 0.05, all tests were two-tailed. The statistical software R version 3.0.1 
was used for all statistical analyses (http://www.r-project.org/).
resuLTs
Patient characteristics
After applying inclusion and exclusion criteria, our study cohort consisted of 363 patients. The median 
age at start of treatment was 60 years (interquartile range [IQR] 51-67), and 59% of patients was 
male. Sunitinib was the most frequently used TKI in our study cohort, with a total of 110 treated 
patients. The median QTc-interval at baseline visit was 401 ms (IQR 388-415), where 346 patients 
(95.3%) had a normal QTc-interval (CTCAE grade 0), 14 (3.9%) had grade 1, 2 patients (0.6%) had grade 
2, and 1 patient (0.3%) had a grade 3 QTc-interval. A total number of 37 patients (10.2%) had a known 
history of relevant CVD, while 34 patients (9.4%) used co-medication, that can lead to QTc-interval 
prolongation.15 Patients’ demographics and disease characteristics are presented in Table 1.
Variables modulating QTc-interval at baseline visit
At baseline measurements, QTc was slightly, but significantly longer in females than in males (QTc
females
 
= 404 ms [IQR 392-417] vs. QTc
males
 = 399 ms [IQR 385-414], P = 0.027), which is consistent with 
previous studies.15 Patients treated with co-medication known to prolong the QTc-interval, such as 
anti-depressants, anti-epileptics and anti-emetics, had a statistically significant higher baseline QTc-
interval than the patients who did not use such co-medication (409 ms [IQR 398-424] vs. 400 ms 
[IQR 387-414] respectively, P = 0.035). Consistent with previous studies, patients suffering from 
hypokalaemia had longer median QTc-intervals than patients with normokalaemia and hyperkalaemia 
(median QTc in hypokalaemic, normokalaemic and hyperkalaemic patients 416 ms [IQR 376-431], 401 
ms [IQR 389-415] and 391 ms [IQR 381-408], P = 0.028, respectively). A more detailed report about 
baseline QTc-intervals according to the evaluated variables is found in supplementary Table 1.
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Table 1 Patient characteristics
Variable N (%) or median (IQr)
Gender
Male 215 (59)
Female 148 (41)
Age (years) 60 (51-67)
QTc-interval baseline 401 (388-415)
QTc-interval therapy 415 (397-431)
Tumour type
RCC 101 (27.8)
GIST 49 (13.5)
HCC 45 (12.4)
Lung cancer 27 (7.4)
Breast cancer 16 (4.4)
Melanoma 69 (19.0)
Other 56 (15.4)
Type of TKI
Sunitinib 110 (30.3)
Vemurafenib 67 (18.5)
Sorafenib 52 (14.3)
Pazopanib 46 (12.7)
Imatinib 41 (11.3)
Erlotinib 21 (5.8)
Lapatinib 16 (4.4)
Gefitinib 10 (2.8)
WHo Ps baseline
0 155 (42.7)
1 195 (53.7)
2 12 (3.3)
3 1 (0.3)
cVD 37 (10.2)
QTc co-medications 34 (9.4)
Race
Caucasian 349 (96.1)
Other 14 (3.5)
site
EMC 184 (50.7)
NKI 118 (32.5)
LUMC 54 (14.9)
SMF 7 (1.9)
Abbreviations: GIST, gastro-intestinal stromal tumour; RCC, renal cell cancer; HCC, 
hepatocellular carcinoma; TKI, tyrosine kinase inhibitor; WHO PS, world health organisation 
performance score; CVD, cardiovascular disease; EMC, Erasmus MC - Cancer Institute; NKI, 
Netherlands Cancer Institute – Antoni van Leeuwenhoek; LUMC, Leiden University Medical 
Centre; SMF, Salvatore Maugeri Foundation
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Figure 1: ΔQTc in the whole cohort and in specific TKIs.
White bars represent the median baseline QTc-interval, grey bars represent the median QTc-interval during 
treatment. At the y-axis, the QTc-interval is expressed in ms.
Quantitative variations of the QTc-interval
Start of any type of TKIs resulted in a statistically significant increase in QTc-interval, with a median 
ΔQTc of +11 ms (P < 0.00001). The distribution of ΔQTc was significantly different across TKIs (P = 
0.0001). When analysing subgroups of patients treated with specific TKIs, patients treated with 
sunitinib (N = 110), vemurafenib (N = 67), sorafenib (N = 52), imatinib (N = 41) and erlotinib (N = 21) 
showed a statistically significant increase in QTc-interval after start of treatment (median ΔQTc ranging 
from +7 to +24 ms, P < 0.004; Figure 1). For lapatinib (N = 16) and pazopanib (N = 46) no statistically 
significant increase in QTc-interval after start of treatment was found, probably due to low patient 
numbers (Table 2).
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Table 2 TKI-induced change in QTc-interval
QTc-Interval (ms)
P-valuemedian (IQr)
TKI n Baseline Therapy
Whole 363 401 (388-415) 415 (397-431) < 0.00001
Sunitinib 110 393 (380-410) 406 (390-424) < 0.00001
Vemurafenib 67 401 (394-417) 427 (415-442) < 0.00001
Sorafenib 52 400 (386-412) 410 (394-425) 0.0004
Pazopanib 46 402 (390-411) 412 (395-431) 0.079
Imatinib 41 410 (396-424) 425 (410-439) 0.002
Erlotinib 21 412 (398-430) 421 (414-440) 0.004
Lapatinib 16 413 (405-423) 414 (397-428) 0.982
Gefitinib 10 403 (396-417) 409 (390-429) 0.919
Abbreviations: TKI, tyrosine kinase inhibitor; n, number of patients within each TKI group; ΔQTc, median 
difference between QTc-interval during TKI treatment and QTc-interval at baseline
Increase in cTcAe grade and prevalence of high-risk patients
A statistically significant increase in CTCAE grade for QTc-intervals was observed after start of TKI 
therapy in the whole cohort (P = 0.0003). In detail, 33 patients (9.1%) were characterized by a worsened 
CTCAE grade. Of these, 31 passed from grade = 0 to grade ≥ 1, while the remaining 2 individuals passed 
from grade = 1 to grade 2 or 3. Of the remaining patients, 321 (88.4%) did not have an increase or 
decrease in CTCAE grade after start of TKI treatment, while 9 patients (2.5%) had a reduced CTCAE 
grade for QTc-interval (Table 3).
Similarly, a statistically significant increase in the prevalence of high risk patients was observed after 
TKI therapy start (QTc
baseline 
≥ 470 ms = 1.7% vs. QTc
therapy 
≥ 470 ms = 5.8%, P = 0.005), with 20 individuals 
(5.5%) who transitioned from a low-risk to a high-risk condition. Moreover, five patients (1.4%) 
developed QTc ≥ 500 ms (CTCAE grade 3) after therapy start, and 76 patients (20.9%) experienced a 
clinically relevant QTc increase after TKI start. All five patients who developed QTc ≥ 500 ms after start 
of therapy had a ΔQTc ≥ 100 ms.
When focusing on specific TKI subgroups, we observed that individuals treated with vemurafenib (N 
= 67) were characterized by a statistically significant increase both in terms of CTCAE grade for QTc-
intervals (P = 0.008) and in the probability of becoming high risk patients (P = 0.023), also showing the 
greatest probability of clinically relevant QTc increase (34.3%). No statistically significant variations in 
the evaluated outcomes were observed in the other TKI subgroups. 
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characterization of TKI-induced QTc variability
The median age of patients who did have a worsening of the CTCAE grade for QTc-interval was 
significantly higher than that of patients who did not (62 years [IQR 59-72] vs. 60 years [IQR 51-67] 
respectively, P = 0.023). These patients also more often suffered from hypokalaemia (20.7% vs. 3.1%, 
P = 0.0009; Table 4). Multivariate logistic regression confirmed that age and hypokalaemia were 
independent predictors of worsened CTCAE grade for QTc-interval (OR = 1.10, 95% CI = 1.05-1.16, P = 
0.0002 and OR = 10.30, 95% CI = 2.22-4.64, P = 0.002).
Similarly, patients who did became at high risk for developing ventricular arrhythmia after start of TKI 
treatment were significantly older than patients who did not (66 years [IQR 60-76] and 60 years [IQR 
51-66] respectively, P = 0.007) and were more frequently treated with QTc-prolonging co-medication 
(25% vs. 8.5%, P = 0.030). This was confirmed by multivariate logistic regression (OR = 1.10, 95% CI = 
1.04-1.15, P = 0.0004 and OR = 4.38, 95% CI = 1.14-15.25, P = 0.023).
We did not identify variables that have a statistically significant impact on quantitative ΔQTc or on the 
probability of clinically relevant ΔQTc (supplementary Table 2).
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DIscussIoN
We found a significant increase in QTc-intervals after start of treatment with sunitinib, vemurafenib, 
sorafenib, imatinib and erlotinib. In most cases, the increase in QTc-interval is only modest and under 
normal conditions not clinically relevant. However, in 76 of the 363 patients the start of TKI treatment 
resulted in a clinically relevant increase of the QTc-interval. Still, only for vemurafenib treated patients 
and for the whole group of patients taken together, the incidence of high risk patients, defined as QTc 
≥ 470 ms,3 increased during treatment. 
These findings suggest that although a substantial part of the treated patients have a clinically relevant 
increase in QTc-interval, this occurs mostly in patients with low QTc-interval at the start of treatment, 
and only in a small proportion of patients leads to a high risk of developing arrhythmias. Unfortunately 
it is not possible to differentiate which patient is at risk at the start of treatment.
Therefore, treating physicians should anticipate on this phenomenon by performing ECGs during 
treatment with TKI, and being aware of symptoms, such as palpitation, seizures and collapse, which 
may be the result of long QTc syndrome (LQTS). In those diseases where alternative treatment are 
available, such as in metastatic renal cell carcinoma where sunitinib and pazopanib have equivalent 
efficacy,22 switch to a less cardio-toxic TKI may be possible in case of the occurrence of severe LQTS.
Furthermore, many patients use co-medication during TKI treatment. As drugs of a broad variety are 
known for drug induced QTc-interval prolongation, it is likely that patients use several drugs which 
can lead to QTc-interval prolongation and thereby intensifying the effect on the QTc-interval. This was 
shown in this study, where patients using such co-medication were more likely to become a high risk 
individual. In those cases, extra awareness may be necessary and switching towards drugs that are not 
likely to have an effect on QTc-interval should be considered.
This study has several limitations. This was a retrospective study in patients treated with cancer, 
and therefore in most cases ECGs were not made on predefined times before, during and after TKI 
therapy. Since fluctuations in QTc-interval are frequent and may be caused by many factors,4, 5 this is 
a weakness of our study, and may have influenced outcome.23 Furthermore, there may be a bias in 
patient selection since patients with cardiac events may be more likely to have had ECGs performed. 
Patients who died from arrhythmia may not have been included in analyses when no ECGs were 
available. Possible effects from electrolyte disorders on the QTc-interval may have been missed, 
because of missing data. However, we showed in a large group of patients treated with TKIs that 
there is an overall increase in QTc-interval after start of treatment, which may possibly be harmful for 
patients treated with these drugs. Future prospective studies could improve the current knowledge 
about TKI-induced QTc prolongation.
Overall, we may conclude that most TKIs tend to cause an increase in QTc-intervals. In some cases, 
this increase is clinically relevant, and therefore the QTc-interval should be verified in patients 
before starting TKI treatment and during therapy. Monitoring QTc-intervals during TKI treatment is 
particularly important in patients with a history of QTc-interval prolongation, in patients using co-
medication which can prolong the QTc-interval, in patients with electrolyte disorders and in patients 
7
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with pre-existing CVD. Furthermore, during treatment with TKIs physicians should be aware of clinical 
symptoms, which may be attributed to QTc-interval prolongation.
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supplementary Table 1 Impact of predictors and confounders on baseline QTc interval
Variable N
statistic
P-valuerho or 
median QTc (IQr)
Age (years) 363 0.01 0.8532
Gender 0.0266
   Male 215 399 (385-414)
   Female 148 404 (392-417)
Co-medication 0.0349
   No 329 400 (387-414)
   Yes 34 409 (398-424)
CVD 0.0792
   No 326 400 (388-415)
   Yes 37 408 (396-429)
DM 0.628
   No 320 401 (389-415)
   Yes 43 401 (384-415)
Baseline Ca2+ 0.5699
   Hypocalciemie 22 409 (385-418)
   Normocalciemie 193 400 (388-411)
   Hypercalciemie 10 391 (383-411)
Baseline K+ 0.0276
   Hypokaliemie 3 416 (376-431)
   Normokaliemie 255 401 (389-415)
   Hyperkaliemie 41 391 (381-408)
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; Ca2+, calcium; K+, 
potassium; n, number of patients
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ABsTrAcT
Introduction A rise in mean corpuscular volume (MCV) of the erythrocyte is frequently seen during the 
treatment with the tyrosine kinase inhibitors (TKIs) imatinib and sunitinib. We investigated whether 
macrocytosis also occurs as a class-effect in other TKIs and whether occurrence of macrocytosis is 
associated with outcome.
methods In this retrospective study in 533 patients with solid tumours using imatinib, pazopanib, 
sorafenib, sunitinib or vemurafenib, we investigated levels of MCV prior to and during the treatment 
with these TKIs. Macrocytosis and MCV increases were correlated to progression free survival (PFS) 
and overall survival (OS) in specific tumour-treatment combinations.
results Patients treated with imatinib, pazopanib or sunitinib had a significant increase in MCV levels 
starting 3 months after start of treatment and plateauing at 6 months (p < 0.001). Macrocytosis as 
well as a substantial increase in MCV (from baseline of +10fL (∆MCV +10fL)), when included as a 
time-dependent covariate, were associated with improved OS in patients with renal cell cancer (RCC) 
treated with sunitinib (p ≤ 0.001), but not in other cohorts. Also, when corrected for the time to onset 
of macrocytosis or time to ∆MCV +10fL, this correlation remained significant for OS (macrocytosis HR 
= 0.61, 95%CI 0.39-0.96, p = 0.031, ∆MCV +10fL HR = 0.58, 95%CI 0.37-0.90, p = 0.016).
conclusions These observations show that imatinib, pazopanib and sunitinib induce an increase in 
MCV. The finding that occurrence of macrocytosis is associated with a good outcome to sunitinib in 
patients with RCC is worthwhile to explore further. 
8
143Macrocytosis as a potential parameter associated with outcome in the treatment with Tyrosine Kinase Inhibitors
INTroDucTIoN
Tyrosine kinase inhibitors (TKIs) are frequently used in anticancer treatment. They act by targeting the 
ATP-binding site of one or more tyrosine kinases, that are frequently constitutively activated in cancer 
cells.1 Since the introduction of imatinib as targeted therapy in the treatment of chronic myeloid 
leukemia (CML) and gastrointestinal stromal tumors (GISTs), several TKIs have been registered for the 
treatment of cancer patients. 
In patients treated with imatinib or sunitinib the mean corpuscular volume (MCV) of the red blood 
cells increases.2-8 In several cases this even resulted in macrocytosis (defined as MCV > 100 fL), which 
is usually only seen in patients with vitamin B12 or folic acid deficiency, alcoholism, hypothyroidism 
and myelodysplastic syndromes.9 Since TKI-induced macrocytosis can occur in the absence of such 
conditions,6 increase in MCV levels are considered a direct (side-)effect of the drug itself, as is seen 
with other drugs (i.e. hydroxyurea, methotrexate, zidovudine, azathioprine, capecitabine, cladribine 
and stavudine).10-15 The increase in MCV levels in patients treated with imatinib or sunitinib  may be 
caused by inhibition of the stem cell factor (c-KIT).7 C-KIT is expressed on the surface of hematopoietic 
progenitor cells, where it regulates survival, proliferation and differentiation of the red blood cells 
by the activation of signal transduction molecules.16 Interference with the c-KIT pathway in rodents 
resulted in macrocytic anemia.17 Additionally, treatment with sorafenib, which is a weaker inhibitor of 
c-KIT than imatinib and sunitinib, did not result in macrocytosis.7
Whether macrocytosis is a clinically relevant side-effect of TKIs remains unknown. Furthermore, it is 
not known which TKIs, other than imatinib and sunitinib, give rise to an increase in the MCV. To study 
this, we set up an exploratory retrospective study in which we collected data from patients with solid 
tumors who have been treated with the TKIs imatinib, pazopanib, sorafenib, sunitinib or vemurafenib 
at the department of Medical Oncology of the Erasmus MC Cancer Institute, examined whether the 
use of these drugs was accompanied by a MCV rise, and if so, whether or not this was associated with 
outcome in terms of progression-free and overall survival. 
8
144 Chapter 8
PATIeNTs AND meTHoDs
study design
Patients who have had a solid tumor and have been treated with one of these 5 TKIs were included 
in this study if at least one baseline MCV level and one MCV level during treatment were available. 
Patients with subsequent use of TKIs were included as unique cases for each TKI if the time between 
treatments was at least one week and if a baseline MCV level was measured within this off-treatment 
period. 
Data were retrospectively collected from the electronic patient record. Patient characteristics were 
collected as well as survival estimates and laboratory values. The variables considered to be relevant 
for the analysis were hematological parameters (hemoglobin [Hb], MCV, and red cell distribution width 
[RDW]). In addition to their baseline level, levels were collected during the first year of treatment or 
until date of stop if this occurred within a year after start of treatment. Due to the retrospective 
character of this study, no written informed consent was necessary from patients.
 
statistical design and data analysis
One-way analysis of variance (ANOVA) test was used to discover any baseline differences between TKI 
treatments. For each TKI, and each individual patient, differences between baseline and corresponding 
on-treatment laboratory values were analyzed by using the paired-sample Student’s t-test. To detect 
differences in the occurrence of baseline macrocytosis and on-treatment macrocytosis, the McNemar’s 
test was used.
 
PFS was defined as the time between first day of treatment and the day of progressive disease (PD) 
or death from any cause, whichever came first. OS was defined as the time between the first day of 
treatment and the date of death from any cause. If progression or death had not occurred or if the 
patient was lost to follow-up, PFS and OS were censored at the date of last follow-up. Macrocytosis and 
a difference in MCV between baseline and on-treatment (∆MCV) of more than +10 fL were included 
as a time-dependent covariate for PFS and OS in a univariate Cox regression analysis in the diverse 
specific indications for TKI treatment. 
The statistical package software system version 21.0 (SPSS Inc, Chicago, IL) was used for all data 
analyses, except the time-dependent COX-regression analysis which was performed using STATA 
version 13.1 (StataCorp. 2013. Stata: Release 13. Statistical Software. College Station, TX: StataCorp 
LP). Results from statistical analyses with a two-sided p-value ≤ 0.05 were considered statistically 
significant in all analyses. 
8
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resuLTs
study population and baseline variables
A total of 533 individual patients with a solid tumor for which the patient has been treated with 
imatinib, pazopanib, sorafenib, sunitinib, or vemurafenib were included in this study. There were 45 
patients with subsequent use of 2 TKIs (usually imatinib followed by sunitinib in patients with GIST), 
and 2 patients with subsequent use of 3 TKIs, resulting in 582 cases with the use of a TKI.  Sunitinib 
and imatinib were the most frequently used TKIs in the study population, with 213 and 182 cases 
respectively. Other TKIs were sorafenib (n=97), pazopanib (n=66) and vemurafenib (n=24). The median 
amount of MCV measurements in the entire population during the first year of treatment was 9 (IQR 
5-13). The mean age at start of the TKI was 61 years, and 64% of patients was male (Table 1). The mean 
time of follow-up was 27.2 months.
At baseline visit, the mean MCV was 88.8 ± 6.6 fL, and there was no significant difference in baseline 
MCV among the TKIs used (p = 0.29). Twenty patients already had macrocytosis at baseline. None of 
these 20 patients was known with vitamin B12 or folic acid deficiency or with hypothyroidism, but 4 
out of 20 patients used 3 or more alcohol units/day. 
changes in laboratory levels after start of treatment
The mean on-treatment MCV, calculated per patient from all on treatment MCV values, was 
significantly higher than baseline MCV for patients who have been treated with imatinib (mean ∆MCV 
= 4.47 fL, p < 0.001), pazopanib (mean ∆MCV = 2.13, p < 0.001) and sunitinib (mean ∆MCV = 4.78, p 
< 0.001, see Table 2). When MCV levels from the first year were plotted, it was seen that for imatinib, 
pazopanib and sunitinib, the MCV remained more or less stable within the first 3 months of treatment, 
and increased thereafter. For sorafenib and vemurafenib treated patients however, MCV significantly 
decreased within the first 3 months of treatment, but also showed a slight increase after 3 months of 
treatment (Figure 1-A). In Figure 1-B it is shown that RDW increases within the first months after start 
of treatment with imatinib, pazopanib and sunitinib, indicating an increased spread in the volume of 
erythrocytes. After 3 months the RDW decreases again. This was statistically significant for all TKIs.
The prevalence of macrocytosis was statistically significantly higher during the treatment with 
imatinib, pazopanib or sunitinib treatment, than at baseline (p < 0.001), but not for patients treated 
with sorafenib or vemurafenib. Hemoglobin levels significantly differed between baseline and on-
treatment measurement for patients treated with imatinib, sorafenib and vemurafenib, but differences 
were small. 
Macrocytosis as a potential parameter associated with outcome in the treatment with Tyrosine Kinase Inhibitors
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Table 1 Descriptive characteristics
Variable N (%) or Mean (sd)
Gender
   Male 339 (63.6)
   Female 194 (36.4)
Age 60.9 (11.2)
No of subsequent TKI treatments
   1 486 (91.2)
   2 45 (8.4)
   3 2 (0.4)
Type of TKI*
   Imatinib 182 (31.3)
   Pazopanib 66 (11.3)
   Sorafenib 97 (16.7)
   Sunitinib 213 36.6)
   Vemurafenib 24 (4.1)
Tumour type
   Colorectal 14 (2.6)
   GIST 186 (34.9)
   HCC 81 (15.2)
   pNET 4 (0.8)
   RCC 161 (30.2)
   Sarcoma 6 (1.1)
   Other 54 (10.1)
MCV baseline 88.8 (6.6)
MCV on-treatment 91.9 (6.6)
Reticulocytes baseline 61.0 (28.6)
Reticulocytes on-treatment 57.9 (23.6)
RDW baseline 14.7 (1.9)
RDW on-treatment 15.8 (1.9)
Abbreviations: No, number; TKI, tyrosine kinase inhibitor, GIST, gastrointestinal 
stromal tumour, HCC, hepatocellular carcinoma, pNET, neuro-endocrine tumour 
of the pancreas; RCC, renal cell carcinoma; MCV, mean corpuscular volume (of the 
erythrocyte); RDW, red cell distribution width. On-treatment values are expressed 
as the mean of all 
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A     B
Figure 1 The course of MCV levels (Figure 1A) and RDW levels (Figure 1B) during the first 12 months of TKI treatment.
Table 2 Comparison between baseline and on-treatment levels
TKI Variable
Baseline On-treatment
P-value
Mean (sd) or N (%) Mean (sd) or N (%)
Imatinib
Hb (mmol/L) 8.0 (1.16) 7.7 (0.85) <0.01
MCV (fL) 88.3 (6.41) 92.8 (5.36) <0.01
Macrocytosis (N (%)) 5 (2.7) 45 (24.7) <0.01
RDW 14.6 (2.0) 15.0 (1.37) <0.01
Pazopanib
Hb (mmol/L) 7.7 (1.09) 7.8 (1.20) 0.26
MCV (fL) 88.7 (6.85) 90.9 (7.77) <0.01
Macrocytosis 3 (4.5) 20 (30.3) <0.01
RDW 14.7 (1.68) 16.2 (1.75) <0.01
Sorafenib
Hb (mmol/L) 8.3 (1.04) 8.5 (1.07) 0.01
MCV (fL) 90.1 (7.54) 89.0 (7.25) <0.01
Macrocytosis 5 (5.5) 9 (9.3) 0.29
RDW 14.9 (1.94) 15.7 (2.12) <0.01
Sunitinib
Hb (mmol/L) 7.6 (1.20) 7.7 (0.93) 0.62
MCV (fL) 88.7 (6.44) 93.4 (6.41) <0.01
Macrocytosis 7 (3.3) 94 (44.1) <0.01
RDW 14.9 (2.02) 16.5 (1.87) <0.01
Vemurafenib 
Hb (mmol/L) 8.7 (1.09) 8.3 (1.17) <0.01
MCV (fL) 89.2 (4.35) 86.8 (4.89) <0.01
Macrocytosis 0 (0) 0 (0) NA
RDW 13.5 (0.90) 14.1 (0.88) 0.01
Macrocytosis as a potential parameter associated with outcome in the treatment with Tyrosine Kinase Inhibitors
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survival analyses
Because in most patients MCV or ∆MCV > +10fL  occurred somewhere after start of treatment, these 
parameters had to be included as time-dependent covariates in univariate Cox regression analyses for 
PFS and OS. In patients with RCC who were treated with sunitinib, MCV (hazard ratio (HR) = 0.61, 95% 
confidence interval (CI) 0.39-0.96, p = 0.031) as well as ∆MCV +10fL (HR = 0.58, 95% CI 0.37-0.90, p = 
0.016) were associated with improved OS (Figure 2).
For other tumor-treatment combinations, there were no clear associations between macrocytosis or 
impact of MCV and ∆MCV +10fL with PFS or OS in univariate analyses.
Figure 2 Influence of MCV according to original definition of macrocytoses (A), or defined as increase of ≥ 10 fL (B) 
on survival in patients with RCC treated with sunitinib. De black line represents patients with macrocytosis or MCV 
increase of ≥ 10 fL, the grey line represents patients without macrocytosis of MCV increase of ≥ 10 fL.
DIscussIoN
This study shows an increase in MCV levels in patients treated with imatinib, pazopanib or sunitinib. 
For sorafenib and vemurafenib, a rise in MCV is seen after a nadir MCV value in the first 6 months 
of treatment. In the subgroup of patients with advanced RCC treated with sunitinib, OS was 
clinically relevantly longer in patients with a rise in MCV of more than 10 fL or if a level above 100 fL 
(macrocytosis) was reached.
The increase in MCV levels in patients treated with imatinib and sunitinib is in line with previous research 
in small groups of patients.2-8 To the best of our knowledge, in patients treated with pazopanib or 
vemurafenib, MCV levels had never been investigated before. We found an overall decrease in MCV 
levels in the first year of treatment with sorafenib and vemurafenib. Interestingly, this decrease occurs 
only in the first three months of treatment, after which in patients treated with sorafenib the MCV levels 
slowly rise. In the group of vemurafenib treated patients, none of the patients developed macrocytosis, 
nor an increase in MCV > 10fL. In patients treated with imatinib, pazopanib or sunitinib, the rise in MCV 
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levels generally occurs roughly after 3 months of treatment, without a decrease in the first 3 months. 
Importantly, a patients needs to be exposed for a certain period of time to a TKI before a rise in MCV 
occurs. In the entire population, the time to onset of macrocytosis was 4.3 months. In tumor types 
such as melanoma and HCC, a substantial part of the population has already progressed at this stage, 
and as a result, may never have got the chance to develop macrocytosis or a substantial increase in 
the MCV levels. 
Thus far it remains unknown how the effect of imatinib and sunitinib on the MCV occurs. The 
hypothesis was that binding of the TKI to c-KIT on the hematopoietic stem cell resulted in disturbed cell 
maturation and the release of larger erythrocytes into the blood stream.7 Our study was not designed 
to detect any mechanism behind TKI-induced macrocytosis. Still, we found increases in MCV levels 
in imatinib, pazopanib and sunitinib, which are all inhibitors of c-KIT. Sorafenib is also an inhibitor of 
c-KIT, but sorafenib treated patients did not show a significant increase in MCV levels, possibly due to 
a drop in MCV during the first months of treatment. Most of the patients treated with sorafenib (83%) 
were treated for HCC, and the median time of treatment was 4.3 months. MCV levels significantly 
decreased in the first 3 months of treatment, and significantly rose thereafter. However, 3 months 
after initiation of sorafenib only 61% of patients was still being treated with sorafenib, and at 6 months 
this was 34%, which may have caused a bias in the analysis. 
Side-effects of TKI-treatment, such as an increase in blood pressure in RCC patients treated with 
sunitinib and rash in patients treated with anti-EGFR function, are known for their prognostic abilities 
in these treatments.18-20 One of the aims of our study was to investigate if macrocytosis/ MCV rise 
is associated with survival in specific subgroups of patients, which indeed appeared to be the case 
for overall survival in patients with RCC treated with sunitinib. Patients who developed macrocytosis 
had a significantly longer OS than patients with normocytosis or microcytosis. In the same group of 
patients, an increase in MCV levels from baseline to on-treatment of > 10 fL was associated with 
prolonged OS. Clearly, the correlations found have to be validated in a prospective setting. For other 
tumor-TKI combinations there was no significant difference in survival between patients with and 
without macrocytosis or substantial increase in MCV levels from baseline. 
Since the effect of TKIs on the MCV is speculated to be driven by c-KIT, it was expected that the effects 
on survival would be seen in patients with GIST, since the anti-tumor effect of imatinib and sunitinib in 
GIST is driven by c-KIT. The anti-tumor effect of pazopanib and sunitinib in patients with RCC is caused 
by blocking of vascular endothelial growth factor (VEGF), and not by blocking c-KIT. These results 
suggest another, yet unknown, mechanism by which MCV is increased by TKIs.
Altogether we may conclude that a rise in MCV or even macrocytosis occurs in the treatment of 
several TKIs. In the treatment of patients with RCC with sunitinib, the occurrence of macrocytosis, 
or a substantial increase in MCV levels after start of treatment, could potentially serve as a positive 
prognostic factor, if validated prospectively. 
Macrocytosis as a potential parameter associated with outcome in the treatment with Tyrosine Kinase Inhibitors
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For many drugs there is a broad inter-patient variability in the pharmacokinetic (PK) processes 
absorption, distribution, metabolism and excretion (ADME), which results in a certain amount of inter-
individual variability in exposure to these drugs. Differences in the activity of ADME may be caused 
by several factors, such as the use of co-medication, genetic differences, lifestyle habits and probably 
many more (currently unknown) factors. The tyrosine kinase inhibitor sunitinib is such a drug. 
Although there is an average 30-35% inter-patient variability in both pharmacokinetics and 
pharmacodynamics for sunitinib, it is (still) prescribed in a fixed dosing schedule. Severe side effects 
occur frequently in sunitinib treatment and not occasionally patients require dose reductions or 
discontinuations due to adverse effects. Furthermore, not all patients respond similarly to sunitinib 
treatment. These observations suggest that therapeutic drug monitoring (TDM) could add to further 
personalize sunitinib treatment. The work described in the first part of this thesis includes research 
that focuses on a pharmacokinetic approach towards improved sunitinib treatment (chapters 2 to 4).
Thesis part I
In chapter 2, hepatobiliary clearance of technetium-99m-2-methoxy isobutyl isonitrile (99mTc-MIBI), as a 
phenotyping probe for the adenosine triphosphate binding cassette transporter ABCB1 and midazolam 
clearance test as a probe for cytochrome P450 3A (CYP3A) were correlated to the pharmacokinetics 
of sunitinib and its active metabolite SU12662. A population pharmacokinetic model was built, which 
included the phenotype tests as covariate. In 52 patients, both phenotyping probes were insufficient 
to predict sunitinib pharmacokinetics strongly enough to be useful in clinical practice. Interestingly, 
we found that patients with low sunitinib clearance had significantly more frequent severe toxicities, 
suggesting an exposure-toxicity relationship for sunitinib. Such a relationship suggests that patients 
who are treated with sunitinib may benefit from TDM of sunitinib. Since it was unknown whether 
sunitinib dosing based on the pharmacokinetics was safe, a pharmacokinetic study was performed 
to determine the safety and feasibility of sunitinib dosing based on total trough levels of sunitinib 
and SU12662 (chapter 3). Twenty-nine patients with a broad variety of tumour types for whom no 
standard therapy was available were administered sunitinib 37.5 mg on a daily base. At 3 times during 
the study period of 8 weeks, PK sampling of sunitinib and SU12662 took place. The sunitinib dose was 
elevated when total trough levels of sunitinib and SU12662 dropped below a predefined target level 
of 50 ng/mL, and sunitinib dose was decreased when patients suffered unacceptable toxicity. In this 
study period of 8 weeks, it was possible to increase sunitinib dose levels in 5 patients (17%) without 
additional severe toxicity. Nine patients (31%), who underwent initial dose escalation, required a dose 
reduction due to toxicity. In the 15 patients who reached target TTL at the starting dose of 37.5 mg, 6 
patients (21%) required dose reduction because of toxicity. This could be the basis for future studies 
and the implementation of a PK-guided dosing strategy in clinical practice.
There is increasing evidence that circadian rhythms in physiology may influence the PK of drugs. 
However, for TKIs, this has never been investigated before. chapter 4 describes the results of preclinical 
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and clinical studies where the effect of the time of administration of sunitinib on its PK has been 
investigated. A study was performed in mice, treated with sunitinib at 6 different times of the day. In 
parallel, a prospective randomized cross-over PK study was performed in which patients took sunitinib 
once daily at 3 courses at 8AM, 1PM and 6PM. Primary endpoint in both studies was the difference in 
plasma area under the curve (AUC) between dosing times.
Although a clear ~12-hour rhythm in sunitinib PK was observed in mice, leading to 30% more exposure 
to the compound when administered around noon than when administered in morning or evening, 
there was no significant difference in AUC between the three dosing times in patients. However, in 
patients, sunitinib trough levels were higher when the drug was taken at 1PM or 6PM, than when 
taken at 8AM resulting in better balanced concentrations of sunitinib during the day. This is interesting, 
since it could have implications for dosing based on therapeutic drug monitoring if a patient takes 
sunitinib in the morning, or in the afternoon or evening. Using TDM, a drug can be dosed based on its 
trough level. If in the case of sunitinib the trough levels are lower when the patient takes the drug in 
the morning than when taking the drug at noon or in the evening, without differences in overall daily 
exposure, the dose of sunitinib may falsely be increased in patients taking sunitinib in the morning.
Thesis part II
The second part of this thesis focusses on the pharmacodynamics (both survival and toxicity) of 
several TKIs. As already mentioned for sunitinib, there is a broad spread in how long patients respond 
to TKI treatment. To further personalize treatment in patients treated with TKIs, it is meaningful to 
get better insight into the factors predicting the efficacy of a drug before starting, especially when 
alternative treatment options exist such as in the case of advanced GIST. A possible approach towards 
personalized treatment is by predicting treatment response levels based on genetic polymorphisms 
(SNPs). 
The purpose of the study described in chapter 5 and chapter 6 was to identify SNPs that can serve as 
predictive biomarkers for the treatment with respectively first line imatinib and second line sunitinib 
in patients with advanced GIST. Chapter 5 explores the effects of 36 SNPs in 18 genes related to the 
PK and PD of imatinib on its efficacy in 255 patients with advanced GIST treated with imatinib. In 
a multivariate model PFS was significantly shorter in patients synchronous metastasis at the time 
of the diagnosis GIST, patients with KIT exon 9 mutation, and patients with the TT-genotype in KDR 
rs2305948 and the AA genotype in VEGFA rs1570360. OS was also significantly shorter in patients 
with synchronous metastasis at the time of the diagnosis GIST, and further in patients with the AA-
genotype in KDR rs1870377 or the AA-genotype in VEGFA rs1570360, whereas a T-allele in SLCO1B3 
rs4149117 was associated with longer OS. 
In chapter 6, we retrospectively studied if 49 SNPS in genes within the pharmacokinetic and 
pharmacodynamic pathway of sunitinib were associated with PFS and OS in 127 patients with advanced 
GIST who had been treated with sunitinib. PFS was significantly shorter in carriers of the C-allele in 
POR rs1056878 C/T. The presence of the T-allele in CYP1A2 rs4149117 G/T, the CCC-CCC alleles in the 
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SLC22A5 haplotype, and the GC-GC alleles in the IL4R haplotype were predictive for OS. When these 
factors were combined in a favorable genetic model, both PFS and OS were significantly longer with 
an increasing number of favorable genetic factors. If validated prospectively, this may identify patients 
that are likely to survive longer on sunitinib and therefore be a useful tool in therapeutic decision 
making. For now however, it is still too early to use SNPs in clinical practice of sunitinib treatment.
Almost all patients who are treated with a TKI are subject to side-effects of the given drug, varying 
from modest to severe side effects for which treatment needs to be discontinued or even stopped. The 
last two chapters of this thesis focus on the occurrence of side effects due to TKI treatment. 
Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc-interval on the ECG. QTc-
interval prolongation increases the risk for life threatening arrhythmias. However, studies evaluating 
the effects of TKIs on QTc-intervals are limited and only consist of limited patient numbers. In chapter 
7, we investigated ECGs prior to and during treatment with erlotinib, gefitinib, imatinib, lapatinib, 
pazopanib, sorafenib, sunitinib, or vemurafenib. A significant increase in QTc interval was observed 
in patients treated with sunitinib, vemurafenib, sorafenib, imatinib and erlotinib. Especially patients 
who had been treated with vemurafenib were found to be at increased risk of developing a QTc ≥ 470 
ms, a threshold associated with an increased risk for arrhythmias. These observations indicate that it 
is advisable to perform ECGs during treatment with these TKIs to prevent patients from arrhythmia. 
Another side effect that has been observed in TKI treatment is the increase of the mean corpuscular 
volume (MCV) of the erythrocyte. This has previously been shown for patients treated with sunitinib 
and imatinib. For other TKIs, it has never been investigated before. chapter 8 describes a study in 
which we explored which TKIs can cause an increase in MCV or even macrocytosis (MCV >100 fL) and 
related this to clinical relevance. Therefore, we retrospectively studied >500 patients treated with 
imatinib, pazopanib, sorafenib, sunitinib or vemurafenib. We found  a significant increase in MCV 
levels in patients treated with imatinib, pazopanib or sunitinib. Patients with renal cell cancer treated 
with sunitinib appeared to have a longer PFS if they developed macrocytosis than patients who did 
not develop macrocytosis. This may therefore serve as a potential parameter associated with outcome 
during treatment with TKIs. 
Altogether we may conclude that treatment with TKIs is only ‘personalized’ in a limited way thus far. 
Many new TKIs are currently being developed and in the nearby future there will probably be several 
TKI-options available for a specific tumour type, as is already the case for renal cell cancer where both 
sunitinib and pazopanib are registered in the first line of treatment. Therefore, future research should 
focus on which patient could be treated best with which TKI. This can be achieved by investigating 
patient characteristics and tumour characteristics. Many current studies are focussing on tumour 
characteristics. Different signalling pathways may be found to drive tumour growth even in the same 
tumour types or in tumours that originate in the same tissue. By selectively inhibiting the pathway 
that is overexpressed in the tumour, regardless of the tumour type, future anti-cancer treatment may 
Chapter 9
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be improved.
Otherwise, treatment with TKIs may be improved by TDM. The knowledge obtained from the 
studies described in this thesis focus on the pharmacokinetics of sunitinib, and may be a first step 
towards personalized sunitinib dosing. However, evidence is limited whether this improves survival. 
Some retrospective studies have been performed, showing an association between parameters 
of pharmacokinetics and efficacy and toxicity of treatment, but this has not yet been validated 
prospectively. 
Many studies have been performed in which genetic polymorphisms are associated with survival or 
toxicity levels. However, this has not yet resulted in implementation of testing genetic polymorphisms 
in the clinical treatment setting to improve survival or decrease toxicity levels. Since the effects of most 
genetic polymorphisms on survival or toxicity is small it is of doubt whether this will change in the 
future. However, more research in the field of pharmacogenetics is required before final conclusions 
can be drawn. The same is true for other potential markers for efficacy and toxicity. 
Summary
9
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Kanker is, na hart- en vaatziekten, wereldwijd de op een na meest voorkomende doodsoorzaak . In 
2012 stierven ongeveer 8.4 miljoen mensen aan de gevolgen van kanker. Nog steeds neemt het aantal 
mensen dat kanker heeft toe. Behandeling met chemotherapie en hormonale therapie heeft in de 
afgelopen decennia de overleving van patiënten met kanker aanzienlijk verbeterd. In de meest recente 
jaren hebben de zogenaamde ‘biologicals’ de overleving van specifieke tumoren nog eens aanzienlijk 
doen verbeteren, en er wordt verwacht dat dit in de toekomst nog beter wordt. Tyrosine kinase 
remmers, afgekort TKIs, vallen onder de biologicals. Het zijn middelen die oraal worden ingenomen, 
meestal op dagelijkse basis. 
In 2000 was imatinib de eerste TKI die op de markt kwam voor de behandeling van uitgezaaide 
(gemetastaseerde) gastro-intestinale stromacel tumoren (GIST). Deze tumoren reageren nauwelijks 
op de behandeling met conventionele chemotherapie en de overleving van patiënten met deze 
vorm van kanker was dan ook slecht, zo’n 6 maanden vanaf het moment waarop werd vastgesteld 
dat de ziekte was uitgezaaid. Nu kan de gemiddelde patiënt 2-2.5 jaar imatinib gebruiken zonder dat 
de tumor groeit. Indien de tumor tijdens behandeling groeit, is dit een teken dat de GIST niet meer 
reageert op imatinib. Verder behandelen met imatinib is dan niet meer zinvol. Er kan dan worden 
overgegaan op een vervolgbehandeling (‘tweede lijn’) met sunitinib. Sunitinib is een TKI die in 2006 
werd geregistreerd voor 2 indicaties, namelijk uitgezaaide nierkanker en uitgezaaide GIST na eerdere 
behandeling met imatinib. Sinds enkele jaren is het middel ook geregistreerd voor neuro-endocriene 
tumoren van de alvleesklier, waardoor er nu drie indicaties zijn voor behandeling met sunitinib.
Naast imatinib en sunitinib zijn er momenteel nog 15 andere TKIs op de markt voor verschillende 
vormen van kanker, en dit aantal zal vermoedelijk aanzienlijk stijgen.
Zoals elk medicament, hebben ook TKIs belangrijke bijwerkingen. Welke bijwerkingen optreden en 
in welke ernst, is erg verschillend tussen patiënten. Nog steeds moet regelmatig de dosis van een 
TKI worden verlaagd en soms zelfs de behandeling definitief worden gestaakt vanwege bijwerkingen. 
Daarnaast zit er een groot verschil in hoe lang de groei van de tumor effectief wordt onderdrukt door 
de TKI. In het voorbeeld van imatinib, bij patiënten met uitgezaaide GIST, wordt ongeveer 10% van 
de patiënten langer dan 10 jaar effectief behandeld met imatinib, zonder dat de tumor groeit. Daar 
tegenover staat dat ongeveer 10% van de patiënten binnen 6 maanden na start van de behandeling 
al groei van de tumor heeft en het middel dus niet effectief (meer) is. Daartussen zit een grote groep 
patiënten die tussen de 6 maanden en 10 jaar baat heeft bij behandeling met imatinib.
Voor het verschil in zowel effectiviteit als in het optreden van bijwerkingen zijn verschillende 
mogelijke verklaringen. Hiertoe worden allereerst twee basisprincipes uit de medicijnleer uitgelegd, 
de zogenaamde ‘farmacokinetiek’ en de ‘farmacodynamiek’.
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Farmacokinetiek staat voor wat doet het lichaam met het medicijn. Dit omvat vier processen, 
namelijk absorptie, distributie, metabolisme en excretie, samen afgekort tot ADME. Nadat een 
tablet wordt geslikt moet het oplossen tot kleine partikels en vanuit het maagdarmkanaal worden 
opgenomen in de bloedbaan (absorptie). Via de bloedbaan wordt het geneesmiddel, al dan niet 
aan eiwit gebonden,  verspreid door het lichaam (distributie). Onder andere in de lever wordt het 
medicijn door verschillende enzymen (dit zijn eiwitten) omgezet in andere stoffen (metabolisme). 
De nieuwe stoffen die hierdoor ontstaan worden afbraakproducten of metabolieten genoemd. Deze 
metabolieten worden in sommige gevallen ook weer omgezet in andere metabolieten. Gelijktijdig 
wordt een geneesmiddel en diens metaboliet(en) via de lever en/of de nieren uitgescheiden (excretie). 
De activiteit van deze vier processen tezamen bepalen hoeveel van het geneesmiddel in het lichaam 
aanwezig is; oftewel hoe hoog de blootstelling aan een bepaald medicijn in een bepaald persoon 
is. Dit laatste kan gemeten worden in bijvoorbeeld het bloed van de patiënt. Er is een grote variatie 
tussen mensen in de farmacokinetiek van geneesmiddelen. Dit wil zeggen: als meerdere mensen 
eenzelfde dosering van een bepaald medicijn innemen, dan zal er een variatie zitten in de gemeten 
medicijnspiegels. Dit wordt veroorzaakt door verschillen in de activiteit van deze vier processen.
Farmacodynamiek staat voor welk effect het medicijn heeft op het lichaam. Het betreft zowel gunstige 
als ongunstige effecten van een medicijn. In het geval van medicijnen tegen kanker zien we als gunstig 
(therapeutisch) effect dat een tumor niet verder groeit, of zelfs kleiner wordt. Ongunstige effecten 
(bijwerkingen) zijn onbedoelde neveneffecten van een medicijn. Voorbeelden zijn diarree, afwijkingen 
aan hart- en bloedvaten, hoge bloeddruk, lever- en nierfunctiestoornissen, schildklierafwijkingen, 
veranderingen van haar en huid, en nog veel meer.
In het eerste deel van dit proefschrift wordt een drietal studies besproken die tot doel hebben om de 
behandeling met sunitinib bij patiënten te verbeteren, gebaseerd op de farmacokinetiek van sunitinib. 
Patiënten die worden behandeld met sunitinib vertonen een grote spreiding in de blootstelling 
aan het middel in het bloed. Dit houdt in dat als 10 patiënten eenzelfde dosis sunitinib innemen, 
bijvoorbeeld 50mg, dat de ene patiënt dan bijvoorbeeld een spiegel van 20 ng/mL zal hebben en de 
ander een spiegel van 80 ng/mL. Mogelijk is het zo dat verschillen in het optreden van bijwerkingen 
en verschillen in hoe effectief het middel is om de groei van kanker af te remmen, hieraan gerelateerd 
is. Om de behandeling met sunitinib in patiënten met kanker in de toekomst te verbeteren hebben wij 
de volgende drie studies gedaan.  
De eerste studie, weergegeven in hoofdstuk 2 van dit proefschrift, is een studie waarbij we van 2 
eenvoudig uit te voeren tests, de zogenaamde ‘midazolam klaringstest’ en de ‘sestamibi scan’ van 
de lever, hebben onderzocht of de uitkomst voorspellend is voor de medicijnspiegels van sunitinib. 
De midazolam klaringstest kan worden gebruikt als maat voor de activiteit van CYP3A4 in de lever. 
CYP3A4 is een enzym dat belangrijk is voor de omzetting van medicijnen in metabolieten. Het komt 
162 Appendix 1
onder andere voor in de lever en het maagdarmkanaal. De sestamibi scan van de lever is een maat 
voor de activiteit van het transporteiwit ABCB1. Dit eiwit zorgt er in de lever voor dat veel medicijnen, 
waaronder sunitinib, in de gal worden uitgescheiden. Zowel de midazolam klaringstest als de sestamibi 
scan van de lever bleken de medicijnspiegels van sunitinib onvoldoende te kunnen voorspellen om 
toegepast te kunnen worden in de klinische praktijk. Wel zagen we, dat patiënten met een lage klaring 
van sunitinib, en daarmee hogere medicijnspiegels, vaker ernstige bijwerkingen hadden dan patiënten 
met een hoge klaring en daarmee lagere medicijnspiegels. Dit suggereert dat er voor het medicijn 
sunitinib een relatie bestaat tussen de blootstelling en het optreden van toxiciteit.
Hieruit volgt de vraag of het beter zou zijn om sunitinib te doseren aan de hand van de medicijnspiegels, 
in plaats van een standaard dosis. Doseren op basis van de medicijnspiegels gebeurt al regelmatig 
bij de behandeling met onder andere antibiotica, en medicijnen ter voorkoming van afstoting na 
transplantaties. In hoofdstuk 3 van dit proefschrift hebben we onderzocht, in patiënten die geen 
standaard behandelingsopties meer hebben voor hun kanker, of sunitinib gedoseerd kan worden op 
basis van de medicijnspiegels. Patiënten startten met 37.5 mg sunitinib per dag en 2 weken later werd 
voor de eerste keer een medicijnspiegel afgenomen. Indien deze spiegel onder de 50 ng/mL was, 
werd de dosis sunitinib opgehoogd met 12.5 mg naar 50 mg per dag. In de 4e week van behandeling 
werd nogmaals een medicijnspiegel afgenomen. Indien deze nog steeds of juist nu onder de 50ng/
mL was, werd de dosis wederom met 12.5 mg opgehoogd. Patiënten die ernstige bijwerkingen van de 
medicijnen ondervonden werden in dosis gereduceerd en nadien niet meer opgehoogd. Deze studie 
liet zien, dat het in 17% van de patiënten die behandeld werden met sunitinib, mogelijk is om de dosis 
aan de hand van de spiegels op te hogen tot boven de minimale waarde van 50 ng/mL, zonder dat 
dit gepaard ging met het optreden van ernstige bijwerkingen. We concludeerden dat het veilig is om 
sunitinib te doseren op basis van de spiegels. Toekomstige studies zullen moeten uitwijzen of dit ook 
daadwerkelijk resulteert in een verbetering van de behandeling met sunitinib (een betere effectiviteit 
en minder bijwerkingen).
Er is steeds meer bewijs dat circadiane ritmes (‘de klok’) de farmacokinetiek van medicijnen kunnen 
beïnvloeden. Voor sunitinib (of andere TKIs) was dit nooit eerder uitgezocht. In hoofdstuk 4 van 
dit proefschrift hebben we onderzocht of de farmacokinetiek van sunitinib anders is wanneer het 
middel op een ander tijdstip gedurende de dag wordt ingenomen. Dit zou veroorzaakt kunnen worden 
door het dag-nachtritme waaraan ons lichaam onderhevig is. We hebben dit onderzocht in zowel 
muizen als in patiënten. Bij muizen zagen we dat wanneer sunitinib om 4 uur ’s middags of 4 uur ’s 
nachts werd toegediend, de blootstelling aan sunitinib 14-27% hoger lag dan wanneer sunitinib om 
8 uur ’s ochtends of 8 uur ’s avonds werd toegediend. De patiënten in onze studie namen sunitinib 
in 3 achtereenvolgende kuren op 3 verschillende tijdstippen in; om 8 uur ’s ochtends, om 1 uur ’s 
middags en om 6 uur ’s avonds. De blootstelling gedurende de dag was bij patiënten niet verschillend 
bij verschillende tijdstippen van inname. Wel zagen we dat patiënten bij middag- of avond inname 
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van sunitinib hogere spiegels hadden vlak voor de inname van een nieuwe capsule (de zogenaamde 
‘dalspiegel’), en dat daarmee een meer stabiele blootstelling/concentratie gedurende de dag werd 
bereikt. Dit is relevant mocht sunitinib in de toekomst op basis van de dalspiegel worden gedoseerd 
(ook wel therapeutic drug monitoring of TDM genaamd). Immers, patiënten die sunitinib in de ochtend 
innemen kunnen een lagere dalspiegel hebben dan patiënten die sunitinib in de middag of avond 
innemen. Hypothetisch gezien zou bij deze patiënten de dosering kunnen worden verhoogd, terwijl 
de blootstelling gedurende niet lager is.
Het tweede deel van mijn promotieonderzoek gaat over de farmacodynamiek van verschillende TKIs, 
dus wat TKIs doen met het lichaam. Oftewel, treden er bijwerkingen op en is het middel effectief in 
de  bestrijding tegen kanker? 
De hoofdstukken 5 en 6 beschrijven een tweetal studies waarin we onderzochten of kleine afwijkingen 
in het menselijk DNA, ‘single nucleotide polymorfismen’ ofwel SNPs genaamd, een verschil in 
overleving kunnen verklaren bij patiënten met een uitgezaaide vorm van GIST. Dit werd onderzocht 
bij zowel gebruik van eerstelijns therapie met imatinib (hoofdstuk 5) en tweedelijns behandeling met 
sunitinib (hoofdstuk 6). 
In hoofdstuk 5 werden 36 SNPs in 18 genen die betrokken zijn bij de farmacokinetiek en 
farmacodynamiek van imatinib gerelateerd aan de progressie vrije overleving (PFS) en algehele 
overleving (OS) na start van imatinib behandeling in 255 patiënten met een GIST. PFS bleek significant 
korter in patiënten die ten tijde van het stellen van de diagnose al uitzaaiingen hadden, in patiënten 
met een zogenaamde KIT exon 9 mutatie en patiënten met het TT-genotype in de SNP rs2305948 in 
KDR of het AA-genotype in de SNP rs1570360 in VEGFA. OS was ook significant korter in patiënten 
met synchrone metastasen ten tijde van de diagnose, en verder in patiënten met het AA-genotype in 
KDR rs1870377, of het AA-genotype in VEGFA rs1570360. Patiënten die een T-allel hadden in SLCO1B3 
rs4149117 hadden juist een langere overleving.
In hoofdstuk 6 werden 49 SNPs in genen betrokken bij de farmacokinetiek en farmacodynamiek van 
sunitinib geassocieerd met PFS en OS na start van sunitinib behandeling in 127 patiënten met een 
uitgezaaide vorm van GIST. PFS was korter in patiënten met een C-allel in de SNP POR rs1056878. De 
aanwezigheid van een T-allel in CYP1A2 rs4149117, een dubbel CCC-allel in SLC22A5 en een dubbel 
GC-allel in IL4R waren voorspellend voor OS. Wanneer deze factoren werden gecombineerd in een 
genetisch model, bleken zowel PFS als OS significant langer naarmate het aantal gunstige genetische 
factoren in een patiënt groter was. 
Wanneer de resultaten van deze beide studies ook zouden worden gevonden in een volgende studie, 
zou het mogelijk zijn om patiënten op voorhand te identificeren die een grotere kans hebben om te 
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reageren op de behandeling.
In hoofdstuk 7 van dit proefschrift beschrijven we het optreden van een verlengde ‘QTc-tijd’ op 
het electrocardiogram, of ECG. Het ECG is een optelsom van positieve en negatieve stromen door 
de hartcellen, die optreden tijdens activiteit van het hart, ook wel depolarisatie en repolarisatie 
genoemd.  De QTc-tijd is een onderdeel van het ECG, die de tijd aangeeft die het hart nodig heeft om 
in de ruststand te komen. Dit is de repolarisatiefase. Dit is belangrijk, omdat in geval van verlenging 
van de QTc-tijd een ernstige hartritmestoornis kan ontstaan, die zonder behandeling kan leiden tot 
de dood. Zo’n verlenging van de QTc-tijd is een frequent voorkomende bijwerkingen van medicijnen 
en kan soms zelfs reden zijn om medicijnen van de markt te halen. Van TKIs was tot voor kort weinig 
bekend over het effect op de QTc-tijd. In onze studie hebben we bij 363 patiënten die behandeld zijn 
met een TKI onderzocht of deze de QTc-tijd verlengd. Dit bleek het geval te zijn voor de TKIs sunitinib, 
vemurafenib, sorafenib, imatinib en erlotinib, en als we de hele groep patiënten als een geheel zagen. 
Tenslotte, in hoofdstuk 8 van dit proefschrift wordt ingegaan op een ander verschijnsel wat optreedt 
na de start van behandeling met een TKI. Dit betreft het veranderen van de grootte van de rode 
bloedcellen, aangegeven met de term mean corposcular volume of MCV. Voor imatinib en sunitinib 
was eerder al eens beschreven in de literatuur dat het MCV toenam na de start van behandeling. In 
deze studie hebben wij dit eveneens aangetoond voor imatinib en sunitinib, en daarnaast voor het 
middel pazopanib. De klinische betekenis hiervan was altijd onduidelijk. Wij hebben aangetoond dat 
patiënten met gemetastaseerde nierkanker die behandeld werden met sunitinib en waarbij het MCV 
steeg tot boven de 100 fL tijdens de behandeling, een betere overleving hadden dan die patiënten 
waarbij het MCV in mindere mate of algeheel niet steeg tijdens de behandeling. Het stijgen van het 
MCV is hier dus een gunstig prognostisch teken voor de behandeling.
Al met al kunnen we concluderen dat de behandeling met TKIs tot dusver weinig op de individuele patiënt 
is afgestemd. Momenteel bevinden zich veel TKIs in de ontwikkelingsfase en in de nabije toekomst zullen er 
meerdere TKI-behandelingen beschikbaar zijn voor specifieke tumor types. Dit is inmiddels al het geval voor 
niercelkanker, waar zowel sunitinib als pazopanib geregistreerd zijn voor de eerstelijns behandeling. Daarom 
is het belangrijk dat er verder onderzoek gedaan wordt naar welke patiënt het beste met welk medicament 
behandeld kan worden. Dit kan bereikt worden door het onderzoeken van patiënten karakteristieken, maar 
ook door te focussen op tumor karakteristieken. Verschillende cascades van tumor activatie kunnen worden 
gevonden in een identiek tumor type of in tumoren die stammen uit hetzelfde soort weefsel. Door selectief 
een cascade van tumor activatie te blokkeren met TKIs, onafhankelijk van het tumortype, kan de behandeling 
van kanker in de toekomst aanzienlijk verbeterd worden.
Anderzijds kan de behandeling met TKIs verbeterd worden door de introductie van TDM. De kennis verkregen 
uit de studies in het eerste deel van dit proefschrift kunnen een eerste stap zijn in de richting van een “tailor 
made” behandeling met sunitinib. Echter, er is nog weinig bewijs of dit ook daadwerkelijk resulteert in een 
betere behandeling met sunitinib, en toekomstige studies zullen zich hierop moeten richten.
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Veel studies zijn verricht waarbij SNPs werden geassocieerd met overleving en bijwerkingen van een 
bepaald middel. Tot op heden heeft dit er echter niet toe geleid dat dit ook is geïmplementeerd in 
de klinische praktijk om de overleving te verbeteren en bijwerkingen te minimaliseren. Aangezien 
de effecten van SNPs op overleving en bijwerkingen in het algemeen heel klein zijn, is het ook maar 
de vraag of dit in de toekomst zal veranderen. Hoe dan ook, meer onderzoek op het gebied van 
farmacogenetica is nodig, en datzelfde geldt voor andere potentiele markers voor effectiviteit en 
toxiciteit van TKIs.
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Jacqueline Saskia Leonore Kloth werd geboren op 3 februari 1985 in Dordrecht. In 2003 behaalde 
zij haar VWO diploma aan de Rijks Scholen Gemeenschap de Hoeksche Waard. Aansluitend startte 
zij haar studie geneeskunde aan de Erasmus Universiteit te Rotterdam. In 2008 behaalde zij haar 
doctoraal examen. Van 2007-2009 doorliep zij haar coschappen in verschillende ziekenhuizen in 
de regio Rotterdam. Deze periode werd afgesloten met een oudste-coschap op de afdeling Interne 
Geneeskunde van het Maasstad ziekenhuis te Rotterdam.
Direct na het behalen van haar artsdiploma op 11 september 2009 was Jacqueline werkzaam als arts 
niet in opleiding tot specialist op de afdeling Interne Geneeskunde van het Maasstad ziekenhuis. Zij 
werkte op de afdelingen MDL, spoedeisende hulp, reumatologie en nefrologie. 
In januari 2011 maakte Jacqueline de overstap naar de Daniel den Hoed kliniek. Hier was zij 10 maanden 
werkzaam als arts niet in opleiding tot specialist op de afdeling Interne Oncologie (afdelingshoofd prof. 
dr. J. Verweij), onder begeleiding van dr. A. van der Gaast. In die periode werd tevens begonnen aan de 
opzet van wetenschappelijk onderzoek naar een verbetering van de behandeling met tyrosine kinase 
remmers bij patiënten met kanker. 
In november 2011 werd dit onderzoek gecontinueerd in het kader van een promotietraject onder 
supervisie van aanvankelijk prof. dr. J. Verweij en dr. R.H.J. Mathijssen. Bij de aanstelling van prof. dr. 
J. Verweij als decaan werd de supervisie overgedragen aan prof. dr. R.H.J. Mathijssen en dr. E.A.C. 
Wiemer (afdelingshoofd prof. dr. S. Sleijfer), wat resulteerde in dit proefschrift.
In december 2014 startte Jacqueline als arts in opleiding tot specialist op de afdeling Interne 
Geneeskunde van het Maasstad ziekenhuis (opleider dr. M.A. van den Dorpel), in het kader van haar 
opleiding tot reumatoloog (opleiders dr. R.J.E.M. Dolhain en dr. E. Barendregt).
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1. PhD training
Year
Workload
ecTs
General courses
-        Basic introduction course on SPSS, MolMed 2012 0.8
-        BROK (Basiscurcus Regelgeving Klinisch Onderzoek) course, 
Erasmus MC
2012 1
-        Integrity in research, Erasmus MC 2013 1
-        Training OpenClinica, Erasmus MC 2013 0.4
-        Biomedical English Writing and Presenting, MolMed 2014 3
specific courses (e.g. research school, medical Training)
-        Genomics in Molecular Medicine, NIHES 2012 1
-        Biostatistical Methods: Basic Principles, NIHES 2012 5.7
seminars and workshops
-        Personalized Medicine research meeting Medical Oncology 2012 1
-        Principles of Clinical Pharmacology, NIH course 2012 1
-        Graphic style and plot vs table, Erasmus MC workshop 2012 0.2
-        How to write a successful grant proposal, Erasmus MC 
workshop
2012 0.2
-        Clinical Pharmacology, COIG workshop 2012 1
-        Systematic literature search in Pubmed, Erasmus MC 
Workshop
2012 0.2
-        Endnote, Erasmus MC Workshop 2012 0.2
-        Systematic literature search in other databases, Erasmus 
MC Workshop
2012 0.2
-         Genomic approaches to cancer, MolMed lecture 2013 0.1
-         Photoshop & Illustrator CS5, MolMed workshop 2013 0.3
-         Indesign CS5, MolMed workshop 2014 0.3
-        Clinical Pharmacology meeting, Erasmus MC 2014 0.5
Presentations
-        Research Meeting Medical Oncology, oral presentation 2011 0.5
-        ESMO Annual Meeting 2012, poster presentation 2012 1
-        ESMO Annual Meeting 2013, poster presentation 2013 1
-        ASCO Annual Meeting 2014, poster presentation 2014 1
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(Inter)national conferences
-        ESMO Annual Meeting 2012, Vienna, Austria 2012 1
-        NVKF&B Annual Meeting 2013, Utrecht 2013 0.3
-        ESMO Annual Meeting 2013, Amsterdam 2013 1
-        NVKF&B Annual Meeting 2014, Leiden 2014 0.3
-        ASCO Annual Meeting 2014, Chicago, Illinois, USA 2014 1
other
-        Research meeting Medical Oncology, Erasmus MC 2011 / 2013 0.4
-        IKNL networking days Vlissingen / Middelburg 2011 / 2013 1
-        PhD day Erasmus MC 2012- 2014 1
-        MOLMED research day, Erasmus MC 2012-2013 0.8
-        Clinical Oncology meeting, Erasmus MC 2011-2013 1.5
-        OMBO training 2011-2013 1
-        Rheumatology journal club, Cicero 2013-2014 0.5
2. Teaching
Lecturing
-        Personalized Medicine research meeting Medical Oncology 2011-2013 2
-        Clinical lessons to Oncology nurses, Erasmus MC 2012 0.2
supervising master’s thesis
-        Anna Pagani 2012-2013 1
-        Pauline Mendelaar 2014 1
PhD Portfolio
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De afgelopen 3.5 jaar heb ik me bezig gehouden met dit onderzoek. Het was een leerzame periode 
waarin ik zowel op professioneel als op persoonlijk gebied ben gegroeid. Dit proefschrift, waar ik 
ontzettend trots op ben, is het eindresultaat van mijn werk. Alleen was mij dit nooit gelukt. Vele 
anderen hebben op verschillende wijze bijgedragen aan de totstandkoming van dit proefschrift. Hen 
wil ik graag bedanken voor alle hulp en inzet.
Allereerst wil ik alle patiënten bedanken. Veelal belangeloos heeft u zich ingezet voor de wetenschap, 
in tijden waarin u wist dat het leven niet voor altijd zou zijn. Ik heb de diepste bewondering voor 
uw inzet en doorzettingsvermogen. Ziekenhuisopnames, extra bloedafnames overdag en ‘s nachts, 
hartfilmpjes, polibezoeken, en noem zo maar op, niets was u te gek. Zonder de bereidheid van patiënten 
om deel te nemen aan wetenschappelijk onderzoek zou de geneeskunde nog in de kinderschoenen 
staan. Ik dank u hartelijk voor al uw inzet.
Prof. dr. R. Mathijssen. Beste Ron, jij zag potentie in mij op een moment waarop ik het zelf niet meer 
zag en wist me op te monteren en te motiveren. Bedankt dat je me naar de Daniel den Hoed kliniek 
haalde en mij uiteindelijk deze promotieplaats kon aanbieden. Eerst als copromotor en later als 
promotor zorgde je ervoor dat er altijd vaart in mijn onderzoek bleef zitten. Ik weet dat ik af en toe 
koppig en direct kan zijn, maar ik heb oprecht genoten van de discussies die we hadden en die alleen 
mogelijk waren door jouw laagdrempeligheid. 
Dr. E. Wiemer. Beste Erik, pas in het tweede jaar van mijn promotie werd jij betrokken in mijn traject. 
Als pre-clinicus heb je mij enorm geholpen bij het begrijpen en interpreteren van proeven waar ik zelf 
geen kaas van gegeten had. Hartelijk dank voor al je hulp bij het “muizenexperiment,” waarbij je zelfs 
een nacht met Lisette en mij doorwerkte om te helpen bij het tijdig opofferen van de muizen. Bedankt 
ook voor je geduld en uitleg als ik weer iets niet begreep van een bepaalde techniek of methode.
Prof. dr. J. Verweij. Beste Jaap, dank voor het eerste jaar van mijn promotie waarin jij mijn promotor 
was en me de beginselen van onderzoek hebt bijgebracht.
Prof.dr. T. van Gelder, prof.dr. H.J. Guchelaar en prof.dr. W. de Graaf, bedankt voor uw zitting in mijn 
kleine commissie en voor de snelle beoordeling van mijn manuscript. De verlossende woorden dat het 
proefschrift was goedgekeurd hadden even tijd nodig om te landen, maar heeft de lading van deze 
boodschap niet gedrukt.
Prof.dr. S. Sleijfer. Beste Stefan, hartelijk dank voor al je snelle en kritische beoordelingen op de stukken 
waarop jij co-auteur was. Meer dan eens gaf me dit een andere kijk op de studie, waarvan ik denk ik 
veel heb geleerd. Dank dat je deel wilt uitmaken van de grote commissie.
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Prof.dr. G.T.J. van der Horst. Beste Bert, bedankt voor je deelname in de grote commissie. Ik herinner 
me goed hoe diep ik me schaamde toen ik ergens tussen  twee opofferingen van muizen door jou 
moest worden wakker gemaakt. Dank voor al je hulp.
Dr. N. Steeghs. Beste Neeltje, bedankt voor je deelname in mijn grote commissie, en ook voor je 
gastvrijheid op de dagen waarop ik in het NKI data kwam opzoeken.
Prof.dr. J. Schellens, hartelijk dank voor uw deelname in mijn grote commissie.
Het laboratorium Translationele Farmacologie, in het bijzonder Peter, zonder jou was dit nooit gelukt. 
Jij hebt me zoveel bijgebracht over de farmacologie. Bedankt voor al je uitleg, de tijd die je altijd had 
voor al mijn vragen en brainstormsessies, de metingen die je allemaal voor me hebt gedaan en de vele 
figuren die je telkens naar mijn zin maakte.
Mei en Inge, bedankt voor het doormeten van al mijn samples en al het andere waar jullie bij hebben 
geholpen. Mei, je tips voor gerechten met wilde spinazie heb ik vaak uitgeprobeerd, wanneer gaan 
we weer samen boodschappen doen op de markt? Inge, bedankt voor je altijd aanwezige lach, de 
interesse die je altijd in een ander toont, alles wat je altijd regelde en voor dat je altijd zo attent bent.
Ton, Herman, Patricia en Xander, bedankt voor jullie hulp voor, tijdens en na het muizenexperiment. 
Inmiddels hebben jullie allemaal de groep Translationele Farmacologie verlaten. Ik hoop dat jullie allen 
gelukkig zijn in jullie nieuwe baan en wens jullie alle geluk en succes voor de toekomst.
Mijn mede-promovendi, Sander en de “meisjes van Ron” (Lisette, Annemieke en Anne-Joy), Ellen, 
Caroline, Marijn, Roelof, Eric, Wendy, Johan, Astrid en Evelien, bedankt voor alle keren dat ik bij jullie 
stoom kon afblazen en bij jullie terecht kon voor advies. Annemieke, ik zal nooit vergeten hoe jij in een 
van je eerste week als promovenda je pieper wist te lozen. Ik heb ontzettend met en om jou kunnen 
lachen, waarvoor ik je heel erg dankbaar ben. Lisette, bedankt voor de fijne samenwerking in de 
chronostudie. Avonden op B0-zuid, ’s ochtends vroeg en de hele dag door in een donker hok van 1.5x1.5 
meter cellen behandelen en nachtenlang muizen ontleden is voor mij een onvergetelijke ervaring 
geweest. Anne-Joy, bedankt voor de gezellige tijd op G4-80 in het eerste jaar van mijn promotie. Je had 
geen idee wat er gebeurde toen ik op mijn eerste ochtend begon met het opruimen en soppen van 
andermans troep op mijn nieuwe werkplek, maar uiteindelijk raakte je er wel aan gewend en kon je 
het volgens mij ook wel waarderen. Sander, bedankt voor je luchtige kijk op situaties en droge grappen, 
maar vooral voor de goede discussies die ik met je kon voeren. Hoewel de chesterfields, whisky en 
sigaren als omgeving ontbraken en werden vervangen door vergane kantoorstoelen, koffie/thee uit 
de automaat en Tl-licht, was de inhoud van dezelfde orde van grootte. Jij blijft als laatste van ons over 
en kan nu de scepter zwaaien in de kamer. Geen ongewenste geuren meer van nagellak, deodorant of 
parfum, en de verwarming gewoon het hele jaar op stand 0. Succes met het verloop van je promotie 
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en carrière daarna, dat komt wel goed. Roelof, met je Lancet Oncology paper legde je de lat voor ons 
allen hoog. Ik weet nog steeds niet of ik je hiervoor moet bedanken, aangezien het mij vele extra 
submissies heeft bezorgd. Bedankt voor de energie die jij stak in meer buiten-werkse activiteiten. Ik 
waardeer deze houding oprecht. Wendy, bedankt voor alle tips en hulp die je hebt gegeven als ik weer 
eens vastliep met iets wat jij allang had meegemaakt. Johan, ik herinner me goed de dagen waarop 
wij als oudste coassistent op de SEH van het Maasstad ziekenhuis stonden. Allebei vonden we het best 
spannend. Waar jij direct nadien het onderzoek in ging, koos ik voor de kliniek, maar toch kruisten 
onze paden elkaar in de Daniel den Hoed kliniek. Ik weet zeker dat je een ontzettend fijne oncoloog 
wordt. Heel veel succes met het vervolg van je opleiding. Astrid, tussen het presenteren van posters en 
de interviews voor Oncologie TV door vonden we voldoende tijd om Chicago te verkennen, af en toe 
een borreltje te drinken en heerlijk te lunchen in Chinatown. Bedankt voor de leuke tijd. 
Karel, jij ging mij voor. Hoewel ik de ClearSun studie twee jaar lang als een dood paard bleef meezeulen 
ben ik je er dankbaar voor dat ik deze studie van je kon overnemen en voor al het werk dat jij al 
verricht had voor mij.
Leni, bedankt voor al je enthousiasme en interesse. Ik bewonder oprecht je inzet in werk en studie 
en hoop dat je een goed vervolg kunt geven aan je net afgeronde studie. Ik vind het heel leuk dat 
wij dezelfde interesses hebben voor exposities en niet wetenschappelijke literatuur, en geniet van je 
enthousiasme als je het hebt over een goed boek dat je net gelezen hebt.
Alle stafleden van de afdeling Interne Oncologie wil ik bedanken voor de leuke en leerzame tijd die ik 
heb gehad in de periodes waarin ik op de afdeling werkte. Hielke, Ate, Esther, Ronald, Karin, Jan en 
Anne-Marie, bedankt voor de begeleiding op de afdeling en de ruimte die ik kreeg om mijn onderzoek 
op te starten en later uit te voeren. Ook dank aan iedereen voor het includeren van patiënten in mijn 
studies.
Alle arts-assistenten en fellows waar ik in de loop der jaren mee heb gewerkt wil ik bedanken voor de 
fijne samenwerking. In het bijzonder wil ik hier Eva, Cynthia, Sophie, Hilal, Florence (Florans), Wendy, 
Brigitte en Yorick noemen. Bedankt voor de ondersteuning en goede sfeer tijdens alle periodes waarin 
ik op B0-zuid, B0 of B1 werkte. Ik wens jullie alle geluk toe in het verloop van jullie carrière. Hilal, op 
naar jouw promotie en daarna verder als collega’s bij de reumatologie, ik kijk er al naar uit. Cynthia, 
Sophie en Florence, hoe bijzonder is het dat wij dit jaar als vier oud-collega’s afreizen naar Nepal.
In de afgelopen jaren ben ik werkzaam geweest op alle afdelingen Interne Oncologie in de Daniel 
den Hoed kliniek. Alle medewerkers bedankt voor de fijne samenwerking. In het bijzonder wil ik hier 
de verpleging, secretaresses en voedingsassistentes van afdeling B0-zuid noemen. Hier heb ik zoveel 
tijd doorgebracht en jullie hebben voor een groot deel bijgedragen aan het plezier dat ik had in het 
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werk op de afdeling. Dank voor de goede zorg en lieve woorden die jullie hebben voor alle patiënten, 
hiervoor heb ik het diepste respect. Ook dank voor alle keren dat jullie voor mij bloedafnames hebben 
gedaan zodat ik ’s avonds met een gerust hart naar huis kon en wist dat jullie zorg zouden hebben dat 
mijn studie volgens protocol verder zou gaan. Willy, bedankt voor alles wat je voor me hebt gedaan. 
Patiënten ontvangen, afspraken maken, statussen opvragen, formulieren inscannen en nog veel meer, 
heel erg bedankt. 
Diane, bedankt voor alle patiënten die je op de poli hebben gezien voor mijn studies. 
Researchverpleegkundigen, in het bijzonder Diana, bedankt voor alles wat je hebt gedaan voor de 
M10PKS. Ik kwam net kijken bij onderzoek en had werkelijk geen idee wat ik allemaal moest regelen bij 
het opzetten en uitvoeren van een prospectieve studie. Bedankt voor je hulp hierbij. Data-managers, 
Cindy en Robert, bedankt voor jullie hulp bij de M10PKS en de chronostudie. Cindy, uiteraard ook veel 
dank voor de hulp bij het muizenexperiment.
Dr. Heinz-Josef Klümpen and Prof. Howard Gurney, thanks for the convenient cooperation in the 
Clearsun study.
Prof. Dr. H. Gelderblom, Dr. An Reijnders, Dr. Jesse Swen en Michiel Verboom, bedankt voor de 
samenwerking in het SUTOX consortium. Michiel, heel veel succes met het afronden van je promotie.
Annelieke de Wit en Inez Machado, bedankt voor al jullie hulp bij het uitzetten van de SIMH4 cellen en 
het uitvoeren van de q-PCR in de chronostudie.
Anna Pagani, thanks for all the work you did for the QTc-project. I still don’t understand how you 
managed to find all those data in horribly written patient files without speaking Dutch. Hopefully, your 
PhD-project is proceeding as well.
Dr. Paul Hamberg, bedankt voor het includeren van patiënten uit het Sint Franciscus Gasthuis in mijn 
studies, en ook voor al het werk dat je al had gedaan voor het macrocytose project. Het is nu bijna af 
en hopelijk leidt dit spoedig tot een mooie publicatie.
Alle medewerkers van het proefdierenlaboratorium bedankt voor de hulp bij het uitvoeren van wat 
voor jullie misschien ook wel het grootste experiment in de kortste tijd was. Bedankt ook dat wij 36 
uur mochten huizen in jullie koffiekamer.
Alle oud-collega’s uit het Maasstad ziekenhuis,jullie hebben ervoor gezorgd dat ik een onvergetelijke 
tijd heb gehad als ANIOS in het Maasstad ziekenhuis, dank hiervoor! Dr. Han en dr. Barendregt, u ben 
zo enthousiast over het vak reumatologie, en hebt dat van de eerste dag op mij overgebracht. Ik ben 
ontzettend blij dat ik stage mocht lopen op de afdeling reumatologie van het Maasstad ziekenhuis. 
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Zonder die 4 maanden zou ik wellicht niet met mijn toekomstige specialisme in aanraking zijn geweest. 
Heel erg bedankt hiervoor. Alle internisten, longartsen, MDL-artsen en reumatologen wil ik bedanken 
voor de leermomenten op vaak onverwachte momenten.
Mijn huidige collega’s van de afdeling Interne Geneeskunde, de meesten van jullie ken ik nog maar kort, 
maar toch voel ik mij weer helemaal thuis in mijn nieuwe baan. Bedankt voor de fijne samenwerking 
en de ontspannen werksfeer.
Zovelen hebben professioneel bijgedragen aan de totstandkoming van dit proefschrift, maar degenen 
buiten het werk zijn niet minder belangrijk geweest in deze periode en hebben mij gesteund om dit 
te bereiken.
Els en Martin, Germaine, Annemieke en Pieter en Marijn, hoewel we elkaar niet zo vaak meer zien 
als tijdens onze studie, is het altijd gezellig met elkaar en kijk ik er altijd naar uit om jullie weer te 
spreken. Els, jij bent er altijd voor mij en natuurlijk nu ook tijdens mijn promotie. Het zal niemand 
verbazen dat jij mijn paranimf bent, ik had het me niet anders kunnen voorstellen. Samen hebben 
we veel mooie momenten beleefd op bijzondere plaatsen. Ik denk dagelijks terug aan de vakanties 
en uitstapjes die wij hebben gemaakt en hoop dat er nog veel van zullen volgen. Bedankt voor al die 
keren dat je er voor me bent. Annemieke en Marijn, ik sta nu aan het begin van mijn opleiding en jullie 
hebben die inmiddels al afgerond. Voor mijn gevoel zijn jullie al zoveel verder, petje af! Germaine, ik 
ben ontzettend trots op jou. Jouw enthousiasme voor werk is uitzonderlijk. Naast een goede vriendin 
ben je nu ook een fijne collega van me. Heel veel succes met je opleiding tot cardioloog. 
Sanne, samen zaten we op de Veertig Mergen en de RSG Hoeksche Waard en inmiddels zijn we al ruim 
25 jaar vriendinnen. Net als velen heb je na meerdere keren uitleg nog geen flauw idee van wat ik nou 
eigenlijk doe, en toch kan jij mij als geen ander bijstaan als paranimf. Dank daarvoor. Jij kent me door 
en door en weet me altijd zelfvertrouwen te geven. Bedankt voor alle mooie momenten die we samen 
al hebben beleefd, er komen er vast nog veel bij. 
Charlotte, team nefrologie in de zomer van 2010 waarna nog vele etentjes en borrels volgden. Bedankt 
voor al je wijze raad die je me gegeven hebt. “Het komt altijd goed.” Ik zou niet weten hoe vaak ik je 
dat heb horen zeggen. Het feit dat dit boekje nu voor je ligt is wat mij betreft bewijzend voor deze 
uitspraak.
Simone, wij houden van exact dezelfde festivals en evenementen. De Parade en Rotterdamse Kost met 
jou staan als vaste prik in mijn agenda. Op dit soort momenten kan ik altijd echt even ontspannen van 
de werkdruk, dank hiervoor. 
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Anna en Marlijn, om verschillende redenen staat hardlopen bij ons allen nu even op een lager pitje. 
Hoewel ik lang niet altijd zin had om te gaan is hardlopen voor mij echt een uitlaatklep aan het einde 
van een dag werken. Samen hebben we nu twee keer de marathon van Rotterdam voorbereid en 
gelopen. Bedankt voor de gezelligheid voor, tijdens en na het lopen en voor alle keren dat jullie mijn 
enige motivatie waren om mijn hardloopschoenen aan te trekken en de deur uit te gaan. 
Tot slot wil ik mijn familie bedanken, bij wie ik zo graag ben en die mij altijd in alles gesteund heeft. 
Irene en Marjolein, mijn lieve en zorgzame zussen, bedankt voor al jullie steun in al die jaren. De 
hechte band die wij al van kind af aan hebben is erg belangrijk voor mij. Ik kan me geen leven zonder 
jullie voorstellen. Sjoerd en Hans, jullie zijn al zo lang in de familie dat het soms lijkt alsof jullie er 
altijd al bij waren. Bedankt voor alle keren dat jullie je (toen) kleine schoonzusje hebben geholpen of 
weer eens ergens mee op sleeptouw namen. Patrick en Mariëlle, jullie zijn de enigen in de familie die 
daadwerkelijk een poging hebben gedaan een van mijn publicaties te lezen. Dank voor de interesse die 
jullie tonen in mij en in mijn werk.
Lieve Jesse, Hylke, Pelle, Lotte, Tibbe, Carlijn en Maas, bij jullie kan ik echt even alles vergeten. Jullie 
zijn de liefste kinderen en ik ben er trots op dat ik jullie tante Jacqie ben. Mijn deur zal altijd voor jullie 
open blijven staan.
Lieve papa en mama, bedankt dat jullie er altijd voor mij zijn. Hoewel het voor jullie helemaal niet 
gewoon was dat al jullie dochters naar de universiteit zouden gaan, maakten jullie het als een 
vanzelfsprekendheid. Jullie hebben mij altijd gestimuleerd om het beste uit mezelf te halen, waarvoor 
ik jullie eeuwig dankbaar ben. Zonder jullie zou ik hier niet staan.
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